BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 1003] [Article Influence: 395.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Yu H, Zhang D, Wang G, Song W, Liu Y, Ma S, Tang Z, Liu Z, Sakurai K, Chen X. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma. Acta Biomater 2019;92:229-40. [PMID: 31100462 DOI: 10.1016/j.actbio.2019.05.028] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
2 Cui Y, Jiang N. Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden. Hum Cell 2022. [PMID: 35622212 DOI: 10.1007/s13577-022-00708-2] [Reference Citation Analysis]
3 Lin X, Xiao M, Gu YJ, Zhu HK, Li MX, Zhuang L, Zheng SS, Li QY. The "No-touch" technique improves the survival of patients with advanced hepatocellular carcinomas treated by liver transplantation: A single-center prospective randomized controlled trial. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00120-5. [PMID: 35568681 DOI: 10.1016/j.hbpd.2022.05.002] [Reference Citation Analysis]
4 Su Q, Fan M, Wang J, Ullah A, Ghauri MA, Dai B, Zhan Y, Zhang D, Zhang Y. Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma. Cell Death Dis 2019;10:939. [PMID: 31819036 DOI: 10.1038/s41419-019-2173-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
5 Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study. BMC Gastroenterol 2021;21:182. [PMID: 33879085 DOI: 10.1186/s12876-021-01765-x] [Reference Citation Analysis]
6 Cheng N, Lou B, Wang H. An intelligent serological SERS test toward early-stage hepatocellular carcinoma diagnosis through ultrasensitive nanobiosensing. Nano Res . [DOI: 10.1007/s12274-022-4114-z] [Reference Citation Analysis]
7 Zheng X, Cao F, Qian L, Dong J. Body Composition Changes in Hepatocellular Carcinoma: Prediction of Survival to Transcatheter Arterial Chemoembolization in Combination With Clinical Prognostic Factors. Cancer Control 2021;28:10732748211038445. [PMID: 34569304 DOI: 10.1177/10732748211038445] [Reference Citation Analysis]
8 Ivanics T, Murillo Perez CF, Claasen MPAW, Patel MS, Morgenshtern G, Erdman L, Shwaartz C, Rajendran L, O'Kane GM, Hansen BE, Cleary SP, Sapisochin G. Dynamic risk profiling of HCC recurrence after curative intent liver resection. Hepatology 2022. [PMID: 35178739 DOI: 10.1002/hep.32411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ding Y, Sun Z, Zhang S, Li Y, Han X, Xu Q, Zhou L, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:7020637. [PMID: 34195281 DOI: 10.1155/2021/7020637] [Reference Citation Analysis]
10 Liu L, Yang X, Li NF, Lin L, Luo H. Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma. Cell Cycle 2019;18:2939-53. [PMID: 31522588 DOI: 10.1080/15384101.2019.1664223] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
11 Rizzo A. Optimizing outcomes in HCC: Comment on "optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et al. Transl Oncol 2021;14:101246. [PMID: 34656968 DOI: 10.1016/j.tranon.2021.101246] [Reference Citation Analysis]
12 Chen X, Tang FR, Arfuso F, Cai WQ, Ma Z, Yang J, Sethi G. The Emerging Role of Long Non-Coding RNAs in the Metastasis of Hepatocellular Carcinoma. Biomolecules 2019;10:E66. [PMID: 31906046 DOI: 10.3390/biom10010066] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 14.0] [Reference Citation Analysis]
13 Wu J, Huang WJ, Xi HL, Liu LY, Wang ST, Fan WZ, Peng BG. Tumor-suppressive miR-3650 inhibits tumor metastasis by directly targeting NFASC in hepatocellular carcinoma. Aging (Albany NY) 2019;11:3432-44. [PMID: 31163018 DOI: 10.18632/aging.101981] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
14 Wang X, Wang R, Bai S, Xiong S, Li Y, Liu M, Zhao Z, Wang Y, Zhao Y, Chen W, Billiar TR, Cheng B. Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway. J Exp Clin Cancer Res 2019;38:505. [PMID: 31888685 DOI: 10.1186/s13046-019-1508-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
15 Zhou Y, Zhao L, Zhong X, Ding J, Zhou H, Wang F, Jing X. A thermochromic tissue-mimicking phantom model for verification of ablation plans in thermal ablation. Ann Transl Med 2021;9:354. [PMID: 33708981 DOI: 10.21037/atm-21-523] [Reference Citation Analysis]
16 Gao L, Yan H, Zhu S, Wang X, Tan Y, Du J, Feng D, Zhang H, Gu Z. Targeted delivery of Bi2Se3 Nanoflowers to orthotopic liver tumor via transarterial infusion for enhanced microwave ablation sensibilization. Nano Today 2021;41:101314. [DOI: 10.1016/j.nantod.2021.101314] [Reference Citation Analysis]
17 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Front Oncol 2021;11:653846. [PMID: 33869059 DOI: 10.3389/fonc.2021.653846] [Reference Citation Analysis]
18 Chong HH, Yang L, Sheng RF, Yu YL, Wu DJ, Rao SX, Yang C, Zeng MS. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm. Eur Radiol 2021;31:4824-38. [PMID: 33447861 DOI: 10.1007/s00330-020-07601-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
19 Wu C, Lin J, Weng Y, Zeng DN, Xu J, Luo S, Xu L, Liu M, Hua Q, Liu CQ, Li JQ, Liao J, Sun C, Zhou J, Chen MS, Liu C, Guo Z, Zhuang SM, Huang JH, Zheng L. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest 2020;130:4679-93. [PMID: 32497024 DOI: 10.1172/JCI135048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
20 Li J, Wang W, Zhou Y, Liu L, Zhang G, Guan K, Cui X, Liu X, Huang M, Cui G, Sun R. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma. Front Cell Dev Biol 2021;9:687756. [PMID: 34277630 DOI: 10.3389/fcell.2021.687756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Turgeon MK, Shah SA, Delman AM, Tran BV, Agopian VG, Wedd JP, Magliocca JF, Kim A, Cameron A, Olyaei A, Orloff SL, Anderson MP, Kubal CA, Cannon RM, Locke JE, Simpson MA, Akoad ME, Wongjirad CP, Emamaullee J, Moro A, Aucejo F, Feizpour CA, Vagefi PA, Nguyen MH, Esquivel CO, Dhanireddy K, Subramanian V, Chavarriaga A, Kazimi MM, Anderson MS, Sonnenday CJ, Kim SC, Foley DP, Abdouljoud M, Salgia RJ, Moris D, Sudan DL, Ganesh SR, Humar A, Doyle M, Chapman WC, Maithel SK. Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. Ann Surg 2021;274:613-20. [PMID: 34506316 DOI: 10.1097/SLA.0000000000005070] [Reference Citation Analysis]
22 Yin LC, Xiao G, Zhou R, Huang XP, Li NL, Tan CL, Xie FJ, Weng J, Liu LX. MicroRNA-361-5p Inhibits Tumorigenesis and the EMT of HCC by Targeting Twist1. Biomed Res Int 2020;2020:8891876. [PMID: 33381597 DOI: 10.1155/2020/8891876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, Kogai T, Tomaru T, Usui I, Aso Y. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E5237. [PMID: 31652578 DOI: 10.3390/ijms20205237] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
24 Baglieri J, Brenner DA, Kisseleva T. The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E1723. [PMID: 30959975 DOI: 10.3390/ijms20071723] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Wang Z, Zhang N, Lv J, Ma C, Gu J, Du Y, Qiu Y, Zhang Z, Li M, Jiang Y, Zhao J, Du H, Zhang Z, Lu W, Zhang Y. A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients. Biomed Res Int 2020;2020:4037639. [PMID: 33163533 DOI: 10.1155/2020/4037639] [Reference Citation Analysis]
26 Kong J, Wang T, Shen S, Zhang Z, Yang X, Wang W. A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma. PeerJ 2019;7:e7942. [PMID: 31687273 DOI: 10.7717/peerj.7942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lee SR, Lee JG, Heo JH, Jo SL, Ryu J, Kim G, Yon JM, Lee MS, Lee GS, An BS, Shin HJ, Woo DC, Baek IJ, Hong EJ. Loss of PGRMC1 Delays the Progression of Hepatocellular Carcinoma via Suppression of Pro-Inflammatory Immune Responses. Cancers (Basel) 2021;13:2438. [PMID: 34069911 DOI: 10.3390/cancers13102438] [Reference Citation Analysis]
28 Luo Z, Lu L, Tang Q, Wei W, Chen P, Chen Y, Pu J, Wang J. CircCAMSAP1 promotes hepatocellular carcinoma progression through miR-1294/GRAMD1A pathway. J Cell Mol Med 2021;25:3793-802. [PMID: 33484498 DOI: 10.1111/jcmm.16254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Yang P, Zheng Y, Chen J, Ma H, Yu K, Chen Y, Yang Y, Wu B. Immediate risk of non-cancer deaths after a cancer diagnosis. BMC Cancer 2021;21:963. [PMID: 34452598 DOI: 10.1186/s12885-021-08707-6] [Reference Citation Analysis]
30 Zhang L, Tao H, Li J, Zhang E, Liang H, Zhang B. Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma. Aging (Albany NY) 2021;13:15990-6008. [PMID: 34049287 DOI: 10.18632/aging.203056] [Reference Citation Analysis]
31 Wei M, Lin M, Zhong X, Dai Z, Shen S, Li S, Peng Z, Kuang M. Role of Preoperational Imaging Traits for Guiding Treatment in Single ≤ 5 cm Hepatocellular Carcinoma. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11344-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Liu S, Zhao W, Li X, Zhang, Gao Y, Peng Q, Du C, Jiang N. AGTRAP Is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma. Front Oncol 2021;11:713017. [PMID: 34595113 DOI: 10.3389/fonc.2021.713017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Louis C, Leclerc D, Coulouarn C. Emerging roles of circular RNAs in liver cancer. JHEP Rep 2022;4:100413. [PMID: 35036887 DOI: 10.1016/j.jhepr.2021.100413] [Reference Citation Analysis]
34 Bala MM, Riemsma RP, Wolff R, Pedziwiatr M, Mitus JW, Storman D, Swierz MJ, Kleijnen J. Cryotherapy for liver metastases. Cochrane Database Syst Rev 2019;7:CD009058. [PMID: 31291464 DOI: 10.1002/14651858.CD009058.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Shirai D, Shinkawa H, Takemura S, Tanaka S, Amano R, Kimura K, Kinoshita M, Kawada N, Kubo S. Impact of alcohol abstinence on survival after hepatic resection for hepatocellular carcinoma in patients with alcohol-related liver disease. Ann Med Surg (Lond) 2021;68:102644. [PMID: 34386231 DOI: 10.1016/j.amsu.2021.102644] [Reference Citation Analysis]
36 Posadas K, Ankola A, Yang Z, Yee NS. Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study. Biomedicines 2018;6:E46. [PMID: 29673151 DOI: 10.3390/biomedicines6020046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
37 Plahuta I, Jelenko M, Potrč S, Ivanecz A. Abandonment of surveillance, followed by emergency surgery for a second spontaneous rupture of hepatocellular carcinoma: A case report and review of the literature. Clin Case Rep 2019;7:789-96. [PMID: 30997087 DOI: 10.1002/ccr3.2097] [Reference Citation Analysis]
38 Zhou Y, Xue R, Wang J, Ren H. Puerarin inhibits hepatocellular carcinoma invasion and metastasis through miR-21-mediated PTEN/AKT signaling to suppress the epithelial-mesenchymal transition. Braz J Med Biol Res 2020;53:e8882. [PMID: 32294699 DOI: 10.1590/1414-431X20198882] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
39 Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLoS One 2020;15:e0240542. [PMID: 33052942 DOI: 10.1371/journal.pone.0240542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 Rodríguez MM, Onorato A, Cantero MJ, Domínguez L, Bayo J, Fiore E, García M, Atorrasagasti C, Canbay A, Malvicini M, Mazzolini GD. 4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice. Sci Rep 2021;11:6310. [PMID: 33737571 DOI: 10.1038/s41598-021-85491-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
41 Liu H, Yang M, Dong Z. HSPB11 is a Prognostic Biomarker Associated with Immune Infiltrates in Hepatocellular Carcinoma. IJGM 2022;Volume 15:4017-27. [DOI: 10.2147/ijgm.s363679] [Reference Citation Analysis]
42 Li L, Li B, Zhang M. Postoperative adjuvant transarterial chemoembolization improves the prognosis of hepatocellular carcinoma patients with microvascular invasion: a systematic review and meta-analysis. Acta Radiol 2020;61:723-31. [PMID: 31594382 DOI: 10.1177/0284185119878357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Guo B, Xu X, Shao M, Yang X, He G, Qi K, Gu J, Wang L. UDP-glucose 6-dehydrogenase lessens sorafenib sensitivity via modulating unfolded protein response. Biochem Biophys Res Commun 2022;613:207-13. [PMID: 35617808 DOI: 10.1016/j.bbrc.2022.05.048] [Reference Citation Analysis]
44 Mansur A, Garg T, Shrigiriwar A, Etezadi V, Georgiades C, Habibollahi P, Huber TC, Camacho JC, Nour SG, Sag AA, Prologo JD, Nezami N. Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors. Diagnostics 2022;12:1300. [DOI: 10.3390/diagnostics12061300] [Reference Citation Analysis]
45 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Reference Citation Analysis]
46 Fukushima T, Morimoto M, Kobayashi S, Ueno M, Sano Y, Kawano K, Asama H, Nagashima S, Maeda S. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. Mol Clin Oncol 2021;14:119. [PMID: 33903825 DOI: 10.3892/mco.2021.2281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Tian Z, Hong B, Chen J, Tang Z. Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis. Front Oncol 2022;12:891724. [PMID: 35719978 DOI: 10.3389/fonc.2022.891724] [Reference Citation Analysis]
48 Cui H, Rong W, Ma J, Zhu Q, Jiang B, Zhang L, Li C, Zhuo Z, Chen M. DNA N6-Adenine methylation in HBV-related hepatocellular carcinoma. Gene 2022;822:146353. [PMID: 35189250 DOI: 10.1016/j.gene.2022.146353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Fan Y, Sun Y, Man C, Lang Y. Preoperative Serum Prealbumin Level and Adverse Prognosis in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis. Front Oncol 2021;11:775425. [PMID: 34746015 DOI: 10.3389/fonc.2021.775425] [Reference Citation Analysis]
50 Xu Q, Xu H, Deng R, Li N, Mu R, Qi Z, Shen Y, Wang Z, Wen J, Zhao J, Weng D, Huang W. Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy. Front Cell Dev Biol 2021;9:669145. [PMID: 34422799 DOI: 10.3389/fcell.2021.669145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Zhao Y, Li K, Sun J, He N, Zhao P, Zang C, Yang X, Hu C, Long J, Zhang H, Wang Q, Zhao Y, Zhang Y. Genomic DNA methylation profiling indicates immune response following thermal ablation treatment for HBV-associated hepatocellular carcinoma. Oncol Lett 2020;20:677-84. [PMID: 32565992 DOI: 10.3892/ol.2020.11636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Tsunoda J, Nishi T, Ito T, Inaguma G, Matsuzaki T, Seki H, Yasui N, Sakata M, Shimada A, Matsumoto H. Laparoscopic repair of diaphragmatic hernia associating with radiofrequency ablation for hepatocellular carcinoma: A case report. World J Clin Cases 2022; 10(20): 7020-7028 [DOI: 10.12998/wjcc.v10.i20.7020] [Reference Citation Analysis]
53 Gao Z, Zhong M, Ye Z, Wu Z, Xiong Y, Ma J, Chen H, Zhu Y, Yang Y, Zhao Y, Zhang Z. PAK3 promotes the metastasis of hepatocellular carcinoma by regulating EMT process. J Cancer 2022;13:153-61. [PMID: 34976179 DOI: 10.7150/jca.61918] [Reference Citation Analysis]
54 Yeow YL, Wu J, Wang X, Winteringham L, Feindel KW, Tirnitz-Parker JEE, Leedman PJ, Ganss R, Hamzah J. ECM Depletion Is Required to Improve the Intratumoral Uptake of Iron Oxide Nanoparticles in Poorly Perfused Hepatocellular Carcinoma. Front Oncol 2022;12:837234. [PMID: 35273916 DOI: 10.3389/fonc.2022.837234] [Reference Citation Analysis]
55 Hassouna MM, Naguib M, Radwan EM, Abdel-Samiee M, Estaphan S, Abdelsameea E. DNA Methyltransferases as Potential Biomarkers for HCV Related Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2020;21:3357-63. [PMID: 33247696 DOI: 10.31557/APJCP.2020.21.11.3357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Yan WT, Quan B, Yu JJ, Yang T. Should we invariably follow the current guidelines to treat our HCC patients? Hepatobiliary Pancreat Dis Int 2019;18:301-2. [PMID: 30686653 DOI: 10.1016/j.hbpd.2019.01.005] [Reference Citation Analysis]
57 Salman A, Aon M, Hussein A, Salman M, Tourky M, Mahmoud A, Aljarad F, Elkaseer M, Shaaban HE, Moustafa A, El-Mikkawy A, Gaballa N, Abdallah H, Zaky Rashed ZF, Elkassar H. Impact of Hypothyroidism on Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. Int J Gen Med 2021;14:5711-8. [PMID: 34557025 DOI: 10.2147/IJGM.S326315] [Reference Citation Analysis]
58 Zou X, Tang XY, Qu ZY, Sun ZW, Ji CF, Li YJ, Guo SD. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. Int J Biol Macromol 2022;202:539-57. [PMID: 35074329 DOI: 10.1016/j.ijbiomac.2022.01.113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Xue S, Lu F, Sun C, Zhao J, Zhen H, Li X. LncRNA ZEB1-AS1 regulates hepatocellular carcinoma progression by targeting miR-23c. World J Surg Oncol 2021;19:121. [PMID: 33865414 DOI: 10.1186/s12957-021-02176-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Qu D, Wang Y, Xia Q, Chang J, Jiang X, Zhang H. Intratumoral Microbiome of Human Primary Liver Cancer. Hepatol Commun 2022. [PMID: 35191218 DOI: 10.1002/hep4.1908] [Reference Citation Analysis]
61 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Piñero F, Rubinstein F, Marciano S, Fernández N, Silva J, Zambelo Y, Anders M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?Dig Dis Sci. 2019;64:718-728. [PMID: 30511199 DOI: 10.1007/s10620-018-5390-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
63 Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Sci Rep 2020;10:17054. [PMID: 33051476 DOI: 10.1038/s41598-020-73930-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Pinter M, Sieghart W. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? Memo 2018;11:185-92. [PMID: 30220924 DOI: 10.1007/s12254-018-0431-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Chen J, Cao J, Wang P, He X. NT5DC2 is a novel prognostic marker in human hepatocellular carcinoma. Oncol Lett 2020;20:70. [PMID: 32863903 DOI: 10.3892/ol.2020.11931] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Zhang Y, Li L, Liu R, Zeng C. DNA Primase Subunit 1 Expression in Hepatocellular Carcinoma and Its Clinical Implication. Biomed Res Int 2020;2020:9689312. [PMID: 32908930 DOI: 10.1155/2020/9689312] [Reference Citation Analysis]
67 Chen X, Liao L, Li Y, Huang H, Huang Q, Deng S. Screening and Functional Prediction of Key Candidate Genes in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Biomed Res Int 2020;2020:7653506. [PMID: 33102593 DOI: 10.1155/2020/7653506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Li W, Dong X, He C, Tan G, Li Z, Zhai B, Feng J, Jiang X, Liu C, Jiang H, Sun X. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res 2019;38:183. [PMID: 31053148 DOI: 10.1186/s13046-019-1177-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 16.7] [Reference Citation Analysis]
69 Gao L, Morine Y, Yamada S, Saito Y, Ikemoto T, Tokuda K, Takasu C, Miyazaki K, Shimada M. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells. PLoS One 2021;16:e0256755. [PMID: 34473785 DOI: 10.1371/journal.pone.0256755] [Reference Citation Analysis]
70 Takahashi H, Kawaguchi T, Yan L, Peng X, Qi Q, Morris LGT, Chan TA, Tsung A, Otsuji E, Takabe K. Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1221. [PMID: 32414098 DOI: 10.3390/cancers12051221] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
71 Dipasquale A, Marinello A, Santoro A. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. J Hepatocell Carcinoma 2021;8:241-51. [PMID: 33884259 DOI: 10.2147/JHC.S270532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Gundlach JP, Linecker M, Dobbermann H, Wadle F, Becker T, Braun F. Patients Benefit from Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria without Harming the Health Care System. Cancers (Basel) 2022;14:1136. [PMID: 35267443 DOI: 10.3390/cancers14051136] [Reference Citation Analysis]
73 Liu ZG, Chen XH, Yu ZJ, Lv J, Ren ZG. Recent progress in pulsed electric field ablation for liver cancer. World J Gastroenterol 2020; 26(24): 3421-3431 [PMID: 32655266 DOI: 10.3748/wjg.v26.i24.3421] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Zhou Q, Zhou Q, Liu Q, He Z, Yan Y, Lin J, Chen Z, He C, Mao K, Wang J, Zhou Z, Xiao Z, Zhang J. PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK. Theranostics 2020;10:10345-59. [PMID: 32929353 DOI: 10.7150/thno.42069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Fang C, Xie H, Zhao J, Wang W, Hou H, Zhang B, Zhou D, Geng X. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma. Anticancer Drugs 2021;32:822-8. [PMID: 33783376 DOI: 10.1097/CAD.0000000000001074] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Kaushik AC, Kumar A, Yu C, Kuo S, Liang S, Singh SP, Wang X, Wang Y, Yen C, Dai X, Wei D, Pan C, Shiue Y. PCL–DOX microdroplets: an evaluation of the enhanced intracellular delivery of doxorubicin in metastatic cancer cells via in silico and in vitro approaches. New J Chem 2019;43:12241-56. [DOI: 10.1039/c9nj01902b] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
77 Li Q, Ma L, Shen S, Guo Y, Cao Q, Cai X, Feng J, Yan Y, Hu T, Luo S, Zhou L, Peng B, Yang Z, Hua Y. Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment. J Exp Clin Cancer Res. 2019;38:303. [PMID: 31296243 DOI: 10.1186/s13046-019-1271-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Liu Z, Fu Z, Li G, Lin D. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report. Onco Targets Ther 2020;13:10267-73. [PMID: 33116607 DOI: 10.2147/OTT.S261521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Zhang Q, Zhang X, Dong W. TRAF7 contributes to tumor progression by promoting ubiquitin-proteasome mediated degradation of P53 in hepatocellular carcinoma. Cell Death Discov 2021;7:352. [PMID: 34775479 DOI: 10.1038/s41420-021-00749-w] [Reference Citation Analysis]
80 Maegawa FB, Shehorn L, Aziz H, Kettelle J, Jie T, Riall TS. Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma. JAMA Netw Open 2019;2:e187142. [PMID: 30657533 DOI: 10.1001/jamanetworkopen.2018.7142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
81 Zhang DG, Gong CC, Wu XJ, Ren X, Sedaka RS, Chen WC, Huo FC, Chen C, Du WQ, Pei DS. P21-activated kinase 5 potentiates the chemoresistant phenotype of liver cancer. Signal Transduct Target Ther 2021;6:47. [PMID: 33542180 DOI: 10.1038/s41392-020-00409-y] [Reference Citation Analysis]
82 Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
83 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
84 Dang W, Chen W, Ju E, Xu Y, Li K, Wang H, Wang K, Lv S, Shao D, Tao Y, Li M. 3D printed hydrogel scaffolds combining glutathione depletion-induced ferroptosis and photothermia-augmented chemodynamic therapy for efficiently inhibiting postoperative tumor recurrence. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01454-1] [Reference Citation Analysis]
85 Liu Y, Deng H, Liang L, Zhang G, Xia J, Ding K, Tang N, Wang K. Depletion of VPS35 attenuates metastasis of hepatocellular carcinoma by restraining the Wnt/PCP signaling pathway. Genes Dis 2021;8:232-40. [PMID: 33997170 DOI: 10.1016/j.gendis.2020.07.009] [Reference Citation Analysis]
86 Yang D, Zhuang B, Wang Y, Xie X, Xie X. Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis. BMC Gastroenterol 2020;20:402. [PMID: 33246417 DOI: 10.1186/s12876-020-01544-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Meng L, Xu KX, Zhao MX, Li K, Zhu K, Yuan DW, Wang HN, Dai PG, Yan R. Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2611-8. [PMID: 34561331 DOI: 10.1097/CM9.0000000000001655] [Reference Citation Analysis]
88 O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 2018; 24(39): 4436-4447 [PMID: 30357021 DOI: 10.3748/wjg.v24.i39.4436] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
89 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
90 Cui R, Yu J, Gu Y, Cao F, Liu FY, Dong LN, Liang P. Microwave ablation assisted by three-dimensional visualization system as local therapy for relapsed hepatoblastoma: a small pilot study. Abdom Radiol (NY) 2019;44:2909-15. [PMID: 31089779 DOI: 10.1007/s00261-019-02011-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
91 Alunni-Fabbroni M, Weber S, Öcal O, Seidensticker M, Mayerle J, Malfertheiner P, Ricke J. Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers (Basel) 2021;13:521. [PMID: 33572923 DOI: 10.3390/cancers13030521] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Pan Q, Yi C, Zhang Y. Overall Survival Signature of 5-Methylcytosine Regulators Related Long Non-Coding RNA in Hepatocellular Carcinoma. Front Oncol 2022;12:884377. [PMID: 35686101 DOI: 10.3389/fonc.2022.884377] [Reference Citation Analysis]
93 Michelakos T, Xourafas D, Qadan M, Pieretti-Vanmarcke R, Cai L, Patel MS, Adler JT, Fontan F, Basit U, Vagefi PA, Elias N, Tanabe KK, Berger D, Yeh H, Markmann JF, Chang DC, Ferrone CR. Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation? J Gastrointest Surg 2019;23:1135-42. [PMID: 30218342 DOI: 10.1007/s11605-018-3946-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
94 Liu Y, Xia H, Li M, Chen Y, Zhou W, Chen Y, Wu Y, Ali L. Overexpressed RING Finger 44 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Journal of Healthcare Engineering 2022;2022:1-18. [DOI: 10.1155/2022/3522866] [Reference Citation Analysis]
95 Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. [PMID: 33877527 DOI: 10.1007/s12072-021-10184-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Li XY, Shen Y, Zhang L, Guo X, Wu J. Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochim Biophys Acta Rev Cancer 2022;:188720. [PMID: 35304295 DOI: 10.1016/j.bbcan.2022.188720] [Reference Citation Analysis]
97 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Yong-jiea T, Zhuob L, Liuc L, Yuanc C, Xiao-did H, Xue-feic T. STAT3 Inhibition by Centipede Scolopendra Extract in Liver Cancer HepG2 Cells and Orthotopic Mouse Models of Hepatocellular Carcinoma. Digital Chinese Medicine 2020;3:67-79. [DOI: 10.1016/j.dcmed.2020.06.002] [Reference Citation Analysis]
99 Zhen Z, Shen Z, Sun P. Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway. Bioengineered 2022;13:9467-81. [PMID: 35389768 DOI: 10.1080/21655979.2022.2060778] [Reference Citation Analysis]
100 Sorop A, Constantinescu D, Cojocaru F, Dinischiotu A, Cucu D, Dima SO. Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:4997. [PMID: 34066780 DOI: 10.3390/ijms22094997] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Hao Q, Han Y, Xia W, Wang Q, Qian H. Systematic Review and Meta-Analysis of the Utility of Circular RNAs as Biomarkers of Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2019;2019:1684039. [PMID: 31187026 DOI: 10.1155/2019/1684039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
102 Sun X, Zhang Q, Mei J, Yang Z, Chen M, Liang T. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09405-7] [Reference Citation Analysis]
103 Li W, Wu H, Xu X, Zhang Y. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. Aging (Albany NY) 2021;13:11564-94. [PMID: 33867349 DOI: 10.18632/aging.202853] [Reference Citation Analysis]
104 Jiang Y, Fang Y, Ye Y, Xu X, Wang B, Gu J, Aschner M, Chen J, Lu R. Anti-Cancer Effects of 3, 3'-Diindolylmethane on Human Hepatocellular Carcinoma Cells Is Enhanced by Calcium Ionophore: The Role of Cytosolic Ca2+ and p38 MAPK. Front Pharmacol 2019;10:1167. [PMID: 31649538 DOI: 10.3389/fphar.2019.01167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
105 Raghunath A, Sundarraj K, Arfuso F, Sethi G, Perumal E. Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers (Basel) 2018;10:E481. [PMID: 30513925 DOI: 10.3390/cancers10120481] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 17.0] [Reference Citation Analysis]
106 Jiang Z, Xing C, Wang P, Liu X, Zhong L. Identification of Therapeutic Targets and Prognostic Biomarkers Among Chemokine (C-C Motif) Ligands in the Liver Hepatocellular Carcinoma Microenvironment. Front Cell Dev Biol 2021;9:748269. [PMID: 34938730 DOI: 10.3389/fcell.2021.748269] [Reference Citation Analysis]
107 Li C, Wang MD, Lu L, Wu H, Yu JJ, Zhang WG, Pawlik TM, Zhang YM, Zhou YH, Gu WM, Wang H, Chen TH, Han J, Xing H, Li ZL, Lau WY, Wu MC, Shen F, Yang T. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis. Hepatol Int 2019;13:736-47. [PMID: 31486964 DOI: 10.1007/s12072-019-09981-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
108 Wu Y, Tu C, Shao C. The value of preoperative systemic immune-inflammation index in predicting vascular invasion of hepatocellular carcinoma: a meta-analysis. Braz J Med Biol Res 2021;54:e10273. [PMID: 33656054 DOI: 10.1590/1414-431X202010273] [Reference Citation Analysis]
109 Wang Y, Huang Q, Deng T, Li BH, Ren XQ. Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study. Med Sci Monit 2019;25:3894-901. [PMID: 31128068 DOI: 10.12659/MSM.913556] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
110 Hanafy AS, Mohamed MS, Taleb MA, Mohammed HM, Ibrahim TMH, Saber S, Atia HA. Predictors of residual hepatic reserve and hepatic decompensation in cirrhotic patients after ablated hepatocellular carcinoma treated by DDAs or systemic therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00151-2] [Reference Citation Analysis]
111 Fernández-Varo G, Perramón M, Carvajal S, Oró D, Casals E, Boix L, Oller L, Macías-Muñoz L, Marfà S, Casals G, Morales-Ruiz M, Casado P, Cutillas PR, Bruix J, Navasa M, Fuster J, Garcia-Valdecasas JC, Pavel MC, Puntes V, Jiménez W. Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. Hepatology 2020;72:1267-82. [PMID: 31961955 DOI: 10.1002/hep.31139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
112 Wang R, Liu Y, Sun H, Wang T, Li C, Fan J, Wang Z. Estradiol is significantly associated with prognosis in non-surgical liver cancer patients: from bench to bedside. Aging (Albany NY) 2021;13:3483-500. [PMID: 33428602 DOI: 10.18632/aging.202280] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? Front Oncol 2021;11:803133. [PMID: 34976841 DOI: 10.3389/fonc.2021.803133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Wang L, Guo Y, Zhang H, Li H, Wang F, Zhang J, Li X, M.a B. Risk Factors for Brain Metastasis of Hepatocellular Carcinoma. Journal of Healthcare Engineering 2022;2022:1-5. [DOI: 10.1155/2022/7848143] [Reference Citation Analysis]
115 Chen F, Zhang K, Huang Y, Luo F, Hu K, Cai Q. SPC25 may promote proliferation and metastasis of hepatocellular carcinoma via p53. FEBS Open Bio 2020;10:1261-75. [PMID: 32351050 DOI: 10.1002/2211-5463.12872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
116 Yang Y, Jin M, Dai Y, Shan W, Chen S, Cai R, Yang H, Tang L, Li L. Involvement and Targeted Intervention of Mortalin-Regulated Proteome Phosphorylated-Modification in Hepatocellular Carcinoma. Front Oncol 2021;11:687871. [PMID: 34395254 DOI: 10.3389/fonc.2021.687871] [Reference Citation Analysis]
117 Wang C, Jiang X, Huang B, Zhou W, Cui X, Zheng C, Liu F, Bi J, Zhang Y, Luo H, Yuan L, Yang J, Yu Y. Inhibition of matrix stiffness relating integrin β1 signaling pathway inhibits tumor growth in vitro and in hepatocellular cancer xenografts. BMC Cancer 2021;21:1276. [PMID: 34823500 DOI: 10.1186/s12885-021-08982-3] [Reference Citation Analysis]
118 Huang JC, Emran AA, Endaya JM, McCaughan GW, Gorrell MD, Zhang HE. DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1637. [PMID: 33915844 DOI: 10.3390/cancers13071637] [Reference Citation Analysis]
119 Cao P, Ma B, Sun D, Zhang W, Qiu J, Qin L, Xue X. hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis. Cancer Sci 2021. [PMID: 34890089 DOI: 10.1111/cas.15238] [Reference Citation Analysis]
120 Lee JS, Chon YE, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kang W, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Kim HY, Kim TH, Yoo K, Ha Y, Kim MN, Lee JH, Hwang SG, Kim SS, Cho HJ, Cheong JY, Cho SW, Park SH, Heo NY, Hong YM, Yoon KT, Cho M, Park JG, Kang MK, Park SY, Kweon YO, Tak WY, Jang SY, Sinn DH, Kim SU; Korean TACE Study Group. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Med J 2021;62:12-20. [PMID: 33381930 DOI: 10.3349/ymj.2021.62.1.12] [Reference Citation Analysis]
121 Xu M, Zhu S, Xu R, Lin N. Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma. BMC Cancer 2020;20:313. [PMID: 32293343 DOI: 10.1186/s12885-020-06813-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Dai X, Guo Y, Hu Y, Bao X, Zhu X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Fang W. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics 2021;11:3489-501. [PMID: 33537099 DOI: 10.7150/thno.54648] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
123 Jin X, Yin J, Zhu H, Li W, Yu K, Liu M, Zhang X, Lu M, Wan Z, Huang X. SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma. Front Pharmacol 2021;12:701454. [PMID: 34456727 DOI: 10.3389/fphar.2021.701454] [Reference Citation Analysis]
124 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
125 Zheng Y, Hlady RA, Joyce BT, Robertson KD, He C, Nannini DR, Kibbe WA, Achenbach CJ, Murphy RL, Roberts LR, Hou L. DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. Clin Epigenetics. 2019;11:145. [PMID: 31639042 DOI: 10.1186/s13148-019-0733-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
126 Chagas AL, Felga GEG, Diniz MA, Silva RF, Mattos AA, Silva RCMA, Boin IFSF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ; Brazilian HCC Study Group. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol 2019;31:1148-56. [PMID: 31247632 DOI: 10.1097/MEG.0000000000001448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
127 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
128 Xu W, Wang Y, Yang Z, Li J, Li R, Liu F. New Insights Into a Classification-Based Microvascular Invasion Prediction Model in Hepatocellular Carcinoma: A Multicenter Study. Front Oncol 2022;12:796311. [PMID: 35433417 DOI: 10.3389/fonc.2022.796311] [Reference Citation Analysis]
129 Mauro E, Forner A. Barcelona Clinic Liver Cancer 2022 update: Linking prognosis prediction and evidence-based treatment recommendation with multidisciplinary clinical decision-making. Liver Int 2022;42:488-91. [PMID: 35194931 DOI: 10.1111/liv.15180] [Reference Citation Analysis]
130 Zhang L, Wu L, Chen Q, Zhang B, Liu J, Liu S, Mo X, Li M, Chen Z, Chen L, You J, Jin Z, Chen X, Zhou Z, Zhang S. Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. EClinicalMedicine 2021;31:100673. [PMID: 33554079 DOI: 10.1016/j.eclinm.2020.100673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
131 Li X, Liu L, Hu Y. Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis. Biosci Rep 2020;40:BSR20200232. [PMID: 32162652 DOI: 10.1042/BSR20200232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
132 Wang J, Zhang C, Li A, Cao F, Liu D, Li F, Luo T. A Prognostic Nomogram Based on Immune Scores Predicts Postoperative Survival for Patients with Hepatocellular Carcinoma. Biomed Res Int 2020;2020:1542394. [PMID: 32724794 DOI: 10.1155/2020/1542394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
134 Zhang L, Makamure J, Zhao D, Liu Y, Guo X, Zheng C, Liang B. Bioinformatics analysis reveals meaningful markers and outcome predictors in HBV-associated hepatocellular carcinoma. Exp Ther Med 2020;20:427-35. [PMID: 32537007 DOI: 10.3892/etm.2020.8722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
135 Xu CY, Dong JF, Chen ZQ, Ding GS, Fu ZR. MiR-942-3p Promotes the Proliferation and Invasion of Hepatocellular Carcinoma Cells by Targeting MBL2. Cancer Control 2019;26:1073274819846593. [PMID: 31046434 DOI: 10.1177/1073274819846593] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
136 Inzerillo A, Meloni MF, Taibbi A, Bartolotta TV. Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography. World J Hepatol 2022; 14(5): 911-922 [DOI: 10.4254/wjh.v14.i5.911] [Reference Citation Analysis]
137 Ricci AD, Rizzo A, Bonucci C, Tavolari S, Palloni A, Frega G, Mollica V, Tober N, Mazzotta E, Felicani C, Serra C, Brandi G. The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. In Vivo 2020;34:3421-9. [PMID: 33144450 DOI: 10.21873/invivo.12181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
138 Yasukawa K, Liew LC, Hagiwara K, Hironaka-Mitsuhashi A, Qin XY, Furutani Y, Tanaka Y, Nakagama H, Kojima S, Kato T, Ochiya T, Gailhouste L. MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion. Cancer Sci 2020;111:869-80. [PMID: 31883160 DOI: 10.1111/cas.14292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
139 Sun J, Liu C, Wang N, Jiang D, Zhang F, Shi J, Cheng S. All-Trans-Retinoic Acid Plus Oxaliplatin/Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis: A Multicenter Retrospective Study. CMAR 2022;Volume 14:1663-70. [DOI: 10.2147/cmar.s354170] [Reference Citation Analysis]
140 Liu Q, Xu X, Sun W. Down-regulated HSA_circ_0003528 inhibits hepatocellular carcinoma aggressiveness via the miR-212-3p/XIAP axis. Bioengineered 2022;13:11269-80. [PMID: 35484994 DOI: 10.1080/21655979.2022.2066046] [Reference Citation Analysis]
141 Wang J, Liu R, Zhao Y, Ma Z, Sang Z, Wen Z, Yang X, Xie H. Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging. Front Oncol 2021;11:743055. [PMID: 34513717 DOI: 10.3389/fonc.2021.743055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
142 Bian Z, Ji W, Xu B, Huang W, Jiao J, Shao J, Zhang X. The role of long noncoding RNA SNHG7 in human cancers (Review). Mol Clin Oncol 2020;13:45. [PMID: 32874575 DOI: 10.3892/mco.2020.2115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Rocque B, Kahn J, Emamaullee J. A Healthy Liver After SVR: Food for Thought. Dig Dis Sci 2021;66:1778-9. [PMID: 32785795 DOI: 10.1007/s10620-020-06547-1] [Reference Citation Analysis]
144 Hsieh YC, Limquiaco JL, Lin CC, Chen WT, Lin SM. Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. Abdom Radiol (NY) 2019;44:1141-51. [PMID: 30460530 DOI: 10.1007/s00261-018-1831-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
145 Chen C, Su N, Li G, Shen Y, Duan X. Long non-coding RNA TMCC1-AS1 predicts poor prognosis and accelerates epithelial-mesenchymal transition in liver cancer. Oncol Lett 2021;22:773. [PMID: 34589152 DOI: 10.3892/ol.2021.13034] [Reference Citation Analysis]
146 Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. Br J Cancer 2021. [PMID: 34400801 DOI: 10.1038/s41416-021-01453-3] [Reference Citation Analysis]
147 Fu J, Cao Z, Zhang J, Chen Q, Wang Y, Wang S, Fang X, Xu X. Identification of two immune-related risk score signatures through integrated analysis of multi-omics data in hepatocellular carcinoma. Gene 2022;829:146519. [PMID: 35447248 DOI: 10.1016/j.gene.2022.146519] [Reference Citation Analysis]
148 Lauko A, Bayik D, Lathia JD. IL-11 drives postsurgical hepatocellular carcinoma recurrence. EBioMedicine 2019;47:18-9. [PMID: 31402232 DOI: 10.1016/j.ebiom.2019.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
149 Chen JY, Han J, Liu ZW, Xin XL, Wang PF, Cai SW. Combined hepatic segment color rendering technique improves the outcome of anatomical hepatectomy in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00132-1. [PMID: 35710483 DOI: 10.1016/j.hbpd.2022.05.014] [Reference Citation Analysis]
150 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
151 Zhang X, Wang F, Gu G, Wu Q. High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients. J Oncol 2021;2021:9938207. [PMID: 34194500 DOI: 10.1155/2021/9938207] [Reference Citation Analysis]
152 Jia KF, Wang H, Yu CL, Yin WL, Zhang XD, Wang F, Sun C, Shen W. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00015-7. [PMID: 35260337 DOI: 10.1016/j.hbpd.2022.02.007] [Reference Citation Analysis]
153 Kalathil SG, Wang K, Hutson A, Iyer R, Thanavala Y. Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. Oncoimmunology 2020;9:1824863. [PMID: 33101775 DOI: 10.1080/2162402X.2020.1824863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
154 Zhang L, Zhou L, Zhang H, Zhang Y, Li L, Xie T, Chen Y, Li X, Ling N, Dai J, Sun X, Liu J, Zhao J, Peng T, Ye M. Development of a DNA Aptamer against Multidrug-Resistant Hepatocellular Carcinoma for In Vivo Imaging. ACS Appl Mater Interfaces 2021;13:54656-64. [PMID: 34779207 DOI: 10.1021/acsami.1c12391] [Reference Citation Analysis]
155 Ke L, Shen J, Feng J, Chen J, Shen S, Li S, Kuang M, Liang L, Lu C, Li D, He Q, Peng B, Hua Y. Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients. Front Mol Biosci 2022;8:800679. [DOI: 10.3389/fmolb.2021.800679] [Reference Citation Analysis]
156 Pan L, Feng F, Wu J, Fan S, Han J, Wang S, Yang L, Liu W, Wang C, Xu K. Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res 2022;:106270. [PMID: 35605812 DOI: 10.1016/j.phrs.2022.106270] [Reference Citation Analysis]
157 Xia F, Zhu P, Chen XP, Zhang BX, Zhang MY. Prognostic Analysis of Postoperative Survival for Ruptured Hepatocellular Carcinoma with or without Cirrhosis. J Oncol 2022;2022:7531452. [PMID: 35342424 DOI: 10.1155/2022/7531452] [Reference Citation Analysis]
158 Wang F, Qi X, Li Z, Jin S, Xie Y, Zhong H. lncRNA CADM1-AS1 inhibits cell-cycle progression and invasion via PTEN/AKT/GSK-3β axis in hepatocellular carcinoma. Cancer Manag Res 2019;11:3813-28. [PMID: 31118799 DOI: 10.2147/CMAR.S197673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
159 Wang H, Qian Y, Wu M, Cong W. Liver Resection Is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma without Microvascular Invasion. J Gastrointest Surg 2020;24:2737-47. [DOI: 10.1007/s11605-019-04251-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
160 Ou H, Chen Z, Xiang L, Fang Y, Xu Y, Liu Q, Hu Z, Li X, Huang Y, Yang D. Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma. Cancer Sci 2019;110:1169-82. [PMID: 30677195 DOI: 10.1111/cas.13949] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
161 Li J, Qin X, Wu R, Wan L, Zhang L, Liu R. Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis. J Cell Mol Med 2020;24:5152-61. [PMID: 32222024 DOI: 10.1111/jcmm.15162] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
162 Tian S, Liao L, Zhou Q, Huang X, Zheng P, Guo Y, Deng T, Tian X. Curcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in murine tumor tissues. Oncol Lett 2021;21:286. [PMID: 33732362 DOI: 10.3892/ol.2021.12547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
163 Li L, Bi Y, Diao S, Li X, Yuan T, Xu T, Huang C, Li J. Exosomal LncRNAs and Hepatocellular Carcinoma: From Basic Research to Clinical Practice. Biochem Pharmacol 2022;:115032. [PMID: 35395241 DOI: 10.1016/j.bcp.2022.115032] [Reference Citation Analysis]
164 El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: Pathologists’ review. World J Gastroenterol 2019; 25(14): 1653-1665 [PMID: 31011252 DOI: 10.3748/wjg.v25.i14.1653] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
165 Ma KW, Chan ACY, Chok KSH, She WH, Cheung TT, Dai WC, Fung JYY, Lo CM. Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion? Hepatobiliary Surg Nutr 2021;10:308-14. [PMID: 34159158 DOI: 10.21037/hbsn.2020.03.09] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Adhoute X, Pénaranda G, Raoul JL, Bronowicki JP, Anty R, Bourlière M. “Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort. World J Hepatol 2020; 12(8): 525-532 [PMID: 32952879 DOI: 10.4254/wjh.v12.i8.525] [Reference Citation Analysis]
167 Yang N, Wang L, Chen T, Liu R, Liu Z, Zhang L. ZNF521 which is downregulated by miR-802 suppresses malignant progression of Hepatocellular Carcinoma through regulating Runx2 expression. J Cancer 2020;11:5831-9. [PMID: 32913476 DOI: 10.7150/jca.45190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
168 Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 2020;5:87. [PMID: 32532960 DOI: 10.1038/s41392-020-0187-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
169 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
170 Zhou T, Li S, Xiang D, Liu J, Sun W, Cui X, Ning B, Li X, Cheng Z, Jiang W, Zhang C, Liang X, Li L, Cheng X, Hui L, Wang H, Ding J. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance. Signal Transduct Target Ther 2020;5:296. [PMID: 33361765 DOI: 10.1038/s41392-020-00299-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
171 Zhu HB, Zheng ZY, Zhao H, Zhang J, Zhu H, Li YH, Dong ZY, Xiao LS, Kuang JJ, Zhang XL, Liu L. Radiomics-based nomogram using CT imaging for noninvasive preoperative prediction of early recurrence in patients with hepatocellular carcinoma.Diagn Interv Radiol. 2020;26:411-419. [PMID: 32490826 DOI: 10.5152/dir.2020.19623] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
172 Chandrapalan S, Bannaga A, Weidner A, Hitchins MP, Arasaradnam RP. A systematic review and meta-analysis: the diagnostic accuracy of methylated SEPTIN9 for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. Scand J Gastroenterol 2021;:1-8. [PMID: 34957898 DOI: 10.1080/00365521.2021.2020331] [Reference Citation Analysis]
173 Low ES, Apostolov R, Wong D, Lin S, Kutaiba N, Grace JA, Sinclair M. Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients. World J Gastrointest Oncol 2021; 13(12): 2149-2160 [DOI: 10.4251/wjgo.v13.i12.2149] [Reference Citation Analysis]
174 Shi Y, Long H, Zhong X, Peng J, Su L, Duan Y, Ke W, Xie X, Lin M. The Value of Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110248] [Reference Citation Analysis]
175 Zhang D, Lin Z, Wu M, Cai Z, Zheng Y, He L, Li Z, Zhou J, Sun L, Chen G, Zeng Y, Li J, Liu J, Yang H, Liu X. Cytosolic Delivery of Thiolated Neoantigen Nano-Vaccine Combined with Immune Checkpoint Blockade to Boost Anti-Cancer T Cell Immunity. Adv Sci (Weinh) 2021;8:2003504. [PMID: 33747739 DOI: 10.1002/advs.202003504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
176 van Doorn DJ, Takkenberg RB, Klümpen HJ. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals (Basel) 2020;14:3. [PMID: 33374927 DOI: 10.3390/ph14010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Patella F, Pesapane F, Fumarola E, Zannoni S, Brambillasca P, Emili I, Costa G, Anderson V, Levy EB, Carrafiello G, Wood BJ. Assessment of the response of hepatocellular carcinoma to interventional radiology treatments. Future Oncol 2019;15:1791-804. [PMID: 31044615 DOI: 10.2217/fon-2018-0747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
178 Zhu G, Xia H, Tang Q, Bi F. An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients. Cancer Cell Int 2021;21:166. [PMID: 33712026 DOI: 10.1186/s12935-021-01864-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Kiruthiga C, Devi KP, Nabavi SM, Bishayee A. Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E562. [PMID: 32121322 DOI: 10.3390/cancers12030562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
180 Duan Y, Li J, Jing X, Ding X, Yu Y, Zhao Q. Fucoidan Induces Apoptosis and Inhibits Proliferation of Hepatocellular Carcinoma via the p38 MAPK/ERK and PI3K/Akt Signal Pathways. Cancer Manag Res 2020;12:1713-23. [PMID: 32210612 DOI: 10.2147/CMAR.S243495] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
181 Zhao D, Jiang M, Zhang X, Hou H. The role of RICTOR amplification in targeted therapy and drug resistance. Mol Med 2020;26:20. [PMID: 32041519 DOI: 10.1186/s10020-020-0146-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
182 Wang X, Chen M, Liang X, Bai Y, Zeng J, Xu X, Li H, Wang J, Fan K, Zhao G. RNF135 Promoter Methylation Is Associated With Immune Infiltration and Prognosis in Hepatocellular Carcinoma. Front Oncol 2022;11:752511. [DOI: 10.3389/fonc.2021.752511] [Reference Citation Analysis]
183 Li L, Xia S, Shi X, Chen X, Shang D. The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma. Sci Rep 2021;11:10728. [PMID: 34021184 DOI: 10.1038/s41598-021-89747-7] [Reference Citation Analysis]
184 Di Sandro S, Danieli M, Ferla F, Lauterio A, De Carlis R, Benuzzi L, Buscemi V, Pezzoli I, De Carlis L. The current role of laparoscopic resection for HCC: a systematic review of past ten years. Transl Gastroenterol Hepatol 2018;3:68. [PMID: 30363804 DOI: 10.21037/tgh.2018.08.05] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
185 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 He F, Song K, Guan G, Huo J, Xin Y, Li T, Liu C, Zhu Q, Fan N, Guo Y, Wu L. The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma. Pharmgenomics Pers Med 2021;14:723-36. [PMID: 34188519 DOI: 10.2147/PGPM.S313848] [Reference Citation Analysis]
187 Oh H, Lee JH. Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Ann Transl Med 2020;8:1530. [PMID: 33313275 DOI: 10.21037/atm-20-3526] [Reference Citation Analysis]
188 Zheng Y, Zhang X, Lu J, Liu S, Qian Y. Association between socioeconomic status and survival in patients with hepatocellular carcinoma. Cancer Med 2021;10:7347-59. [PMID: 34414679 DOI: 10.1002/cam4.4223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Sun H, Feng F, Xie H, Li X, Jiang Q, Chai Y, Wang Z, Yang R, Li R, Hou J. Quantitative examination of the inhibitory activation of molecular targeting agents in hepatocellular carcinoma patient-derived cell invasion via a novel in vivo tumor model. Animal Model Exp Med 2019;2:259-68. [PMID: 31942558 DOI: 10.1002/ame2.12085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
190 Li SS, Chen DM, Chen LB, Wei H, Wang JL, Xiao J, Huang YH, Lian YF. GTSE1 promotes SNAIL1 degradation by facilitating its nuclear export in hepatocellular carcin oma cells. Mol Med Rep 2021;23:454. [PMID: 33880590 DOI: 10.3892/mmr.2021.12093] [Reference Citation Analysis]
191 Cai H, Yang Y, Peng F, Liu Y, Fu X, Ji B. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells. Int J Med Sci 2019;16:1541-8. [PMID: 31839741 DOI: 10.7150/ijms.37427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
192 Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev 2022;1:CD013345. [PMID: 34981511 DOI: 10.1002/14651858.CD013345.pub2] [Reference Citation Analysis]
193 Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R, Albadawi H, Oklu R. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. J Clin Med 2019;8:E55. [PMID: 30621040 DOI: 10.3390/jcm8010055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
194 Shui L, Wang W, Xie M, Ye B, Li X, Liu Y, Zheng M. Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway. Aging (Albany NY) 2020;12:24318-32. [PMID: 33260158 DOI: 10.18632/aging.202237] [Reference Citation Analysis]
195 Du W, Zhang X, Wan Z. miR-3691-5p promotes hepatocellular carcinoma cell migration and invasion through activating PI3K/Akt signaling by targeting PTEN. Onco Targets Ther 2019;12:4897-906. [PMID: 31417285 DOI: 10.2147/OTT.S208127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
196 Pradhan-Sundd T, Monga SP. Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology. Gene Expr 2019;19:69-87. [PMID: 30646969 DOI: 10.3727/105221619X15469715711907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
197 Bai Y, Tong W, Xie F, Zhu L, Wu H, Shi R, Wang L, Yang L, Liu Z, Miao F, Zhao Q, Zhang Y. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Aging (Albany NY) 2021;13:17592-606. [PMID: 34237708 DOI: 10.18632/aging.203249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Hao F, Wang N, Wang X, Chen Y, Wang J. Identification of prognostic long non-coding RNA signature with potential drugs in hepatocellular carcinoma. Aging (Albany NY) 2021;13:18789-805. [PMID: 34285143 DOI: 10.18632/aging.203322] [Reference Citation Analysis]
199 Wei JW, Fu SR, Zhang J, Gu DS, Li XQ, Chen XD, Zhang ST, He XF, Yan JF, Lu LG, Tian J. CT-based radiomics to predict development of macrovascular invasion in hepatocellular carcinoma: A multicenter study. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00198-3. [PMID: 34674948 DOI: 10.1016/j.hbpd.2021.09.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Zhou T, Liang X, Wang P, Hu Y, Qi Y, Jin Y, Du Y, Fang C, Tian J. A Hepatocellular Carcinoma Targeting Nanostrategy with Hypoxia-Ameliorating and Photothermal Abilities that, Combined with Immunotherapy, Inhibits Metastasis and Recurrence. ACS Nano 2020;14:12679-96. [PMID: 32909732 DOI: 10.1021/acsnano.0c01453] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 24.0] [Reference Citation Analysis]
201 Berman RM, Kelada OJ, Gutsche NT, Natarajan R, Swenson RE, Fu Y, Hong J, Ho M, Choyke PL, Escorcia FE. In Vitro Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency. Cancer Biother Radiopharm 2019;34:498-503. [PMID: 31424293 DOI: 10.1089/cbr.2019.2888] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
202 Cabibbo G, Aghemo A, Lai Q, Masarone M, Montagnese S, Ponziani FR. Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.01.122] [Reference Citation Analysis]
203 Bose D, Chaudhary A, Padmavati M, Chatterjee J, Banerjee R. In vitro evaluation of anti-proliferative activity of protein from Litchi chinensis honey against human cervical cancer cell line (HeLa). Journal of Herbal Medicine 2022;31:100518. [DOI: 10.1016/j.hermed.2021.100518] [Reference Citation Analysis]
204 Yamamoto M, Xin B, Nishikawa Y. Mouse Model for Hepatocellular Carcinoma and Cholangiocarcinoma Originated from Mature Hepatocytes. In: Tanimizu N, editor. Hepatic Stem Cells. New York: Springer; 2019. pp. 221-36. [DOI: 10.1007/978-1-4939-8961-4_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
205 Chen QF, Dai L, Wu Y, Huang Z, Chen M, Zhao M. Surveillance Strategy for Barcelona Clinic Liver Cancer B Hepatocellular Carcinoma Achieving Complete Response: An Individualized Risk-Based Machine Learning Study. Front Bioeng Biotechnol 2021;9:667641. [PMID: 34540812 DOI: 10.3389/fbioe.2021.667641] [Reference Citation Analysis]
206 Bortolami M, Comparato A, Benna C, Errico A, Maretto I, Pucciarelli S, Cillo U, Farinati F. Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and "normal" liver tissues. PLoS One 2020;15:e0244356. [PMID: 33362215 DOI: 10.1371/journal.pone.0244356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
207 Shi Y, Yang X, Xue X, Sun D, Cai P, Song Q, Zhang B, Qin L. HANR Enhances Autophagy-Associated Sorafenib Resistance Through miR-29b/ATG9A Axis in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:2127-37. [PMID: 32210579 DOI: 10.2147/OTT.S229913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
208 Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma 2019;6:31-9. [PMID: 30775342 DOI: 10.2147/JHC.S168953] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
209 Kong J, Yao C, Dong S, Wu S, Xu Y, Li K, Ji L, Shen Q, Zhang Q, Zhan R, Cui H, Zhou C, Niu H, Li G, Sun W, Zheng L. ICAM-1 Activates Platelets and Promotes Endothelial Permeability through VE-Cadherin after Insufficient Radiofrequency Ablation. Adv Sci (Weinh) 2021;8:2002228. [PMID: 33643788 DOI: 10.1002/advs.202002228] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
210 Greten TF. Gender disparity in HCC: Is it the fat and not the sex? J Exp Med 2019;216:1014-5. [PMID: 31000682 DOI: 10.1084/jem.20190441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
211 Deng L, Huang S, Chen B, Tang Y, Huang F, Li D, Tang D. Tumor-Linked Macrophages Promote HCC Development by Mediating the CCAT1/Let-7b/HMGA2 Signaling Pathway. Onco Targets Ther 2020;13:12829-43. [PMID: 33363387 DOI: 10.2147/OTT.S283786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Li R, Shui L, Jia J, Wu C. Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma. Front Genet 2020;11:906. [PMID: 32922438 DOI: 10.3389/fgene.2020.00906] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
213 Long J, Liu L, Zhou X, Lu X, Qin L, Ding X. HLA-DQB1-AS1 Promotes Cell Proliferation, Inhibits Apoptosis, and Binds with ZRANB2 Protein in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/7130634] [Reference Citation Analysis]
214 Xiaoqian W, Bing Z, Yangwei L, Yafei Z, Tingting Z, Yi W, Qingjun L, Suxia L, Ling Z, Bo W, Peng Z. DEAD-box Helicase 27 Promotes Hepatocellular Carcinoma Progression Through ERK Signaling. Technol Cancer Res Treat 2021;20:15330338211055953. [PMID: 34855554 DOI: 10.1177/15330338211055953] [Reference Citation Analysis]
215 Zhang J, Song Q, Liu J, Lu L, Xu Y, Zheng W. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma. Dis Markers 2019;2019:8964015. [PMID: 31781310 DOI: 10.1155/2019/8964015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
216 Lee S, Jung J, Park JH, Kim SY, Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Park HH, Kim JH, Yoon SM. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. BMC Cancer 2022;22:175. [PMID: 35172769 DOI: 10.1186/s12885-022-09263-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 He M, Zhang P, Ma X, He B, Fang C, Jia F. Radiomic Feature-Based Predictive Model for Microvascular Invasion in Patients With Hepatocellular Carcinoma. Front Oncol. 2020;10:574228. [PMID: 33251138 DOI: 10.3389/fonc.2020.574228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
218 Gnocchi D, Del Coco L, Girelli CR, Castellaneta F, Cesari G, Sabbà C, Fanizzi FP, Mazzocca A. 1H-NMR metabolomics reveals a multitarget action of Crithmum maritimum ethyl acetate extract in inhibiting hepatocellular carcinoma cell growth. Sci Rep 2021;11:1259. [PMID: 33441568 DOI: 10.1038/s41598-020-78867-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;:1-11. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Reference Citation Analysis]
220 Xu M, Hu J, Zhou B, Zhong Y, Lin N, Xu R. TRIM29 prevents hepatocellular carcinoma progression by inhibiting Wnt/β-catenin signaling pathway. Acta Biochim Biophys Sin (Shanghai) 2019;51:68-77. [PMID: 30566565 DOI: 10.1093/abbs/gmy151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
221 Huang X, Fan M, Huang W. Pleiotropic roles of FXR in liver and colorectal cancers. Mol Cell Endocrinol 2022;543:111543. [PMID: 34995680 DOI: 10.1016/j.mce.2021.111543] [Reference Citation Analysis]
222 Wang Z, Pan L, Guo D, Luo X, Tang J, Yang W, Zhang Y, Luo A, Gu Y, Pan Y. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma. Cancer Med 2021;10:3808-21. [PMID: 33934539 DOI: 10.1002/cam4.3900] [Reference Citation Analysis]
223 Romano J, Forster E. Hepatocellular Carcinoma in a Patient With Hepatic Steatosis. ACG Case Rep J 2020;7:e00378. [PMID: 32607378 DOI: 10.14309/crj.0000000000000378] [Reference Citation Analysis]
224 Wu Q, Hu Y, Ma Q, Yang S, Chen J, Wen S, Liao G, Pan J. Comprehensive Analysis of RAPGEF2 for Predicting Prognosis and Immunotherapy Response in Patients with Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/6560154] [Reference Citation Analysis]
225 Ye QW, Pang SJ, Yang N, Zhang HB, Fu Y, Lin B, Yang GS. Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study. J Gastrointest Surg 2019;23:1549-58. [PMID: 31197690 DOI: 10.1007/s11605-019-04229-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
226 Jia B, Yin X, Wang Y, Qian J, He Y, Yang C, Yu G, Guo B, Meng X. CircRNA-PTN Sponges miR-326 to Promote Proliferation in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:4893-903. [PMID: 32581550 DOI: 10.2147/OTT.S251300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
227 Li X, Wang L, Wang L, Feng Z, Peng C. Single-Cell Sequencing of Hepatocellular Carcinoma Reveals Cell Interactions and Cell Heterogeneity in the Microenvironment. Int J Gen Med 2021;14:10141-53. [PMID: 34992435 DOI: 10.2147/IJGM.S338090] [Reference Citation Analysis]
228 Wang W, Gu D, Wei J, Ding Y, Yang L, Zhu K, Luo R, Rao SX, Tian J, Zeng M. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI. Eur Radiol. 2020;30:3004-3014. [PMID: 32002645 DOI: 10.1007/s00330-019-06585-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
229 Ren W, Wu S, Wu Y, Liu T, Zhao X, Li Y. MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2. Cell Death Dis 2019;10:333. [PMID: 30988277 DOI: 10.1038/s41419-019-1530-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
230 Lu Y, Li X, Liu H, Xue J, Zeng Z, Dong X, Zhang T, Wu G, Yang K, Xu S. β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma. Oncogene 2021;40:1269-83. [PMID: 33420362 DOI: 10.1038/s41388-020-01596-2] [Reference Citation Analysis]
231 Weiz G, Molejon MI, Malvicini M, Sukowati CHC, Tiribelli C, Mazzolini G, Breccia JD. Glycosylated 4-methylumbelliferone as a targeted therapy for hepatocellular carcinoma. Liver Int 2021. [PMID: 34800352 DOI: 10.1111/liv.15084] [Reference Citation Analysis]
232 Villalobos A, Wagstaff W, Guo M, Zhang J, Bercu Z, Whitmore MJ, Cristescu MM, Majdalany BS, Wedd J, Akce M, Magliocca J, Kokabi N. Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:9926704. [PMID: 34336728 DOI: 10.1155/2021/9926704] [Reference Citation Analysis]
233 Miyata T, Matsumoto T, Nakao Y, Higashi T, Imai K, Hayashi H, Nitta H, Chikamoto A, Beppu T, Yamashita YI, Baba H. Major postoperative complications are associated with early recurrence of hepatocellular carcinoma following hepatectomy. Langenbecks Arch Surg 2022. [PMID: 35441947 DOI: 10.1007/s00423-022-02513-9] [Reference Citation Analysis]
234 Xu M, Liang H, Li K, Zhu S, Yao Z, Xu R, Lin N. Value of KPNA4 as a diagnostic and prognostic biomarker for hepatocellular carcinoma. Aging (Albany NY) 2021;13:5263-83. [PMID: 33535183 DOI: 10.18632/aging.202447] [Reference Citation Analysis]
235 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 An Z, He P, Wang G, Liu G, Jiang J. PP-10 induces apoptosis via JNK/SPAK activation and STAT3 inhibition in Hepatocarcinoma cells in vitro. Food Sci Technol. [DOI: 10.1590/fst.102921] [Reference Citation Analysis]
237 Byrne FL, Olzomer EM, Lolies N, Hoehn KL, Wegner MS. Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma. Int J Mol Sci 2022;23:4477. [PMID: 35562868 DOI: 10.3390/ijms23094477] [Reference Citation Analysis]
238 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 82.0] [Reference Citation Analysis]
239 Mishra G, Majeed A, Dev A, Eslick GD, Pinato DJ, Izumoto H, Hiraoka A, Huo T, Liu P, Johnson PJ, Roberts SK. Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. J Gastrointest Canc. [DOI: 10.1007/s12029-022-00832-0] [Reference Citation Analysis]
240 Nenu I, Breaban I, Pascalau S, Bora CN, Stefanescu H. The future is now: beyond first line systemic therapy in hepatocellular carcinoma. Transl Cancer Res 2019;8:S261-74. [PMID: 35117106 DOI: 10.21037/tcr.2018.11.23] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
241 Lu J, Qian J, Yin S, Zhou L, Zheng S, Zhang W. Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology. Front Oncol 2020;10:1105. [PMID: 32733807 DOI: 10.3389/fonc.2020.01105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
242 Jin Y, Liang ZY, Zhou WX, Zhou L. Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms. Hepatol Int 2019;13:180-9. [PMID: 30600477 DOI: 10.1007/s12072-018-9920-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
243 Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: a population-based study. Cancer Manag Res 2019;11:2759-68. [PMID: 31040715 DOI: 10.2147/CMAR.S192896] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
244 Zhu S, Brodin NP, English K, Ohri N, Chuy JW, Rajdev LN, Narang R, Kalnicki S, Guha C, Garg MK, Kabarriti R. Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. EClinicalMedicine 2019;16:23-9. [PMID: 31832617 DOI: 10.1016/j.eclinm.2019.09.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
245 Bredt LC, Peres LAB. Artificial neural network for prediction of acute kidney injury after liver transplantation for cirrhosis and hepatocellular carcinoma. Artif Intell Cancer 2021; 2(5): 51-59 [DOI: 10.35713/aic.v2.i5.51] [Reference Citation Analysis]
246 Wei XC, Liu LJ, Zhu F. Exosomes as potential diagnosis and treatment for liver cancer. World J Gastrointest Oncol 2022; 14(1): 334-347 [DOI: 10.4251/wjgo.v14.i1.334] [Reference Citation Analysis]
247 Lapitz A, Arbelaiz A, Olaizola P, Aranburu A, Bujanda L, Perugorria MJ, Banales JM. Extracellular Vesicles in Hepatobiliary Malignancies. Front Immunol 2018;9:2270. [PMID: 30369925 DOI: 10.3389/fimmu.2018.02270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
248 Romualdo GR, Leroy K, Costa CJS, Prata GB, Vanderborght B, da Silva TC, Barbisan LF, Andraus W, Devisscher L, Câmara NOS, Vinken M, Cogliati B. In Vivo and In Vitro Models of Hepatocellular Carcinoma: Current Strategies for Translational Modeling. Cancers (Basel) 2021;13:5583. [PMID: 34771745 DOI: 10.3390/cancers13215583] [Reference Citation Analysis]
249 Cao F, Yang Y, Si T, Luo J, Zeng H, Zhang Z, Feng D, Chen Y, Zheng J. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Front Oncol 2021;11:783480. [PMID: 34988019 DOI: 10.3389/fonc.2021.783480] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
250 Eisenbrey JR, Gabriel H, Savsani E, Lyshchik A. Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. Abdom Radiol (NY) 2021;46:3579-95. [PMID: 33825927 DOI: 10.1007/s00261-021-03059-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
251 Miyazoe Y, Miuma S, Miyaaki H, Kanda Y, Nakashiki S, Sasaki R, Haraguchi M, Shibata H, Honda T, Taura N, Nakao K. Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP-1 cells. Biomed Rep 2020;12:163-70. [PMID: 32190304 DOI: 10.3892/br.2020.1279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
252 Hou Q, Zhang K, Chen S, Chen J, Zhang Y, Gong N, Guo W, Fang C, Wang L, Jiang J, Dou J, Liang X, Yu J, Liang P. Physical & Chemical Microwave Ablation (MWA) Enabled by Nonionic MWA Nanosensitizers Repress Incomplete MWA-Arised Liver Tumor Recurrence. ACS Nano 2022. [PMID: 35352557 DOI: 10.1021/acsnano.1c10714] [Reference Citation Analysis]
253 Hendriks P, Rietbergen DDD, van Erkel AR, Coenraad MJ, Arntz MJ, Bennink RJ, Braat AE, Crobach ASLP, van Delden OM, van der Hulle T, Klümpen HJ, van der Meer RW, Nijsen JFW, van Rijswijk CSP, Roosen J, Ruijter BN, Smit F, Stam MK, Takkenberg RB, Tushuizen ME, van Velden FHP, de Geus-Oei LF, Burgmans MC; Dutch Hepatocellular Cholangiocarcinoma Group. Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients-A Dose-Finding Study (HORA EST HCC Trial). Cardiovasc Intervent Radiol 2022. [PMID: 35618860 DOI: 10.1007/s00270-022-03162-7] [Reference Citation Analysis]
254 Hu X, Yuan G, Li Q, Huang J, Cheng X, Chen J. DEAH-box polypeptide 32 promotes hepatocellular carcinoma progression via activating the β-catenin pathway. Ann Med 2021;53:437-47. [PMID: 33729094 DOI: 10.1080/07853890.2021.1898674] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 He K, Liu X, Shahzad R, Reimer R, Thiele F, Niehoff J, Wybranski C, Bunck AC, Zhang H, Perkuhn M. Advanced Deep Learning Approach to Automatically Segment Malignant Tumors and Ablation Zone in the Liver With Contrast-Enhanced CT. Front Oncol 2021;11:669437. [PMID: 34336661 DOI: 10.3389/fonc.2021.669437] [Reference Citation Analysis]
256 Yang Z, Liu Z, Zhu J, Xu J, Pu Y, Bao Y. Green synthesis and characterization of gold nanoparticles from Pholiota adiposa and their anticancer effects on hepatic carcinoma. Drug Deliv 2022;29:997-1006. [PMID: 35363110 DOI: 10.1080/10717544.2022.2056664] [Reference Citation Analysis]
257 Zhu L, Sun Y, Zhang S, Wang L. Rap2B knockdown suppresses malignant progression of hepatocellular carcinoma by inactivating the PTEN/PI3K/Akt and ERK1/2 pathways. Mol Cell Biochem 2020;466:55-63. [PMID: 32052247 DOI: 10.1007/s11010-020-03687-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
258 Bennett S, Søreide K, Gholami S, Pessaux P, Teh C, Segelov E, Kennecke H, Prenen H, Myrehaug S, Callegaro D, Hallet J. Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic. Curr Oncol 2020;27:e501-11. [PMID: 33173390 DOI: 10.3747/co.27.6785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
259 Chen L, Huang X, Zhang W, Liu Y, Chen B, Xiang Y, Zhang R, Zhang M, Feng J, Liu S, Duan T, Chen X, Wang W, Pan T, Yan L, Jin T, Li G, Li Y, Xie T, Sui X. Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients. J Cancer. 2020;11:5440-5448. [PMID: 32742491 DOI: 10.7150/jca.46158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
260 Liu Y, Yang H, Guo Q, Liu T, Jiang Y, Zhao M, Zeng K, Tu P. Cucurbitacin E Inhibits Huh7 Hepatoma Carcinoma Cell Proliferation and Metastasis via Suppressing MAPKs and JAK/STAT3 Pathways. Molecules 2020;25:E560. [PMID: 32012950 DOI: 10.3390/molecules25030560] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
261 Liu D, Wu J, Zhu H, Zhu X, Jin Y, Yu Y, Zhang X. Treatment of microvascular invasion in hepatocellular carcinoma with drug-loaded nanocomposite platform under synergistic effect of magnetic field/near-infrared light. J Biomed Mater Res B Appl Biomater 2021. [PMID: 34664385 DOI: 10.1002/jbm.b.34950] [Reference Citation Analysis]
262 Houseni M, Mahmoud MA, Saad S, ElHussiny F, Shihab M. Advanced intra-tumoural structural characterisation of hepatocellular carcinoma utilising FDG-PET/CT: a comparative study of radiomics and metabolic features in 3D and 2D. Pol J Radiol 2021;86:e64-73. [PMID: 33708274 DOI: 10.5114/pjr.2021.103239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
263 Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, Asad A, Preen DB, MacQuillan G, Garas G, Adams LA, Jeffrey GP. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy. Dig Dis Sci 2020;65:647-57. [PMID: 31440998 DOI: 10.1007/s10620-019-05781-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
264 Dong ZR, Sun D, Yang YF, Zhou W, Wu R, Wang XW, Shi K, Yan YC, Yan LJ, Yao CY, Chen ZQ, Zhi XT, Li T. TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage. Hepatology 2020;72:923-39. [PMID: 31867749 DOI: 10.1002/hep.31076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
265 Liu Z, Wang Q, Wang X, Xu Z, Wei X, Li J. Circular RNA cIARS regulates ferroptosis in HCC cells through interacting with RNA binding protein ALKBH5. Cell Death Discov 2020;6:72. [PMID: 32802409 DOI: 10.1038/s41420-020-00306-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
266 Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol 2020; 26(33): 4900-4918 [PMID: 32952338 DOI: 10.3748/wjg.v26.i33.4900] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
267 Song J, Guan Z, Song C, Li M, Gao Z, Zhao Y. Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways. Mol Med Rep 2021;23:429. [PMID: 33846786 DOI: 10.3892/mmr.2021.12068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
268 Yu B, Liang H, Ye Q, Wang Y. Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection. J Gastrointest Surg 2021;25:112-24. [PMID: 32128678 DOI: 10.1007/s11605-020-04554-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
269 Pinzaru I, Sarau C, Coricovac D, Marcovici I, Utescu C, Tofan S, Popovici RA, Manea HC, Pavel IE, Soica C, Dehelean C. Silver Nanocolloids Loaded with Betulinic Acid with Enhanced Antitumor Potential: Physicochemical Characterization and In Vitro Evaluation. Nanomaterials (Basel) 2021;11:E152. [PMID: 33435422 DOI: 10.3390/nano11010152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
270 Kim J, Sinn DH, Choi MS, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment? PLoS One 2019;14:e0213547. [PMID: 30845192 DOI: 10.1371/journal.pone.0213547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
271 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Reference Citation Analysis]
272 Chang PY, Chung CH, Chang WC, Lin CS, Lin HH, Dai MS, Ho CL, Chien WC. The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. PLoS One 2019;14:e0216828. [PMID: 31125347 DOI: 10.1371/journal.pone.0216828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
273 Peng Y, Chen K, Li B, Xu H, Wei Y, Liu F. Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis. Updates Surg 2022. [PMID: 35739381 DOI: 10.1007/s13304-022-01309-2] [Reference Citation Analysis]
274 Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: A need for sustainable actions. Cancer Commun (Lond) 2020;40:205-10. [PMID: 32359212 DOI: 10.1002/cac2.12025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
275 Liu L, Jiang H, Pan H, Zhu X. LncRNA XIST promotes liver cancer progression by acting as a molecular sponge of miR-200b-3p to regulate ZEB1/2 expression. J Int Med Res 2021;49:3000605211016211. [PMID: 34018840 DOI: 10.1177/03000605211016211] [Reference Citation Analysis]
276 Ploeger C, Huth T, Sugiyanto RN, Pusch S, Goeppert B, Singer S, Tabti R, Hausser I, Schirmacher P, Désaubry L, Roessler S. Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria. Cell Death Dis 2020;11:1023. [PMID: 33257655 DOI: 10.1038/s41419-020-03220-3] [Reference Citation Analysis]
277 Grussu F, Bernatowicz K, Casanova-Salas I, Castro N, Nuciforo P, Mateo J, Barba I, Perez-Lopez R. Diffusion MRI signal cumulants and hepatocyte microstructure at fixed diffusion time: Insights from simulations, 9.4T imaging, and histology. Magn Reson Med 2022. [PMID: 35181943 DOI: 10.1002/mrm.29174] [Reference Citation Analysis]
278 Wang H, Wang H, Li K, Li S, Sun B. IGFBP-3 Is the Key Target of Sanguinarine in Promoting Apoptosis in Hepatocellular Carcinoma. Cancer Manag Res 2020;12:1007-15. [PMID: 32104082 DOI: 10.2147/CMAR.S234291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
279 Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, Hao H, Xiong J. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B 2022;12:558-80. [PMID: 35256934 DOI: 10.1016/j.apsb.2021.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
280 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
281 Zhang L, Niu H, Yang P, Ma J, Yuan BY, Zeng ZC, Xiang ZL. Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients. BMC Cancer 2021;21:161. [PMID: 33588789 DOI: 10.1186/s12885-021-07808-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
282 Yang J, Li C, Zhang L, Wang X. Extracellular Vesicles as Carriers of Non-coding RNAs in Liver Diseases. Front Pharmacol. 2018;9:415. [PMID: 29740327 DOI: 10.3389/fphar.2018.00415] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
283 Lin N, Li J, Ke Q, Xin F, Zeng Y, Wang L, Liu J. Does the intermittent Pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review. PLoS One 2020;15:e0229870. [PMID: 32160231 DOI: 10.1371/journal.pone.0229870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
284 Bai Y, Lian Y, Wu J, Chen S, Lai J, Zheng Y, Tian Y, Yan M, Wang Y. A Prognostic Scoring System for Predicting Overall Survival of Patients with the TNM 8th Edition Stage I and II Hepatocellular Carcinoma After Surgery: A Population-Based Study. Cancer Manag Res 2021;13:2131-42. [PMID: 33688256 DOI: 10.2147/CMAR.S289826] [Reference Citation Analysis]
285 Zhang MH, Liu J. Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway. Bioengineered 2022;13:10047-60. [PMID: 35412944 DOI: 10.1080/21655979.2022.2063100] [Reference Citation Analysis]
286 Gan L, Shangguan Q, Zhang F, Tong X, Qi D, Zhao Y, Ye X. HBV HBx-Downregulated lncRNA LINC01010 Attenuates Cell Proliferation by Interacting with Vimentin. Int J Mol Sci 2021;22:12497. [PMID: 34830378 DOI: 10.3390/ijms222212497] [Reference Citation Analysis]
287 Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35152830 DOI: 10.1080/13543784.2022.2042253] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Zhou Y, Chen E, Tang Y, Mao J, Shen J, Zheng X, Xie S, Zhang S, Wu Y, Liu H, Zhi X, Ma T, Ni H, Chen J, Chai K, Chen W. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis 2019;10:843. [PMID: 31695022 DOI: 10.1038/s41419-019-2053-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
289 Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 [PMID: 34721773 DOI: 10.4251/wjgo.v13.i10.1397] [Reference Citation Analysis]
290 Liu P, Han B, Zhang Y, Wang X, Ahmad S. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. Computational Intelligence and Neuroscience 2022;2022:1-14. [DOI: 10.1155/2022/7102500] [Reference Citation Analysis]
291 Qu S, Shi Q, Xu J, Yi W, Fan H. Weighted Gene Coexpression Network Analysis Reveals the Dynamic Transcriptome Regulation and Prognostic Biomarkers of Hepatocellular Carcinoma. Evol Bioinform Online 2020;16:1176934320920562. [PMID: 32523331 DOI: 10.1177/1176934320920562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
292 Cucarull B, Tutusaus A, Rider P, Hernáez-Alsina T, Cuño C, García de Frutos P, Colell A, Marí M, Morales A. Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers (Basel) 2022;14:621. [PMID: 35158892 DOI: 10.3390/cancers14030621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
293 Mazzucco W, Vitale F, Mazzola S, Amodio R, Zarcone M, Alba D, Marotta C, Cusimano R, Allemani C. Does access to care play a role in liver cancer survival? The ten-year (2006-2015) experience from a population-based cancer registry in Southern Italy. BMC Cancer 2021;21:307. [PMID: 33761907 DOI: 10.1186/s12885-021-07935-0] [Reference Citation Analysis]
294 Zhu Z, Zhang Y, Huang C, Tang Y, Sun C, Ju W, He X. Overexpression of RALY promotes migration and predicts poor prognosis in hepatocellular carcinoma. Cancer Manag Res 2018;10:5559-72. [PMID: 30519104 DOI: 10.2147/CMAR.S182996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
295 Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget. 2018;9:37721-37732. [PMID: 30701027 DOI: 10.18632/oncotarget.26507] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
296 Wu JL, Su TH, Chen PJ, Chen YR. Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level. Sci Rep 2022;12:5799. [PMID: 35388082 DOI: 10.1038/s41598-022-09713-9] [Reference Citation Analysis]
297 Yan Y, Nie Y, Peng C, Xing F, Ji S, Liu H, Zhu C. The circular RNA hsa_circ_0001394 promotes hepatocellular carcinoma progression by targeting the miR-527/UBE2A axis. Cell Death Discov 2022;8:81. [PMID: 35210429 DOI: 10.1038/s41420-022-00866-0] [Reference Citation Analysis]
298 Lin Z, Ni X, Dai S, Chen H, Chen J, Wu B, Ao J, Shi K, Sun H. Screening and verification of long noncoding RNA promoter methylation sites in hepatocellular carcinoma. Cancer Cell Int 2020;20:311. [PMID: 32684848 DOI: 10.1186/s12935-020-01407-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
299 Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y, Mori M. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. Hepatol Commun 2021;5:334-48. [PMID: 33553979 DOI: 10.1002/hep4.1643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
300 Zhong BY, Wang WS, Zhang S, Zhu HD, Zhang L, Shen J, Zhu XL, Teng GJ, Ni CF. Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists. J Clin Transl Hepatol 2021;9:521-7. [PMID: 34447681 DOI: 10.14218/JCTH.2021.00049] [Reference Citation Analysis]
301 Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7:267. [PMID: 31627733 DOI: 10.1186/s40425-019-0749-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 12.7] [Reference Citation Analysis]
302 Xu H, Tang Y, Zhao Y, Wang F, Gao X, Deng D, Gu Y. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. Mol Pharm 2021;18:2082-90. [PMID: 33797932 DOI: 10.1021/acs.molpharmaceut.1c00060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Schwartz G, Darling JO, Mindo M, Damicis L. Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. Target Oncol 2020;15:549-65. [PMID: 32770441 DOI: 10.1007/s11523-020-00736-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
304 Xu X, Zhang Y, Wang X, Li S, Tang L. Substrate Stiffness Drives Epithelial to Mesenchymal Transition and Proliferation through the NEAT1-Wnt/β-Catenin Pathway in Liver Cancer. Int J Mol Sci 2021;22:12066. [PMID: 34769497 DOI: 10.3390/ijms222112066] [Reference Citation Analysis]
305 Sun DW, An L, Huang HY, Sun XD, Lv GY. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true? Clin Transl Oncol 2021;23:82-91. [PMID: 32462395 DOI: 10.1007/s12094-020-02390-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
306 Odabas G, Cetin M, Turhal S, Baloglu H, Sayan AE, Yagci T. Plexin C1 Marks Liver Cancer Cells with Epithelial Phenotype and Is Overexpressed in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:4040787. [PMID: 30327758 DOI: 10.1155/2018/4040787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
307 Yang S, Chen Z, Fan D, Zhang R, Zhang Y, Wu S. Retracted Article: MiR-182-5p and miR-96-5p increased hepatocellular carcinoma cell mobility, proliferation and cisplatin resistance partially by targeting RND3. RSC Adv 2018;8:34973-83. [DOI: 10.1039/c8ra07055e] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
308 Lu Q, Long Y, Fan K, Shen Z, Gai Y, Liu Q, Jiang D, Cai W, Wan C, Lan X. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617. Eur J Nucl Med Mol Imaging 2022. [PMID: 35763056 DOI: 10.1007/s00259-022-05884-9] [Reference Citation Analysis]
309 Liang C, Zhang Y, Zhang Y, Li R, Wang Z, Wei Z, Guo J. The prognostic value of LINC01296 in pan-cancers and the molecular regulatory mechanism in hepatocellular carcinoma: a comprehensive study based on data mining, bioinformatics, and in vitro validation. Onco Targets Ther 2019;12:5861-85. [PMID: 31410029 DOI: 10.2147/OTT.S205853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
310 Zhang TQ, Huang ZM, Shen JX, Chen GQ, Shen LJ, Ai F, Gu YK, Yao W, Zhang YY, Guo RP, Chen MS, Huang JH. Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma. Therap Adv Gastroenterol 2019;12:1756284819862966. [PMID: 31489030 DOI: 10.1177/1756284819862966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
311 Kim JH, Choe WH, Kwon SY, Yoo BC. Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients. J Korean Med Sci 2018;33:e335. [PMID: 30584413 DOI: 10.3346/jkms.2018.33.e335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
312 Meischl T, Rasoul-Rockenschaub S, Győri G, Scheiner B, Trauner M, Soliman T, Berlakovich G, Pinter M. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. United European Gastroenterol J 2021;9:209-19. [PMID: 32741316 DOI: 10.1177/2050640620948665] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Wan L, Wang Y, Zhang Z, Wang J, Niu M, Wu Y, Yang Y, Dang Y, Hui S, Ni M, Wan B, Bao D. Elevated TEFM expression promotes growth and metastasis through activation of ROS/ERK signaling in hepatocellular carcinoma. Cell Death Dis 2021;12:325. [PMID: 33771980 DOI: 10.1038/s41419-021-03618-7] [Reference Citation Analysis]
314 Kunadirek P, Ariyachet C, Sriphoosanaphan S, Pinjaroen N, Sirichindakul P, Nookaew I, Chuaypen N, Tangkijvanich P. Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. Sci Rep 2021;11:11201. [PMID: 34045534 DOI: 10.1038/s41598-021-90515-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, Giannini EG, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer 2021;10:126-36. [PMID: 33977089 DOI: 10.1159/000513404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
316 Yan Y, Ren L, Liu Y, Liu L. Development and Validation of Genome Instability-Associated lncRNAs to Predict Prognosis and Immunotherapy of Patients With Hepatocellular Carcinoma. Front Genet 2022;12:763281. [DOI: 10.3389/fgene.2021.763281] [Reference Citation Analysis]
317 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
318 Mezina A, Philips N, Bogus Z, Erez N, Xiao R, Fan R, Olthoff KM, Reddy KR, Samadder NJ, Nielsen SM, Hatchell KE, Esplin ED, Rustgi AK, Katona BW, Hoteit MA, Nathanson KL, Wangensteen KJ. Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants. JCO Precis Oncol 2021;5:PO. [PMID: 34250406 DOI: 10.1200/PO.21.00079] [Reference Citation Analysis]
319 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Reference Citation Analysis]
320 Athavale D, Song Z, Desert R, Han H, Das S, Ge X, Komakula SSB, Chen W, Gao S, Lantvit D, Guzman G, Nieto N. Ablation of high-mobility group box-1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling-deficient mice. Hepatol Commun 2022. [PMID: 35344292 DOI: 10.1002/hep4.1943] [Reference Citation Analysis]
321 Lee J, Lim YS, Lee JH, Gwak GY, Do M, Yeo I, Shin D, Han D, Park T, Kim Y. Inclusive Quantification Assay of Serum Des-γ-Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. Hepatol Commun 2021;5:1767-83. [PMID: 34558815 DOI: 10.1002/hep4.1752] [Reference Citation Analysis]
322 Radosevic A, Quesada R, Serlavos C, Sánchez J, Zugazaga A, Sierra A, Coll S, Busto M, Aguilar G, Flores D, Arce J, Maiques JM, Garcia-Retortillo M, Carrion JA, Visa L, Villamonte M, Pueyo E, Berjano E, Trujillo M, Sánchez-Velázquez P, Grande L, Burdio F. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. Sci Rep 2022;12:316. [PMID: 35013377 DOI: 10.1038/s41598-021-03802-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
323 Qu S, Zhang X, Wu Y, Meng Y, Pan H, Fang Q, Hu L, Zhang J, Wang R, Wei L, Wu D. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Front Oncol 2022;12:874473. [DOI: 10.3389/fonc.2022.874473] [Reference Citation Analysis]
324 Zhao Y, Xue C, Xie Z, Ouyang X, Li L. Comprehensive analysis of ubiquitin-specific protease 1 reveals its importance in hepatocellular carcinoma. Cell Prolif 2020;53:e12908. [PMID: 32951278 DOI: 10.1111/cpr.12908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
325 Chen J, Du F, Dang Y, Li X, Qian M, Feng W, Qiao C, Fan D, Nie Y, Wu K, Xia L. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4. Hepatology 2020;71:1712-31. [PMID: 31529503 DOI: 10.1002/hep.30951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
326 Lin J, Hou Y, Huang S, Wang Z, Sun C, Wang Z, He X, Tam NL, Wu C, Wu L. Exportin-T promotes tumor proliferation and invasion in hepatocellular carcinoma. Mol Carcinog 2019;58:293-304. [PMID: 30334580 DOI: 10.1002/mc.22928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
327 Bucalau AM, Tancredi I, Pezzullo M, Covas A, Verset G. Complete response of a hepatocellular carcinoma with complex macrovascular invasion after combined treatment with chemoembolization and immunotherapy: a case report. Acta Gastroenterol Belg 2021;84:371-4. [PMID: 34217191 DOI: 10.51821/84.2.371] [Reference Citation Analysis]
328 Sha M, Cao J, Zong ZP, Xu N, Zhang JJ, Tong Y, Xia Q. Identification of genes predicting unfavorable prognosis in hepatitis B virus-associated hepatocellular carcinoma. Ann Transl Med 2021;9:975. [PMID: 34277775 DOI: 10.21037/atm-21-2085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Qian Y, Wang JW, Fang Y, Yuan XD, Fan YC, Gao S, Wang K. Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma. Med Sci Monit 2020;26:e927444. [PMID: 33320844 DOI: 10.12659/MSM.927444] [Reference Citation Analysis]
330 He Q, Liu M, Huang W, Chen X, Zhang B, Zhang T, Wang Y, Liu D, Xie M, Ji X, Sun M, Tian D, Xia L. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1. Hepatology 2021;74:3174-93. [PMID: 34288020 DOI: 10.1002/hep.32062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
331 Yu L, Yang X, Huang N, Lang QL, He QL, Jian-Hua W, Liang-Peng G. A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma. Cancer Biol Ther. 2020;21:597-603. [PMID: 32240054 DOI: 10.1080/15384047.2020.1743158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
332 Song H, Sun N, Lin L, Wei S, Zeng K, Liu W, Wang C, Zhong X, Wang M, Wang S, Zhou B, Lv C, Liu W, Zhao Y. Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma. Cancer Sci 2020;111:3665-78. [PMID: 32745318 DOI: 10.1111/cas.14595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
333 Chen LJ, Chang YJ, Chang YJ. Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma. Oncologist 2021;26:e445-53. [PMID: 32969134 DOI: 10.1002/onco.13535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
334 Luo Y, Liu F, Han S, Qi Y, Hu X, Zhou C, Liang H, Zhang Z. Autophagy-Related Gene Pairs Signature for the Prognosis of Hepatocellular Carcinoma. Front Mol Biosci 2021;8:670241. [PMID: 34095224 DOI: 10.3389/fmolb.2021.670241] [Reference Citation Analysis]
335 Bekki S, Hashimoto S, Yamasaki K, Komori A, Abiru S, Nagaoka S, Saeki A, Suehiro T, Kugiyama Y, Beppu A, Kuroki T, Nakamura M, Ito M, Yatsuhashi H. Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma. PLoS One 2020;15:e0241002. [PMID: 33085694 DOI: 10.1371/journal.pone.0241002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
336 Chen X, Li D, Cao Y, Gao J, Jin H, Shan H. Early Therapeutic Vaccination Prediction of Hepatocellular Carcinoma via Imaging OX40-Mediated Tumor Infiltrating Lymphocytes. Mol Pharm 2019;16:4252-9. [PMID: 31454248 DOI: 10.1021/acs.molpharmaceut.9b00590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
337 Vishnevsky VA, Ayvazyan KA, Ikramov RZ, Ionkin DA, Zhavoronkova OI, Stepanova YA, Varava AB, Kovalenko YA, Zharikov YO, Goncharov AB, Olifir AA, Pakhomova AY, Bugaev SA, Zhao AV. Modern principles of hepatocellular carcinoma treatment. Ann hir gepatol 2020;25:15-26. [DOI: 10.16931/1995-5464.2020215-26] [Reference Citation Analysis]
338 Yao J, Hua X, Shi J, Hu X, Lui K, He K, Mai J, Lan T, Lu M. LncRNA THEMIS2-211, a tumor-originated circulating exosomal biomarker, promotes the growth and metastasis of hepatocellular carcinoma by functioning as a competing endogenous RNA. FASEB J 2022;36:e22238. [PMID: 35224785 DOI: 10.1096/fj.202101564R] [Reference Citation Analysis]
339 Lu Q, Li J, Cao H, Lv C, Wang X, Cao S. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep 2020;40:BSR20192424. [PMID: 32039435 DOI: 10.1042/BSR20192424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
340 Jiang N, Li H, Sun Y, Zeng J, Yang F, Kantawong F, Wu J. Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma. Front Pharmacol 2021;12:618522. [PMID: 33746755 DOI: 10.3389/fphar.2021.618522] [Reference Citation Analysis]
341 Chen H, Li Z, Wu F, Ji W, Lu L, Wu Z, Huang Y, Wang W, Li S. BCL10 correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma. IUBMB Life. [DOI: 10.1002/iub.2581] [Reference Citation Analysis]
342 Shao CC, Zhao F, Yu YF, Zhu LL, Pang GD. Value of perfusion parameters and histogram analysis of triphasic computed tomography in pre-operative prediction of histological grade of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:1181-90. [PMID: 34018996 DOI: 10.1097/CM9.0000000000001446] [Reference Citation Analysis]
343 Lee BC, Jeong YY, Heo SH, Kim HO, Park C, Shin SS, Cho SB, Koh YS. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization. Acad Radiol 2022:S1076-6332(21)00483-9. [PMID: 35151549 DOI: 10.1016/j.acra.2021.10.012] [Reference Citation Analysis]
344 Tella SH, Mahipal A, Kommalapati A, Jin Z. Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. Onco Targets Ther. 2019;12:10335-10342. [PMID: 31819517 DOI: 10.2147/ott.s214870] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
345 Xu J, Koval A, Katanaev VL. Beyond TNBC: Repositioning of Clofazimine Against a Broad Range of Wnt-Dependent Cancers. Front Oncol 2020;10:602817. [PMID: 33363033 DOI: 10.3389/fonc.2020.602817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
346 Xu YJ, Lai ZC, He MK, Bu XY, Chen HW, Zhou YM, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Shi M, Li QJ. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:15330338211063848. [PMID: 34898313 DOI: 10.1177/15330338211063848] [Reference Citation Analysis]
347 Pu J, Qin Z, Fang Q, Huang Y, Lu Y, Li W, Wang J, Tang Q, Zeng D, Wei H. Hypoxia-induced HIF1A Activates DUSP18-mediated MAPK14 Dephosphorylation to Promote Hepatocellular Carcinoma Cell Migration and Invasion. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153955] [Reference Citation Analysis]
348 Xu Q, Xu H, Deng R, Wang Z, Li N, Qi Z, Zhao J, Huang W. Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma. Cancer Cell Int 2021;21:342. [PMID: 34217320 DOI: 10.1186/s12935-021-02049-w] [Reference Citation Analysis]
349 Wang MD, Xing H, Li C, Liang L, Wu H, Xu XF, Sun LY, Wu MC, Shen F, Yang T. A novel role of Krüppel-like factor 8 as an apoptosis repressor in hepatocellular carcinoma. Cancer Cell Int 2020;20:422. [PMID: 32874135 DOI: 10.1186/s12935-020-01513-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
350 Yang Z, Abdrakhimov B, Wang S, Xie QF, Zheng SS. Multidisciplinary Treatment of Advanced Hepatocellular Carcinoma. Case Rep Gastroenterol 2020;14:98-102. [PMID: 32231509 DOI: 10.1159/000506185] [Reference Citation Analysis]
351 Wu S, Chen S, Lin N, Yang J. Long non-coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β-catenin signalling pathway by targeting miR-320a. J Cell Mol Med 2020;24:3108-16. [PMID: 31970876 DOI: 10.1111/jcmm.14977] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
352 Zhang X, Zhang H, Liao Z, Zhang J, Liang H, Wang W, Yu J, Dong K. SHC4 promotes tumor proliferation and metastasis by activating STAT3 signaling in hepatocellular carcinoma. Cancer Cell Int 2022;22:24. [PMID: 35033067 DOI: 10.1186/s12935-022-02446-9] [Reference Citation Analysis]
353 Zhang C, Shen L, Yuan W, Liu Y, Guo R, Luo Y, Zhan Z, Xie Z, Wu G, Wu W, Feng Y. Loss of SRSF2 triggers hepatic progenitor cell activation and tumor development in mice. Commun Biol 2020;3:210. [PMID: 32372053 DOI: 10.1038/s42003-020-0893-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
354 Serhal R, Saliba N, Hilal G, Moussa M, Hassan GS, El Atat O, Alaaeddine N. Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: In vitro inhibition of carcinogenesis. World J Gastroenterol 2019; 25(5): 567-583 [PMID: 30774272 DOI: 10.3748/wjg.v25.i5.567] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
355 Zhang Q, Zheng Q, Yu X, He Y, Guo W. Overview of distinct 5-methylcytosine profiles of messenger RNA in human hepatocellular carcinoma and paired adjacent non-tumor tissues. J Transl Med 2020;18:245. [PMID: 32571340 DOI: 10.1186/s12967-020-02417-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
356 Sim JH, Kim SH, Jun IG, Kang SJ, Kim B, Kim S, Song JG. The Association between Prognostic Nutritional Index (PNI) and Intraoperative Transfusion in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma: A Retrospective Cohort Study. Cancers (Basel) 2021;13:2508. [PMID: 34063772 DOI: 10.3390/cancers13112508] [Reference Citation Analysis]
357 Jin X, Fu W, Li D, Wang N, Chen J, Zeng Z, Guo J, Liu H, Zhong X, Peng H, Yu X, Sun J, Zhang X, Wang X, Xu B, Lin Y, Liu J, Kutter C, Li Y. High Expression of LINC01268 is Positively Associated with Hepatocellular Carcinoma Progression via Regulating MAP3K7. Onco Targets Ther 2021;14:1753-69. [PMID: 33727826 DOI: 10.2147/OTT.S295814] [Reference Citation Analysis]
358 Lu Y, Zhang J, Wu Y. Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis. Mol Med Rep 2021;24:609. [PMID: 34184075 DOI: 10.3892/mmr.2021.12247] [Reference Citation Analysis]
359 Jeon T, Ko MJ, Seo YR, Jung SJ, Seo D, Park SY, Park KU, Kim KS, Kim M, Seo JH, Park IC, Kim MJ, Bae JH, Song DK, Cho CH, Lee JH, Lee YH. Silencing CDCA8 Suppresses Hepatocellular Carcinoma Growth and Stemness via Restoration of ATF3 Tumor Suppressor and Inactivation of AKT/β-Catenin Signaling. Cancers (Basel) 2021;13:1055. [PMID: 33801424 DOI: 10.3390/cancers13051055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Ye J, Wu S, Pan S, Huang J, Ge L. Risk scoring based on expression of long non‑coding RNAs can effectively predict survival in hepatocellular carcinoma patients with or without fibrosis. Oncol Rep 2020;43:1451-66. [PMID: 32323856 DOI: 10.3892/or.2020.7528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
361 Wang T, Yang Y, Sun T, Qiu H, Wang J, Ding C, Lan R, He Q, Wang W. The Pyroptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immunotherapeutic Efficiency in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:779269. [PMID: 35712653 DOI: 10.3389/fcell.2022.779269] [Reference Citation Analysis]
362 Huang Z, Zhou JK, Wang K, Chen H, Qin S, Liu J, Luo M, Chen Y, Jiang J, Zhou L, Zhu L, He J, Li J, Pu W, Gong Y, Li J, Ye Q, Dong D, Hu H, Zhou Z, Dai L, Huang C, Wei X, Peng Y. PDLIM1 Inhibits Tumor Metastasis Through Activating Hippo Signaling in Hepatocellular Carcinoma. Hepatology 2020;71:1643-59. [PMID: 31509262 DOI: 10.1002/hep.30930] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
363 Li L, Xu L, Wen T, Wu H, Wang W, Yang J, Chen Z, Wei Y, Xu M, Li B, Zhang M. Poor Prognoses of Young Hepatocellular Carcinoma Patients with Microvascular Invasion: A Propensity Score Matching Cohort Study. Gastroenterol Res Pract 2020;2020:4691425. [PMID: 32148477 DOI: 10.1155/2020/4691425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
364 Wang D, Yang X, Lin J, Bai Y, Long J, Yang X, Seery S, Zhao H. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therap Adv Gastroenterol 2020;13:1756284820932483. [PMID: 32636928 DOI: 10.1177/1756284820932483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
365 Sturm L, Roth L, Zoldan K, Schultheiss M, Boettler T, Huber JP, Kaeser R, Thimme R, Bettinger D. Blood reelin in the progression of chronic liver disease. Adv Med Sci 2021;66:148-54. [PMID: 33561810 DOI: 10.1016/j.advms.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Zhong X, Peng J, Xie Y, Shi Y, Long H, Su L, Duan Y, Xie X, Lin M. A nomogram based on multi-modal ultrasound for prediction of microvascular invasion and recurrence of hepatocellular carcinoma. Eur J Radiol 2022;151:110281. [PMID: 35395542 DOI: 10.1016/j.ejrad.2022.110281] [Reference Citation Analysis]
367 Dimin N, Zhe D, Yongrong W, Si M, Yongjie T, Qing Z, Xuefei T. Niuhuang (Bovis Calculus)-Shexiang (Moschus) combination induces apoptosis and inhibits proliferation in hepatocellular carcinoma via PI3K/AKT/mTOR pathway. Digital Chinese Medicine 2022;5:83-92. [DOI: 10.1016/j.dcmed.2022.03.009] [Reference Citation Analysis]
368 Ji L, Tang Y, Pang X, Zhang Y. Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells. Med Sci Monit 2019;25:5823-32. [PMID: 31379360 DOI: 10.12659/MSM.915754] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
369 Majid A, Wang J, Nawaz M, Abdul S, Ayesha M, Guo C, Liu Q, Liu S, Sun MZ. miR-124-3p Suppresses the Invasiveness and Metastasis of Hepatocarcinoma Cells via Targeting CRKL. Front Mol Biosci 2020;7:223. [PMID: 33094104 DOI: 10.3389/fmolb.2020.00223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
370 Xu T, Wang L, Jia P, Song X, Zhao Z. An Integrative Transcriptomic and Methylation Approach for Identifying Differentially Expressed Circular RNAs Associated with DNA Methylation Change. Biomedicines 2021;9:657. [PMID: 34201256 DOI: 10.3390/biomedicines9060657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
371 Liu J, Wang W, Shi C, Li C, Xue F, Hu L, Wang Y, Ge R. The difference in prolonged continuous and intermittent Pringle maneuver during complex hepatectomy for hepatocellular carcinoma patients with chronic liver disease: A retrospective cohort study. Cancer Med 2021;10:8507-17. [PMID: 34658153 DOI: 10.1002/cam4.4361] [Reference Citation Analysis]
372 Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
373 Tang Y, Yang X, Feng K, Hu C, Li S. High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:174-83. [PMID: 33708434 DOI: 10.21037/jgo-20-534] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
374 Personeni N, Pressiani T, D'Alessio A, Prete MG, Bozzarelli S, Terracciano L, Dal Buono A, Capogreco A, Aghemo A, Lleo A, Lutman RF, Roncalli M, Giordano L, Santoro A, Di Tommaso L, Rimassa L. Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:5665. [PMID: 34830823 DOI: 10.3390/cancers13225665] [Reference Citation Analysis]
375 He L, Zhang Y, Chen J, Liu G, Zhu J, Li X, Li D, Yang Y, Lee CS, Shi J, Yin C, Lai P, Wang L, Fang C. A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma. J Mater Chem B 2021;9:8779-92. [PMID: 34635903 DOI: 10.1039/d1tb01729b] [Reference Citation Analysis]
376 Wu Z, Cheng H, Liu J, Zhang S, Zhang M, Liu F, Li Y, Huang Q, Jiang Y, Chen S, Lv L, Li D, Zeng J. The Oncogenic and Diagnostic Potential of Stanniocalcin 2 in Hepatocellular Carcinoma. JHC 2022;Volume 9:141-55. [DOI: 10.2147/jhc.s351882] [Reference Citation Analysis]
377 Yu Z, Liu J, Fan Q, Yu J, Ren X, Wang X, Andreucci E. Extracellular Vesicle-Encapsulated MicroRNA-375 from Bone Marrow-Derived Mesenchymal Stem Cells Inhibits Hepatocellular Carcinoma Progression through Regulating HOXB3-Mediated Wnt/β-Catenin Pathway. Analytical Cellular Pathology 2022;2022:1-19. [DOI: 10.1155/2022/9302496] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
378 Hu J, Mao F, Li L, Wang X, Cai D, He L, Wu Q, Wang C, Zhang N, Ma Y, Wu X, Qu K, Wang X. Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. J Oncol 2022;2022:1087399. [PMID: 35401750 DOI: 10.1155/2022/1087399] [Reference Citation Analysis]
379 Yan J, Zhou B, Li H, Guo L, Ye Q. Recent advances of GOLM1 in hepatocellular carcinoma. Hepat Oncol 2020;7:HEP22. [PMID: 32647567 DOI: 10.2217/hep-2020-0006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
380 Santambrogio R, Galfrascoli E, Zappa MA. Five recommendations for loco-regional treatments of hepatocellular carcinoma during the COVID-19 pandemic. Dig Liver Dis 2020;52:950-2. [PMID: 32561303 DOI: 10.1016/j.dld.2020.05.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
381 Lin X, Xiang X, Feng B, Zhou H, Wang T, Chu X, Wang R. Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects. Front Oncol 2021;11:670838. [PMID: 34249710 DOI: 10.3389/fonc.2021.670838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Abbas EAER, Barakat AB, Hassany M, Youssef SS. The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. J Genet Eng Biotechnol 2022;20:4. [PMID: 34978646 DOI: 10.1186/s43141-021-00282-4] [Reference Citation Analysis]
383 Xiang YJ, Wang K, Zheng YT, Feng S, Yu HM, Li XW, Cheng X, Cheng YQ, Feng JK, Zhou LP, Meng Y, Zhai J, Shan YF, Cheng SQ. Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. Front Oncol 2022;12:839605. [PMID: 35387113 DOI: 10.3389/fonc.2022.839605] [Reference Citation Analysis]
384 Wang Y, Shang W, Zhong H, Luo T, Niu M, Xu K, Tian J. Tumor Vessel Targeted Self-Assemble Nanoparticles for Amplification and Prediction of the Embolization Effect in Hepatocellular Carcinoma. ACS Nano 2020;14:14907-18. [PMID: 33111520 DOI: 10.1021/acsnano.0c04341] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
385 Martínez-Chantar ML, Avila MA, Lu SC. Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers (Basel) 2020;12:E2729. [PMID: 32977536 DOI: 10.3390/cancers12102729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
386 Tao L, Wang S, Kang G, Jiang S, Yin W, Zong L, Li J, Wang X. PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma. Oncoimmunology 2021;10:2002068. [PMID: 34777920 DOI: 10.1080/2162402X.2021.2002068] [Reference Citation Analysis]
387 Roderburg C, Berres ML, Wree A, Loosen SH, Luedde T, Trautwein C. Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visc Med 2019;35:43-6. [PMID: 31312649 DOI: 10.1159/000497465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
388 Bae WK, Lee BC, Kim HJ, Lee JJ, Chung IJ, Cho SB, Koh YS. A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma. Front Immunol 2022;13:879452. [PMID: 35720374 DOI: 10.3389/fimmu.2022.879452] [Reference Citation Analysis]
389 Fang C, Wang H, Lin Z, Liu X, Dong L, Jiang T, Tan Y, Ning Z, Ye Y, Tan G, Xu G. Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography-Mass Spectrometry-Based Metabolomics. Cancers (Basel) 2022;14:231. [PMID: 35008393 DOI: 10.3390/cancers14010231] [Reference Citation Analysis]
390 Jühling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, Fujiwara N, Oudot MA, Thumann C, Saviano A, Roca Suarez AA, Goto K, Masia R, Sojoodi M, Arora G, Aikata H, Ono A, Tabrizian P, Schwartz M, Polyak SJ, Davidson I, Schmidl C, Bock C, Schuster C, Chayama K, Pessaux P, Tanabe KK, Hoshida Y, Zeisel MB, Duong FH, Fuchs BC, Baumert TF. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut 2021;70:157-69. [PMID: 32217639 DOI: 10.1136/gutjnl-2019-318918] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 31.0] [Reference Citation Analysis]
391 Tang M, Zhao Y, Zhao J, Wei S, Liu M, Zheng N, Geng D, Han S, Zhang Y, Zhong G, Li S, Zhang X, Wang C, Yan H, Cao X, Li L, Bai X, Ji J, Feng XH, Qin J, Liang T, Zhao B. Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. Sci Adv 2022;8:eabn5683. [PMID: 35731873 DOI: 10.1126/sciadv.abn5683] [Reference Citation Analysis]
392 Chen Z, Lin X, Wan Z, Xiao M, Ding C, Wan P, Li Q, Zheng S. High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma. Genes 2022;13:876. [DOI: 10.3390/genes13050876] [Reference Citation Analysis]
393 Shan QY, Hu HT, Feng ST, Peng ZP, Chen SL, Zhou Q, Li X, Xie XY, Lu MD, Wang W, Kuang M. CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. Cancer Imaging. 2019;19:11. [PMID: 30813956 DOI: 10.1186/s40644-019-0197-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 14.7] [Reference Citation Analysis]
394 Fu C, An N, Liu J, A J, Zhang B, Liu M, Zhang Z, Fu L, Tian X, Wang D, Dong JT. The transcription factor ZFHX3 is crucial for the angiogenic function of hypoxia-inducible factor 1α in liver cancer cells. J Biol Chem 2020;295:7060-74. [PMID: 32277050 DOI: 10.1074/jbc.RA119.012131] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
395 Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett 2020;20:2257-65. [PMID: 32782543 DOI: 10.3892/ol.2020.11758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
396 Chen S, Xu XL, Zhou B, Tian J, Luo BM, Zhang LM. Acidic pH-Activated Gas-Generating Nanoparticles with Pullulan Decorating for Hepatoma-Targeted Ultrasound Imaging. ACS Appl Mater Interfaces 2019;11:22194-205. [PMID: 31199110 DOI: 10.1021/acsami.9b06745] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
397 Feng LH, Sun HC, Zhu XD, Zhang SZ, Li XL, Li KS, Liu XF, Lei M, Li Y, Tang ZY. Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma. Ann Transl Med 2021;9:207. [PMID: 33708834 DOI: 10.21037/atm-20-5293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
398 Qi X, Bai Z, Zhu Q, Cheng G, Chen Y, Dang X, Ding H, Han J, Han L, He Y, Ji F, Jin H, Li B, Li H, Li Y, Li Z, Liu B, Liu F, Liu L, Lin S, Ma D, Meng F, Qi R, Ren T, Shao L, Tang S, Tang Y, Teng Y, Wang C, Wang R, Wu Y, Xu X, Yang L, Yuan J, Yuan S, Yang Y, Zhao Q, Zhang W, Yang Y, Guo X, Xie W. Practice guidance for the use of terlipressin for liver cirrhosis–related complications. Therap Adv Gastroenterol 2022;15:175628482210982. [DOI: 10.1177/17562848221098253] [Reference Citation Analysis]
399 Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. Eur J Gastroenterol Hepatol 2021;32:261-8. [PMID: 32282541 DOI: 10.1097/MEG.0000000000001734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
400 Wu X, Huang Z, Lau WY, Li W, Lin P, Zhang L, Chen Y. Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic background: a propensity score matching study. Surg Endosc 2019;33:206-15. [PMID: 29987565 DOI: 10.1007/s00464-018-6296-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
401 Tang P, Qu W, Wang T, Liu M, Wu D, Tan L, Zhou H. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma. Front Genet 2021;12:785185. [DOI: 10.3389/fgene.2021.785185] [Reference Citation Analysis]
402 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer 2020;9:275-92. [PMID: 32647631 DOI: 10.1159/000505190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
403 Gubernatorova EO, Polinova AI, Petropavlovskiy MM, Namakanova OA, Medvedovskaya AD, Zvartsev RV, Telegin GB, Drutskaya MS, Nedospasov SA. Dual Role of TNF and LTα in Carcinogenesis as Implicated by Studies in Mice. Cancers (Basel) 2021;13:1775. [PMID: 33917839 DOI: 10.3390/cancers13081775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
404 Han Z, Liu D, Chen L, He Y, Tian X, Qi L, Chen L, Luo Y, Chen Z, Hu X, Li G, Zhan L, Wang Y, Li Q, Chen P, Liu Z, Guo H. PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway. Cell Death Dis 2021;12:552. [PMID: 34050137 DOI: 10.1038/s41419-021-03837-y] [Reference Citation Analysis]
405 Xu Q, Chen S, Hu Y, Huang W. Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma. Front Genet 2021;12:739975. [PMID: 34589117 DOI: 10.3389/fgene.2021.739975] [Reference Citation Analysis]
406 Mahmoud A, Slater K. Hepatocellular Carcinoma Misdiagnosed as a Liver Abscess - A Story of Misdiagnosis and Long-Term Malignant Disease Control. Cureus 2021;13:e12636. [PMID: 33585123 DOI: 10.7759/cureus.12636] [Reference Citation Analysis]
407 Yu X, Zhang Y, Jiang C, Zhan F, Shen Z, Shen Z, Zhang F. circSLC30A7 Inhibits Hepatocellular Carcinoma Cell Proliferation via the miR-767-5p/FBXW7/NOTCH1 Axis. J Oncol 2021;2021:8800657. [PMID: 34675978 DOI: 10.1155/2021/8800657] [Reference Citation Analysis]
408 Schwarze V, Rübenthaler J, Marschner C, Fabritius MP, Rueckel J, Fink N, Puhr-Westerheide D, Gresser E, Froelich MF, Schnitzer ML, Große Hokamp N, Afat S, Staehler M, Geyer T, Clevert DA. Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI-CEUS) in Oncology. Cancers (Basel) 2020;12:E2821. [PMID: 33007933 DOI: 10.3390/cancers12102821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
409 Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
410 Espejo-Cruz ML, González-Rubio S, Zamora-Olaya J, Amado-Torres V, Alejandre R, Sánchez-Frías M, Ciria R, De la Mata M, Rodríguez-Perálvarez M, Ferrín G. Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. Int J Mol Sci 2021;22:13073. [PMID: 34884878 DOI: 10.3390/ijms222313073] [Reference Citation Analysis]
411 Zhao WJ, Zhu GQ, Wu YM, Wang WW, Bai BL. Comparative Effectiveness of Radiofrequency Ablation, Surgical Resection and Transplantation for Early Hepatocellular Carcinoma by Cancer Risk Groups: Results of Propensity Score-Weighted Analysis. Onco Targets Ther 2019;12:10389-400. [PMID: 31819521 DOI: 10.2147/OTT.S224809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
412 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Yang MJ, Zhou GH, Wang WS, Li Z, Huang P, Zhang S, Zhu XL, Ni CF. Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Oncol 2020;10:525461. [PMID: 33392064 DOI: 10.3389/fonc.2020.525461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
413 Fan Y, Hou J, Liu X, Han B, Meng Y, Liu B, Chen F, Shang Y, Cao P, Tan K. Integrated Bioinformatics Analysis Identifies Heat Shock Factor 2 as a Prognostic Biomarker Associated With Immune Cell Infiltration in Hepatocellular Carcinoma. Front Genet 2021;12:668516. [PMID: 34917120 DOI: 10.3389/fgene.2021.668516] [Reference Citation Analysis]
414 Zhou B, Yang C, Yan X, Shi Z, Xiao H, Wei X, Jiang N, Wu Z. LETM1 Knockdown Promotes Autophagy and Apoptosis Through AMP-Activated Protein Kinase Phosphorylation-Mediated Beclin-1/Bcl-2 Complex Dissociation in Hepatocellular Carcinoma. Front Oncol 2020;10:606790. [PMID: 33552978 DOI: 10.3389/fonc.2020.606790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
415 Deng M, Li S, Mei J, Lin W, Zou J, Wei W, Guo R. High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. Genes (Basel) 2021;12:876. [PMID: 34200261 DOI: 10.3390/genes12060876] [Reference Citation Analysis]
416 Kim J, Randhawa H, Sands D, Lambe S, Puglia M, Serrano PE, Pinthus JH. Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations. BLC 2021;7:261-78. [DOI: 10.3233/blc-211536] [Reference Citation Analysis]
417 Li D, Ding X, Xie M, Huang Z, Han P, Tian D, Xia L. CAMSAP2-mediated noncentrosomal microtubule acetylation drives hepatocellular carcinoma metastasis. Theranostics 2020;10:3749-66. [PMID: 32206120 DOI: 10.7150/thno.42596] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
418 Cao J, Kong FH, Liu X, Wang XB. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2019; 25(27): 3649-3663 [PMID: 31367163 DOI: 10.3748/wjg.v25.i27.3649] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
419 Yang J, Zhang Y, Duan J, Huang X, Yu H, Hu Z. A Glycolysis-Related Gene Signature Correlates With the Characteristics of the Tumor Immune Microenvironment and Predicts Prognosis in Patients With Hepatocellular Carcinoma. Front Mol Biosci 2022;9:834976. [DOI: 10.3389/fmolb.2022.834976] [Reference Citation Analysis]
420 Xu Q, Xu H, Chen S, Huang W. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:710207. [PMID: 34409040 DOI: 10.3389/fcell.2021.710207] [Reference Citation Analysis]
421 Yu H, Wang C, Ke S, Bai M, Xu Y, Lu S, Feng Z, Qian B, Xu Y, Zhou M, Li Z, Yin B, Li X, Hua Y, Zhou Y, Pan S, Fu Y, Ma Y. Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma. Front Immunol 2022;13:892750. [DOI: 10.3389/fimmu.2022.892750] [Reference Citation Analysis]
422 Shen LJ, Sun HW, Chai YY, Jiang QY, Zhang J, Li WM, Xin SJ. The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents. Front Oncol 2021;11:804412. [PMID: 34976842 DOI: 10.3389/fonc.2021.804412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Shiragannavar VD, Gowda NGS, Kumar DP, Mirshahi F, Santhekadur PK. Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC. Front Oncol 2020;10:628506. [PMID: 33585254 DOI: 10.3389/fonc.2020.628506] [Reference Citation Analysis]
424 Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [DOI: 10.12998/wjcc.v10.i11.3321] [Reference Citation Analysis]
425 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel) 2021;13:5018. [PMID: 34638502 DOI: 10.3390/cancers13195018] [Reference Citation Analysis]
426 Wang Z, Fan Q, Wang M, Wang E, Li H, Liu L. Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. Ann Transl Med 2020;8:537. [PMID: 32411760 DOI: 10.21037/atm.2020.02.114] [Reference Citation Analysis]
427 Zhou Q, An Y, Liu T, Liu Z, Li R, Wang C, Zhou F, Liu C, Zhu K. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation. Int J Hyperthermia 2022;39:97-107. [PMID: 34979845 DOI: 10.1080/02656736.2021.2021303] [Reference Citation Analysis]
428 Li L, Su Q, Yang H. Preoperative prediction of microvascular invasion in hepatocellular carcinoma: a radiomic nomogram based on MRI. Clin Radiol 2021:S0009-9260(21)00576-6. [PMID: 34980458 DOI: 10.1016/j.crad.2021.12.008] [Reference Citation Analysis]
429 Lu JW, Lin LI, Sun Y, Liu D, Gong Z. Effect of Lipopolysaccharides on Liver Tumor Metastasis of twist1a/krasV12 Double Transgenic Zebrafish. Biomedicines 2022;10:95. [PMID: 35052775 DOI: 10.3390/biomedicines10010095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Lee HA, Goh HG, Lee YS, Jung YK, Kim JH, Yim HJ, Lee MG, An H, Jeen YT, Yeon JE, Byun KS, Seo YS. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. BMC Gastroenterol 2021;21:258. [PMID: 34118869 DOI: 10.1186/s12876-021-01833-2] [Reference Citation Analysis]
431 Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05706-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
432 Tada T, Kumada T, Hiraoka A, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Sci Rep 2021;11:14474. [PMID: 34262065 DOI: 10.1038/s41598-021-93794-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
433 Yin S, Yang S, Luo Y, Lu J, Hu G, Wang K, Shao Y, Zhou S, Koo S, Qiu Y, Wang T, Yu H. Cyclin-dependent kinase 1 as a potential target for lycorine against hepatocellular carcinoma. Biochem Pharmacol 2021;193:114806. [PMID: 34673013 DOI: 10.1016/j.bcp.2021.114806] [Reference Citation Analysis]
434 Zheng X, Wang P, Li L, Yu J, Yu C, Xu L, Li L, Dai F, Feng L, Zou H, Chen X, Zhang M, Xu M. Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin β1 Signaling. Front Cell Dev Biol 2021;9:678670. [PMID: 34504839 DOI: 10.3389/fcell.2021.678670] [Reference Citation Analysis]
435 Wang G, Lu X, Du Q, Zhang G, Wang D, Wang Q, Guo X. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2020;10:13519. [PMID: 32782270 DOI: 10.1038/s41598-020-70241-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
436 Pan B, Pan W, Lu Z, Xia C. Pharmacological Mechanisms Underlying the Hepatoprotective Effects of Ecliptae herba on Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:5591402. [PMID: 34326886 DOI: 10.1155/2021/5591402] [Reference Citation Analysis]
437 Esparza-Baquer A, Labiano I, Sharif O, Agirre-Lizaso A, Oakley F, Rodrigues PM, Zhuravleva E, O'Rourke CJ, Hijona E, Jimenez-Agüero R, Riaño I, Landa A, La Casta A, Zaki MYW, Munoz-Garrido P, Azkargorta M, Elortza F, Vogel A, Schabbauer G, Aspichueta P, Andersen JB, Knapp S, Mann DA, Bujanda L, Banales JM, Perugorria MJ. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut 2021;70:1345-61. [PMID: 32907830 DOI: 10.1136/gutjnl-2019-319227] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
438 Sun X, Yang Z, Tang Y, Mao S, Xiong P, Wang J, Chen J, Zhang Y, Chen M, Xu L. Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. Immunotherapy 2021. [PMID: 34758630 DOI: 10.2217/imt-2021-0057] [Reference Citation Analysis]
439 Underhill GH, Khetani SR. Emerging trends in modeling human liver disease in vitro. APL Bioeng 2019;3:040902. [PMID: 31893256 DOI: 10.1063/1.5119090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
440 Chen ZX, Jian ZW, Wu XW, Wang JC, Peng JY, Lao XM. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. Cancer Med 2019;8:5097-107. [PMID: 31313476 DOI: 10.1002/cam4.2380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
441 Liu T, Xie XL, Zhou X, Chen SX, Wang YJ, Shi LP, Chen SJ, Wang YJ, Wang SL, Zhang JN, Dou SY, Jiang XY, Cui RL, Jiang HQ. Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4667-4686 [PMID: 34366628 DOI: 10.3748/wjg.v27.i28.4667] [Reference Citation Analysis]
442 Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
443 Zhang Y, Liu Z, Ji K, Li X, Wang C, Ren Z, Liu Y, Chen X, Han X, Meng L, Li L, Li Z. Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:736330. [PMID: 34660697 DOI: 10.3389/fmolb.2021.736330] [Reference Citation Analysis]
444 Wei CY, Chen PC, Chau GY, Lee RC, Chen PH, Huo TI, Huang YH, Su YH, Hou MC, Wu JC, Su CW. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med 2020;8:238. [PMID: 32309385 DOI: 10.21037/atm.2019.12.157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
445 Müller L, Kloeckner R, Mähringer-Kunz A, Stoehr F, Düber C, Arnhold G, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Hahn F. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. Eur Radiol 2022. [PMID: 35394184 DOI: 10.1007/s00330-022-08737-z] [Reference Citation Analysis]
446 Wei H, Tang Q, Wang A, Zhang Y, Qin Z, Li W, Xu Z, Wang J, Pu J. lncRNA MAGI2-AS3 Exerts Antioncogenic Roles in Hepatocellular Carcinoma via Regulating the miR-519c-3p/TXNIP Axis. J Oncol 2021;2021:5547345. [PMID: 34484334 DOI: 10.1155/2021/5547345] [Reference Citation Analysis]
447 Dong X, Zhang X, Liu P, Tian Y, Li L, Gong P. Lipolysis-Stimulated Lipoprotein Receptor Impairs Hepatocellular Carcinoma and Inhibits the Oncogenic Activity of YAP1 via PPPY Motif. Front Oncol 2022;12:896412. [DOI: 10.3389/fonc.2022.896412] [Reference Citation Analysis]
448 Li C, Qin F, Hong H, Tang H, Jiang X, Yang S, Mei Z, Zhou D. Identification of Flap endonuclease 1 as a potential core gene in hepatocellular carcinoma by integrated bioinformatics analysis. PeerJ 2019;7:e7619. [PMID: 31534853 DOI: 10.7717/peerj.7619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
449 Hu J, Dong Y, Ding L, Dong Y, Wu Z, Wang W, Shen M, Duan Y. Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment. Signal Transduct Target Ther 2019;4:28. [PMID: 31637008 DOI: 10.1038/s41392-019-0062-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
450 Siracusano G, Tagliamonte M, Buonaguro L, Lopalco L. Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. Vaccines (Basel) 2020;8:E41. [PMID: 31991677 DOI: 10.3390/vaccines8010041] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
451 Xiong Q, Bai Y, Shi R, Wang J, Xu W, Zhang M, Song T. Preferentially released miR-122 from cyclodextrin-based star copolymer nanoparticle enhances hepatoma chemotherapy by apoptosis induction and cytotoxics efflux inhibition. Bioact Mater 2021;6:3744-55. [PMID: 33898875 DOI: 10.1016/j.bioactmat.2021.03.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Mi N, Cao J, Zhang J, Fu W, Huang C, Gao L, Yue P, Bai B, Lin Y, Meng W, Li X. Identification of hub genes involved in the occurrence and development of hepatocellular carcinoma via bioinformatics analysis. Oncol Lett 2020;20:1695-708. [PMID: 32724412 DOI: 10.3892/ol.2020.11752] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
453 Xia H, Liu Z, Liang W, Zeng X, Yang Y, Chen P, Zhong Z, Ye Q. Vagus Nerve Stimulation Alleviates Hepatic Ischemia and Reperfusion Injury by Regulating Glutathione Production and Transformation. Oxid Med Cell Longev 2020;2020:1079129. [PMID: 32064020 DOI: 10.1155/2020/1079129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Chan LK, Ng IO. Proteomic profiling in liver cancer: another new page. Transl Gastroenterol Hepatol. 2019;4:47. [PMID: 31304424 DOI: 10.21037/tgh.2019.06.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
455 McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol 2020;7:HEP26. [PMID: 32774836 DOI: 10.2217/hep-2020-0003] [Reference Citation Analysis]
456 Long H, Xu W, Zhong X, Chen Z, Su L, Duan Y, Shi Y, Xie X, Lin M. Feasibility of liver stiffness measured using two-dimensional shear wave elastography in assessing preoperative liver function for patients with hepatocellular carcinoma. Abdom Radiol (NY) 2022;47:664-71. [PMID: 34914008 DOI: 10.1007/s00261-021-03374-4] [Reference Citation Analysis]
457 Chao JS, Zhu Q, Chen DS, Chen GM, Xie XQ, Liu AQ, Zhao SL, Sun HC. Combined analysis of imaging tumor capsule with imaging tumor size guides the width of resection margin for solitary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00234-4. [PMID: 35000845 DOI: 10.1016/j.hbpd.2021.12.009] [Reference Citation Analysis]
458 Murali M, Kumar AR, Nair B, Pavithran K, Devan AR, Pradeep GK, Nath LR. Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. Clin Transl Oncol 2021. [PMID: 34595736 DOI: 10.1007/s12094-021-02707-5] [Reference Citation Analysis]
459 Wu D, Zhang G, Ma J, Wu H, Xiong J, Huang X, Tian Y, Deng T, Han X, Sun X, Xiang T, Yu X, Jiang X. Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma. J Oncol 2021;2021:1301671. [PMID: 34659404 DOI: 10.1155/2021/1301671] [Reference Citation Analysis]
460 Dobrzycka M, Spychalski P, Rostkowska O, Wilczyński M, Kobiela P, Grąt M, Dell'Acqua V, Høyer M, Jereczek-Fossa BA. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol 2019;58:1706-13. [PMID: 31464155 DOI: 10.1080/0284186X.2019.1657942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
461 Zhou C, Sun J, Zheng Z, Weng J, Atyah M, Zhou Q, Chen W, Zhang Y, Huang J, Yin Y, Mao H, Zhang Z, Yi Y, Ren N. High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection. Ann Transl Med 2020;8:466. [PMID: 32395510 DOI: 10.21037/atm.2020.03.92] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
462 Xu X, Jiang W, Han P, Zhang J, Tong L, Sun X. MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met. JHC 2022;Volume 9:113-26. [DOI: 10.2147/jhc.s349369] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
463 Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. Cochrane Database Syst Rev 2020;3:CD009498. [PMID: 32163181 DOI: 10.1002/14651858.CD009498.pub4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
464 Schwarze V, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151. [PMID: 32529869 DOI: 10.1177/0300060520930151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
465 Zhu LY, Hou JC, Yang L, Liu ZR, Tong W, Bai Y, Zhang YM. Application value of mixed reality in hepatectomy for hepatocellular carcinoma. World J Gastrointest Surg 2022; 14(1): 36-45 [DOI: 10.4240/wjgs.v14.i1.36] [Reference Citation Analysis]
466 Wu DD, Wang DY, Li HM, Guo JC, Duan SF, Ji XY. Hydrogen Sulfide as a Novel Regulatory Factor in Liver Health and Disease. Oxid Med Cell Longev 2019;2019:3831713. [PMID: 30805080 DOI: 10.1155/2019/3831713] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
467 Kamitani N, Nomi T, Hokuto D, Yoshikawa T, Matsuo Y, Sho M. Primary undifferentiated carcinoma with osteoclast-like giant cells in liver and rapidly developing multiple metastases after curative hepatectomy: a case report. Int Cancer Conf J 2020;9:244-8. [PMID: 32904085 DOI: 10.1007/s13691-020-00436-0] [Reference Citation Analysis]
468 Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol 2022;13:815575. [DOI: 10.3389/fimmu.2022.815575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
469 Wang E, Xia D, Bai W, Wang Z, Wang Q, Liu L, Wang W, Yuan J, Li X, Chen H, Lv Y, Niu J, He C, Guo W, Yin Z, Luo B, Han N, Wang Z, Yu T, Yuan X, Li K, Tie J, Li C, Cai H, Xia J, Fan D, Han G. Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC. Invest New Drugs 2019;37:401-14. [PMID: 30019101 DOI: 10.1007/s10637-018-0640-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
470 Ke Q, Xiang F, Xiao C, Huang Q, Liu X, Zeng Y, Wang L, Liu J. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization. BMC Cancer 2021;21:1117. [PMID: 34663242 DOI: 10.1186/s12885-021-08843-z] [Reference Citation Analysis]
471 Li Y, Chen X, Huang H, Li G, Liao L, Yuan T, Deng S. Identification Of Novel lncRNAs For Detection Of HBV-Associated Hepatocellular Carcinoma. Onco Targets Ther 2019;12:10199-211. [PMID: 31819509 DOI: 10.2147/OTT.S230377] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
472 Liu Y, Nwafor E, Li Z, Wang J, Feng X, Li H, Jia B, Ma H, He J, Pi J, Liu Z. Effects of Berberine on Liver Cancer. Natural Product Communications 2022;17:1934578X2211020. [DOI: 10.1177/1934578x221102032] [Reference Citation Analysis]
473 Hernández-Oliveras A, Izquierdo-Torres E, Hernández-Martínez G, Zarain-Herzberg Á, Santiago-García J. Transcriptional and epigenetic landscape of Ca2+-signaling genes in hepatocellular carcinoma. J Cell Commun Signal 2021;15:433-45. [PMID: 33398721 DOI: 10.1007/s12079-020-00597-w] [Reference Citation Analysis]
474 Telichko AV, Wang H, Bachawal S, Kumar SU, Bose JC, Paulmurugan R, Dahl JJ. Therapeutic Ultrasound Parameter Optimization for Drug Delivery Applied to a Murine Model of Hepatocellular Carcinoma. Ultrasound Med Biol 2021;47:309-22. [PMID: 33153807 DOI: 10.1016/j.ultrasmedbio.2020.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
475 Zhen S, Cai X. Letter to the Editor: Predicting Survival After Hepatocellular Carcinoma Resection Using Deep-Learning on Histological Slides. Hepatology 2021;73:2077-8. [PMID: 32894573 DOI: 10.1002/hep.31543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
476 Koroki K, Ogasawara S, Ooka Y, Kanzaki H, Kanayama K, Maruta S, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kuboki S, Ohtsuka M, Miyazaki M, Yokosuka O, Kato N. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer 2020;9:596-612. [PMID: 33083283 DOI: 10.1159/000508809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
477 Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol 2020;12:1758835920936932. [PMID: 32684988 DOI: 10.1177/1758835920936932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
478 Lu LH, Mei J, Kan A, Ling YH, Li SH, Wei W, Chen MS, Zhang YF, Guo RP. Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation. Cancer Med. 2020;9:2997-3005. [PMID: 32108433 DOI: 10.1002/cam4.2951] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
479 Shi XB, Feng JK, Wang JH, Jiang XQ. Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis. Ann Transl Med 2021;9:641. [PMID: 33987339 DOI: 10.21037/atm-20-6748] [Reference Citation Analysis]
480 Fan Z, Wu M, Tang Z, He A, Liu F, Liang W, Wang Z, Yang D. Predictive Value of Platelet-Related Measures in Patients with Hepatocellular Carcinoma. Technol Cancer Res Treat 2022;21:15330338211064414. [PMID: 35225081 DOI: 10.1177/15330338211064414] [Reference Citation Analysis]
481 Eresen A, Sun C, Zhou K, Shangguan J, Wang B, Pan L, Hu S, Ma Q, Yang J, Zhang Z, Yaghmai V. Early Differentiation of Irreversible Electroporation Ablation Regions With Radiomics Features of Conventional MRI. Acad Radiol 2021:S1076-6332(21)00559-6. [PMID: 34933803 DOI: 10.1016/j.acra.2021.11.020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
482 Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant 2019;19:2210-8. [PMID: 30861298 DOI: 10.1111/ajt.15353] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
483 Dai X, Wang S, Niu C, Ji B, Liu Y. Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. Technol Cancer Res Treat 2020;19:153303382094748. [DOI: 10.1177/1533033820947486] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
484 Zhou M, Zhang G, Hu J, Zhu Y, Lan H, Shen X, Lv Y, Huang L. Rutin attenuates Sorafenib-induced Chemoresistance and Autophagy in Hepatocellular Carcinoma by regulating BANCR/miRNA-590-5P/OLR1 Axis. Int J Biol Sci 2021;17:3595-607. [PMID: 34512168 DOI: 10.7150/ijbs.62471] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Rungsakulkij N, Suragul W, Mingphruedhi S, Tangtawee P, Muangkaew P, Aeesoa S. Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. World J Clin Cases 2018; 6(6): 110-120 [PMID: 29988930 DOI: 10.12998/wjcc.v6.i6.110] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
486 Li Y, Li Y, Zhang J, Ji L, Li M, Sun X, Feng H, Yu Z, Gao Y. Current Perspective of Traditional Chinese Medicines and Active Ingredients in the Therapy of Hepatocellular Carcinoma. JHC 2022;Volume 9:41-56. [DOI: 10.2147/jhc.s346047] [Reference Citation Analysis]
487 Wang HL, Mo DC, Zhong JH, Ma L, Wu FX, Xiang BD, Li LQ. Systematic review of treatment strategy for recurrent hepatocellular carcinoma: Salvage liver transplantation or curative locoregional therapy. Medicine (Baltimore) 2019;98:e14498. [PMID: 30813151 DOI: 10.1097/MD.0000000000014498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
488 Li H, Shi S, Wu M, Shen W, Ren J, Mei Z, Ran H, Wang Z, Tian Y, Gao J, Zhao H. iRGD Peptide-Mediated Liposomal Nanoparticles with Photoacoustic/Ultrasound Dual-Modality Imaging for Precision Theranostics Against Hepatocellular Carcinoma. Int J Nanomedicine 2021;16:6455-75. [PMID: 34584411 DOI: 10.2147/IJN.S325891] [Reference Citation Analysis]
489 Xu G, Feng D, Yao Y, Li P, Sun H, Yang H, Li C, Jiang R, Sun B, Chen Y. Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization. Oncogene 2020;39:1429-44. [PMID: 31659256 DOI: 10.1038/s41388-019-1072-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
490 Li Y, Zhou T, Cheng X, Li D, Zhao M, Zheng WV. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3. Bioengineered 2022;13:4730-43. [DOI: 10.1080/21655979.2022.2031408] [Reference Citation Analysis]
491 Tsochatzis A, Mazioti A, Iliadis G, Velonakis G, Efthymiou E, Kelekis A, Kelekis N, Filippiadis D. Percutaneous Microwave Ablation of Liver Lesions: Differences on the Sphericity Index of the Ablation Zone between Cirrhotic and Healthy Liver Parenchyma. Diagnostics (Basel) 2021;11:655. [PMID: 33916400 DOI: 10.3390/diagnostics11040655] [Reference Citation Analysis]
492 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009 [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
493 Huang Q, Li J, Zeng Q, Tan L, Zheng R, He X, Li K. Value of artificial ascites to assist thermal ablation of liver cancer adjacent to the gastrointestinal tract in patients with previous abdominal surgery. BMC Cancer 2020;20:763. [PMID: 32795279 DOI: 10.1186/s12885-020-07261-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
494 Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T. Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers (Basel) 2021;13:E160. [PMID: 33466496 DOI: 10.3390/cancers13010160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
495 Dong N, Shi X, Wang S, Gao Y, Kuang Z, Xie Q, Li Y, Deng H, Wu Y, Li M, Li JL. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer 2019;121:22-33. [PMID: 31130723 DOI: 10.1038/s41416-019-0482-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
496 Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Chikara O, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), and GLSG (Gunma Liver Study Group). Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatol Res 2021;51:880-9. [PMID: 33837620 DOI: 10.1111/hepr.13644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
497 Zhang W, Liu Z, Xia S, Yao L, Li L, Gan Z, Tang H, Guo Q, Yan X, Sun Z. GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma. Aging (Albany NY) 2021;13:25304-24. [PMID: 34894398 DOI: 10.18632/aging.203748] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
498 Xu Y, Yu X, Sun Z, He Y, Guo W. Roles of lncRNAs Mediating Wnt/β-Catenin Signaling in HCC. Front Oncol 2022;12:831366. [PMID: 35356220 DOI: 10.3389/fonc.2022.831366] [Reference Citation Analysis]
499 Zhou W, Weng J, Wu K, Xu X, Wang H, Zhang J, Zhao C, Yang J, Zhang Y, Shen W. Silencing of TAZ inhibits the motility of hepatocellular carcinoma cells through autophagy induction. Cancer Manag Res 2019;11:8743-53. [PMID: 31576176 DOI: 10.2147/CMAR.S215466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
500 Qiu C, Liu Y, Huang S, Ning B, He S, Zhong L. Rab31 Promotes Activation of Hepatic Stellate Cells by Accelerating TGF-β Receptor II Complex Endocytosis. The International Journal of Biochemistry & Cell Biology 2022. [DOI: 10.1016/j.biocel.2022.106170] [Reference Citation Analysis]
501 Kotsifa E, Vergadis C, Vailas M, Machairas N, Kykalos S, Damaskos C, Garmpis N, Lianos GD, Schizas D. Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? JPM 2022;12:436. [DOI: 10.3390/jpm12030436] [Reference Citation Analysis]
502 Chen M, Xu R, Wu L, Chen X. Relationship between circulating tumor cells undergoing EMT and short-term efficacy following interventional treatment in patients with hepatocellular carcinoma. J Interv Med 2020;3:146-50. [PMID: 34805926 DOI: 10.1016/j.jimed.2020.07.008] [Reference Citation Analysis]
503 Jiang H, Zhao L, Chen Y, Sun L. A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23377. [PMID: 32474975 DOI: 10.1002/jcla.23377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
504 Reis D, Moura M, Freitas LC, Carvalhana S, Nogueira PJ, Gaio R, Marinho RT, Cortez-Pinto H. Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2020. [PMID: 33177383 DOI: 10.1097/MEG.0000000000001974] [Reference Citation Analysis]
505 Al-Harbi SA, Abdulrahman AO, Zamzami MA, Khan MI. Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review. Front Nutr 2021;8:647582. [PMID: 34164422 DOI: 10.3389/fnut.2021.647582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
506 Wang K, Yu G, Lin J, Wang Z, Lu Q, Gu C, Yang T, Liu S, Yang H. Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs. Front Pharmacol 2021;12:632201. [PMID: 34220494 DOI: 10.3389/fphar.2021.632201] [Reference Citation Analysis]
507 Mu H, Yu G, Li H, Wang M, Cui Y, Zhang T, Song T, Liu C. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation. Cell Oncol (Dordr) 2021. [PMID: 34339013 DOI: 10.1007/s13402-021-00625-w] [Reference Citation Analysis]
508 Zhang Q, Cheng S, Cao L, Yang J, Wang Y, Chen Y. LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway. Biosci Rep 2020;40:BSR20192790. [PMID: 32077915 DOI: 10.1042/BSR20192790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
509 Song M, Zhong A, Yang J, He J, Cheng S, Zeng J, Huang Y, Pan Q, Zhao J, Zhou Z, Zhu Q, Tang Y, Chen H, Yang C, Liu Y, Mo X, Weng D, Xia JC. Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma. Aging (Albany NY) 2019;11:10422-53. [PMID: 31761783 DOI: 10.18632/aging.102468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
510 Xu Q, Xu H, Deng R, Li N, Mu R, Qi Z, Shen Y, Wang Z, Wen J, Zhao J, Weng D, Huang W. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma. Cancer Cell Int 2021;21:190. [PMID: 33794886 DOI: 10.1186/s12935-021-01894-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
511 Gao B, Luo J, Liu Y, Su S, Fu S, Yang X, Li B. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma. Int J Nanomedicine 2021;16:4073-85. [PMID: 34163160 DOI: 10.2147/IJN.S308057] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
512 Hucke F, Pinter M, Hucke M, Bota S, Bolf D, Hackl M, Peck-radosavljevic M. Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. Cancers 2022;14:3093. [DOI: 10.3390/cancers14133093] [Reference Citation Analysis]
513 Bender D, Hildt E. Effect of Hepatitis Viruses on the Nrf2/Keap1-Signaling Pathway and Its Impact on Viral Replication and Pathogenesis. Int J Mol Sci 2019;20:E4659. [PMID: 31546975 DOI: 10.3390/ijms20184659] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
514 Omran MM, Farid K, Omar MA, Emran TM, El-Taweel FM, Tabll AA. A combination of α-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. Ann Hepatol 2020;19:179-85. [PMID: 31648804 DOI: 10.1016/j.aohep.2019.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
515 Riaño I, Martín L, Varela M, Serrano T, Núñez O, Mínguez B, Rodrigues PM, Perugorria MJ, Banales JM, Arenas JI. Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). Cancers (Basel) 2020;12:E1900. [PMID: 32674461 DOI: 10.3390/cancers12071900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
516 Shomura M, Okabe H, Sato E, Fukai K, Shiraishi K, Hirose S, Tsuruya K, Arase Y, Anzai K, Kagawa T. Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. Cancers (Basel) 2020;12:E3078. [PMID: 33105621 DOI: 10.3390/cancers12113078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
517 Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R, Uchila R, van der Poorten D, George J, Karsdal MA, Leeming DJ, Willumsen N. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. J Hepatocell Carcinoma 2020;7:301-13. [PMID: 33204663 DOI: 10.2147/JHC.S275008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
518 Lemieux S, Buies A, F Turgeon A, Hallet J, Daigle G, Côté F, Provencher S. Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One 2021;16:e0247958. [PMID: 33662011 DOI: 10.1371/journal.pone.0247958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
519 Kim HO, Lee BC, Park C, Kim JK, Park WJ, Lee JE, Lim HS, Jeong WG. Occupational dose and associated factors during transarterial chemoembolization of hepatocellular carcinoma using real-time dosimetry: A simple way to reduce radiation exposure. Medicine (Baltimore) 2022;101:e28744. [PMID: 35089250 DOI: 10.1097/MD.0000000000028744] [Reference Citation Analysis]
520 Yu L, Xu H, Zhang S, Chen J, Yu Z. SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway. Hum Cell 2020;33:721-9. [PMID: 32314115 DOI: 10.1007/s13577-020-00362-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
521 Long H, Zhong X, Su L, Huang T, Duan Y, Ke W, Xie X, Lin M. Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2021. [PMID: 34379248 DOI: 10.1245/s10434-021-10563-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
522 Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers (Basel) 2020;12:E1867. [PMID: 32664489 DOI: 10.3390/cancers12071867] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
523 Biondetti P, Saggiante L, Ierardi AM, Iavarone M, Sangiovanni A, Pesapane F, Fumarola EM, Lampertico P, Carrafiello G. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers (Basel) 2021;13:5797. [PMID: 34830949 DOI: 10.3390/cancers13225797] [Reference Citation Analysis]
524 Wang J, Ma X, Si H, Ma Z, Ma Y, Wang J, Cao B. Role of long non-coding RNA H19 in therapy resistance of digestive system cancers. Mol Med 2021;27:1. [PMID: 33402118 DOI: 10.1186/s10020-020-00255-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
525 Xu D, Wang Y, Wu J, Zhang Y, Liu Z, Chen Y, Zheng J. Systematic Characterization of Novel Immune Gene Signatures Predicts Prognostic Factors in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:686664. [PMID: 34631695 DOI: 10.3389/fcell.2021.686664] [Reference Citation Analysis]
526 Rimola J, Forner A. Hepatobiliary contrast agents in MR: Where we stand and future perspectives. Liver Int 2021;41:888-90. [PMID: 33861894 DOI: 10.1111/liv.14883] [Reference Citation Analysis]
527 Luo J, Lu C, Feng M, Dai L, Wang M, Qiu Y, Zheng H, Liu Y, Li L, Tang B, Xu C, Wang Y, Yang X. Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. J Exp Clin Cancer Res 2021;40:262. [PMID: 34416907 DOI: 10.1186/s13046-021-02061-y] [Reference Citation Analysis]
528 Zhao W, Li J, Zhong C, Zhang X, Bao Y. Green synthesis of gold nanoparticles from Dendrobium officinale and its anticancer effect on liver cancer. Drug Deliv 2021;28:985-94. [PMID: 34042555 DOI: 10.1080/10717544.2021.1921079] [Reference Citation Analysis]
529 Zhang Z, Chen P, Xie H, Cao P. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med 2020;9:1349-64. [PMID: 31876977 DOI: 10.1002/cam4.2799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
530 Kanogawa N, Ogasawara S, Ooka Y, Inoue M, Wakamatsu T, Yokoyama M, Maruta S, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kanzaki H, Maeda T, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Saito T, Motoyama T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Takemura R, Nozaki-Taguchi N, Shiroh I, Yokosuka O, Kato N. Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. JGH Open 2021;5:273-9. [PMID: 33553667 DOI: 10.1002/jgh3.12483] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
531 Luo JP, Wang J, Huang JH. CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20211103. [PMID: 34405225 DOI: 10.1042/BSR20211103] [Reference Citation Analysis]
532 Cano L, Bertani S, Island ML, Cerapio JP, Ruiz E, Pineau P, Monbet V, Boudjema K, Taxa L, Casavilca-Zambrano S, Ropert M, Turlin B, Loréal O. Metallomic profile in non-cirrhotic hepatocellular carcinoma supports a phenomenon of metal metabolism adaptation in tumor cells. Sci Rep 2021;11:14195. [PMID: 34244548 DOI: 10.1038/s41598-021-93369-4] [Reference Citation Analysis]
533 Deng Z, Wang J, Xu B, Jin Z, Wu G, Zeng J, Peng M, Guo Y, Wen Z. Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma. Biomed Res Int 2019;2019:2408348. [PMID: 31828095 DOI: 10.1155/2019/2408348] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
534 Zhang Q, Yu X, Zheng Q, He Y, Guo W. A Molecular Subtype Model for Liver HBV-Related Hepatocellular Carcinoma Patients Based on Immune-Related Genes. Front Oncol 2020;10:560229. [PMID: 33072587 DOI: 10.3389/fonc.2020.560229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
535 Wu Y, Zhang J, Li Q. Autophagy, an accomplice or antagonist of drug resistance in HCC? Cell Death Dis 2021;12:266. [PMID: 33712559 DOI: 10.1038/s41419-021-03553-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
536 Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2022;5:CD014798. [PMID: 35521901 DOI: 10.1002/14651858.CD014798.pub2] [Reference Citation Analysis]
537 Lin H, Zhou W, Huang Y, Ren M, Xu F, Wang H. Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice. Acta Biochim Biophys Sin (Shanghai) 2020;52:421-9. [PMID: 32250393 DOI: 10.1093/abbs/gmaa010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
538 Shi X, Li Q, Wang Y. Impact of regulatory T cells on the prognosis of hepatocellular carcinoma: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2021;100:e23957. [PMID: 33545975 DOI: 10.1097/MD.0000000000023957] [Reference Citation Analysis]
539 Yukimoto A, Watanabe T, Sunago K, Nakamura Y, Tanaka T, Koizumi Y, Yoshida O, Tokumoto Y, Hirooka M, Abe M, Hiasa Y. The long noncoding RNA of RMRP is downregulated by PERK, which induces apoptosis in hepatocellular carcinoma cells. Sci Rep 2021;11:7926. [PMID: 33846370 DOI: 10.1038/s41598-021-86592-6] [Reference Citation Analysis]
540 Chen L, Sun L, Dai X, Li T, Yan X, Zhang Y, Xiao H, Shen X, Huang G, Xiang W, Zhang Y, Tan D, Yang S, Nie Y, Huang X, Lian J, He F. LncRNA CRNDE Promotes ATG4B-Mediated Autophagy and Alleviates the Sensitivity of Sorafenib in Hepatocellular Carcinoma Cells. Front Cell Dev Biol 2021;9:687524. [PMID: 34409031 DOI: 10.3389/fcell.2021.687524] [Reference Citation Analysis]
541 He Q, Lin Z, Wang Z, Huang W, Tian D, Liu M, Xia L. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET. Oncogene 2020;39:7279-95. [PMID: 33046796 DOI: 10.1038/s41388-020-01500-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
542 Kovac JD, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore RM. An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. Radiol Oncol 2021;55:130-43. [PMID: 33544992 DOI: 10.2478/raon-2021-0004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
543 Wang L, Zhang Z, Li Y, Wan Y, Xing B. Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma. Aging (Albany NY) 2020;13:2480-505. [PMID: 33411682 DOI: 10.18632/aging.202281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
544 Kuroda H, Nagasawa T, Fujiwara Y, Sato H, Abe T, Kooka Y, Endo K, Oikawa T, Sawara K, Takikawa Y. Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:1295. [PMID: 33803926 DOI: 10.3390/cancers13061295] [Reference Citation Analysis]
545 Xie L, Li M, Liu D, Wang X, Wang P, Dai H, Yang W, Liu W, Hu X, Zhao M. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway. Molecules 2019;24:E393. [PMID: 30678274 DOI: 10.3390/molecules24030393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
546 Eresen A, Yang J, Scotti A, Cai K, Yaghmai V, Zhang Z. Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma. Ann Transl Med 2021;9:1089. [PMID: 34423001 DOI: 10.21037/atm-21-539] [Reference Citation Analysis]
547 Xu WP, Liu JP, Feng JF, Zhu CP, Yang Y, Zhou WP, Ding J, Huang CK, Cui YL, Ding CH, Zhang X, Lu B, Xie WF. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Gut 2020;69:1309-21. [PMID: 31727683 DOI: 10.1136/gutjnl-2019-318830] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 19.0] [Reference Citation Analysis]
548 Thrift AP, Natarajan Y, Liu Y, El-Serag HB. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol 2019;17:2117-2125.e3. [PMID: 30625400 DOI: 10.1016/j.cgh.2018.12.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
549 Shao S, Duan W, Xu Q, Li X, Han L, Li W, Zhang D, Wang Z, Lei J. Curcumin Suppresses Hepatic Stellate Cell-Induced Hepatocarcinoma Angiogenesis and Invasion through Downregulating CTGF. Oxid Med Cell Longev 2019;2019:8148510. [PMID: 30800209 DOI: 10.1155/2019/8148510] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
550 Zhang T, Xu J, Ye L, Lin X, Xu Y, Pan X, Weng X, Ye C, Fan L, Ren Y, Shan PF. Age, Gender and Geographic Differences in Global Health Burden of Cirrhosis and Liver Cancer due to Nonalcoholic Steatohepatitis. J Cancer 2021;12:2855-65. [PMID: 33854586 DOI: 10.7150/jca.52282] [Reference Citation Analysis]
551 Lin Y, Pan XB. Differences in Survival Between First-Line Radiofrequency Ablation versus Surgery for Early-Stage Hepatocellular Carcinoma: A Population Study Using the Surveillance, Epidemiology, and End Results Database. Med Sci Monit 2020;26:e921782. [PMID: 32461542 DOI: 10.12659/MSM.921782] [Reference Citation Analysis]
552 Müller L, Hahn F, Jungmann F, Mähringer-Kunz A, Stoehr F, Halfmann MC, Pinto Dos Santos D, Hinrichs J, Auer TA, Düber C, Kloeckner R. Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis? Cancer Imaging 2022;22:5. [PMID: 35016731 DOI: 10.1186/s40644-022-00446-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
553 Selvaggi F, Catalano T, Cotellese R, Aceto GM. Targeting Wnt/β-Catenin Pathways in Primary Liver Tumours: From Microenvironment Signaling to Therapeutic Agents. Cancers 2022;14:1912. [DOI: 10.3390/cancers14081912] [Reference Citation Analysis]
554 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers (Basel) 2021;13:3961. [PMID: 34439116 DOI: 10.3390/cancers13163961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
555 Yang YC, Chien MH, Lai TC, Tung MC, Jan YH, Chang WM, Jung SM, Chen MH, Yeh CN, Hsiao M. Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma. J Biomed Sci 2021;28:29. [PMID: 33888099 DOI: 10.1186/s12929-021-00727-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
556 Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Reference Citation Analysis]
557 Zhang W, Hu Z, Tian J, Fang C. A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. Ann Transl Med 2021;9:171. [PMID: 33569473 DOI: 10.21037/atm-20-5341] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
558 Xin Z, Li J, Zhang H, Zhou Y, Song J, Chen P, Bai L, Chen H, Zhou J, Chen J, Ying B. Cancer Genomic Alterations Can Be Potential Biomarkers Predicting Microvascular Invasion and Early Recurrence of Hepatocellular Carcinoma. Front Oncol 2022;12:783109. [PMID: 35155229 DOI: 10.3389/fonc.2022.783109] [Reference Citation Analysis]
559 Zhang B, Zhou J. CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis. Bioengineered 2022;13:9049-62. [DOI: 10.1080/21655979.2022.2057761] [Reference Citation Analysis]
560 Amoros R, King R, Toyoda H, Kumada T, Johnson PJ, Bird TG. A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma. Metron 2019;77:67-86. [PMID: 31708595 DOI: 10.1007/s40300-019-00151-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
561 Wang MD, Li C, Li J, Zhang WG, Jiang WQ, Yu JJ, Xing H, Wu H, Han J, Li ZL, Xu XF, Chen TH, Zhou YH, Gu WM, Wang H, Zeng YY, Zhang YM, Pawlik TM, Lau WY, Wu MC, Yang JM, Shen F, Yang T. Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort Study. Oncologist 2019;24:e730-9. [PMID: 31127021 DOI: 10.1634/theoncologist.2018-0898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
562 Xiang L, Huang X, Wang S, Ou H, Chen Z, Hu Z, Huang Y, Li X, Yuan Y, Yang D. Deficiency of pseudogene UPAT leads to hepatocellular carcinoma progression and forms a positive feedback loop with ZEB1. Cancer Sci 2020;111:4102-17. [PMID: 32808348 DOI: 10.1111/cas.14620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
563 Shui Y, Zhu X, Wu J, Liang T, Wei Q. Stereotactic body radiotherapy as the initial treatment for hepatocellular carcinoma with extensive inferior vena cava and atrium tumor thrombus. Onco Targets Ther 2019;12:5299-303. [PMID: 31308700 DOI: 10.2147/OTT.S208560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
564 González-Regueiro JA, Ruiz-Margáin A, Cruz-Contreras M, Montaña-Duclaud AM, Cavazos-Gómez A, Demichelis-Gómez R, Macías-Rodríguez RU. Clinical characteristics and treatment outcomes in patients with liver cirrhosis and lymphoma. World Journal of Hepatology 2020; 12(2): 34-45 [PMID: 32184940 DOI: 10.4254/wjh.v12.i2.34] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
565 Wang H, Wang R, Huang D, Li S, Gao B, Kang Z, Tang B, Xie J, Yan F, Liang R, Li H, Yan J. Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway. Front Pharmacol 2021;12:592071. [PMID: 33716735 DOI: 10.3389/fphar.2021.592071] [Reference Citation Analysis]
566 Sun J, Li J, Wu Z, Liang Y, Duan R, Zheng M, Wang J, Kong D. SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis. Int J Biol Sci 2022;18:140-53. [PMID: 34975323 DOI: 10.7150/ijbs.65676] [Reference Citation Analysis]
567 Campani C, Capone M, Liotta F, Arena U, Adotti V, Di Bonaventura C, Aburas S, Colagrande S, Calistri L, Annunziato F, Marra F. Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. Dig Liver Dis 2021:S1590-8658(21)00850-1. [PMID: 34876355 DOI: 10.1016/j.dld.2021.11.010] [Reference Citation Analysis]
568 Wang S, Wang X, Yang X, Liu F, Li J, Li W, Bai Z, Wang H, Mao J, Li T, He K, Wang H. Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues. Proteomics 2021;:e2100141. [PMID: 34932872 DOI: 10.1002/pmic.202100141] [Reference Citation Analysis]
569 Gao W, Wang W, Song D, Yang C, Zhu K, Zeng M, Rao SX, Wang M. A predictive model integrating deep and radiomics features based on gadobenate dimeglumine-enhanced MRI for postoperative early recurrence of hepatocellular carcinoma. Radiol Med 2022. [PMID: 35129757 DOI: 10.1007/s11547-021-01445-6] [Reference Citation Analysis]
570 Li L, Li H, Li Y, Feng J, Guan D, Zhang Y, Fu Y, Li S, Li C. Ferritinophagy-Mediated ROS Production Contributed to Proliferation Inhibition, Apoptosis, and Ferroptosis Induction in Action of Mechanism of 2-Pyridylhydrazone Dithiocarbamate Acetate. Oxid Med Cell Longev 2021;2021:5594059. [PMID: 34691357 DOI: 10.1155/2021/5594059] [Reference Citation Analysis]
571 Jiang YQ, Wang ZX, Deng YN, Yang Y, Wang GY, Chen GH. Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size. Front Oncol. 2019;9:113. [PMID: 30863723 DOI: 10.3389/fonc.2019.00113] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
572 Wang J, Ling S, Ni J, Wan Y. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma. BMC Cancer 2022;22:638. [PMID: 35681134 DOI: 10.1186/s12885-022-09662-6] [Reference Citation Analysis]
573 Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Kariya S, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2021;22:1217-24. [PMID: 33906315 DOI: 10.31557/APJCP.2021.22.4.1217] [Reference Citation Analysis]
574 Marino D, Zichi C, Audisio M, Sperti E, Di Maio M. Second-line treatment options in hepatocellular carcinoma. Drugs Context 2019;8:212577. [PMID: 31024634 DOI: 10.7573/dic.212577] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
575 Hershberger CE, Rodarte AI, Siddiqi S, Moro A, Acevedo-Moreno LA, Brown JM, Allende DS, Aucejo F, Rotroff DM. Salivary Metabolites are Promising Non-Invasive Biomarkers of Hepatocellular Carcinoma and Chronic Liver Disease. Liver Cancer Int 2021;2:33-44. [PMID: 34541549 DOI: 10.1002/lci2.25] [Reference Citation Analysis]
576 Xu W, Li R, Liu F. Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Cancer Manag Res. 2020;12:1693-1712. [PMID: 32214844 DOI: 10.2147/cmar.s241959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
577 Chong H, Zhou P, Yang C, Zeng M. An excellent nomogram predicts microvascular invasion that cannot independently stratify outcomes of small hepatocellular carcinoma. Ann Transl Med 2021;9:757. [PMID: 34268370 DOI: 10.21037/atm-20-7952] [Reference Citation Analysis]
578 Chen T, Sun L, Yao B, Wang L, Wang Y, Niu Y, Liu R, Mo H, Liu Z, Tu K, Liu Q. MicroRNA‑875‑5p inhibits tumor growth and metastasis of hepatocellular carcinoma by targeting eukaryotic translation initiation factor 3 subunit a. Oncol Rep 2020;44:2067-79. [PMID: 33000235 DOI: 10.3892/or.2020.7743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
579 Yamashita R, Long J, Saleem A, Rubin DL, Shen J. Deep learning predicts postsurgical recurrence of hepatocellular carcinoma from digital histopathologic images. Sci Rep 2021;11:2047. [PMID: 33479370 DOI: 10.1038/s41598-021-81506-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
580 He Y, Lu M, Che J, Chu Q, Zhang P, Chen Y. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Front Oncol 2021;11:716844. [PMID: 34552872 DOI: 10.3389/fonc.2021.716844] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
581 Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, Zhao H, Hacker M, Huo L, Li X. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging 2021;48:196-203. [PMID: 32468254 DOI: 10.1007/s00259-020-04882-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
582 Li J, Zhu Y. Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins. Front Cell Dev Biol 2020;8:548335. [PMID: 33117795 DOI: 10.3389/fcell.2020.548335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
583 Guo J, Tang Q. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Ther. 2021;. [PMID: 33500535 DOI: 10.1038/s41417-020-00259-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
584 Thamtorawat S, Patanawanitkul R, Rojwatcharapibarn S, Chaiyasoot W, Tongdee T, Yodying J, Sorotpinya S. Biliary complications and efficacy after ablation of peribiliary tumors using irreversible electroporation (IRE) or radiofrequency ablation (RFA). Int J Hyperthermia 2022;39:751-7. [PMID: 35649727 DOI: 10.1080/02656736.2022.2079733] [Reference Citation Analysis]
585 Yassin NYS, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomed Pharmacother 2021;145:112409. [PMID: 34781148 DOI: 10.1016/j.biopha.2021.112409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
586 Liu J, Zhao J, Gu HAO, Zhu Z. Repeat hepatic resection VS radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma: an updated meta-analysis. Minim Invasive Ther Allied Technol 2020;:1-10. [PMID: 33143517 DOI: 10.1080/13645706.2020.1839775] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
587 Zhu Z, Shen S, Zhao S, Wang Z. Hsa_circ_0006916 Knockdown Represses the Development of Hepatocellular Carcinoma via Modulating miR-599/SRSF2 Axis. Onco Targets Ther 2020;13:11301-13. [PMID: 33177838 DOI: 10.2147/OTT.S267471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
588 Bai L, Yang ZX, Ma PF, Liu JS, Wang DS, Yu HC. Overexpression of SLC25A51 promotes hepatocellular carcinoma progression by driving aerobic glycolysis through activation of SIRT5. Free Radic Biol Med 2022:S0891-5849(22)00067-3. [PMID: 35182732 DOI: 10.1016/j.freeradbiomed.2022.02.014] [Reference Citation Analysis]
589 Roderburg C, Özdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol 2020;7:HEP20. [PMID: 32647565 DOI: 10.2217/hep-2020-0004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
590 Preel A, Hermida M, Allimant C, Assenat E, Guillot C, Gozzo C, Aho-Glele S, Pageaux GP, Cassinotto C, Guiu B. Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation. Cancers (Basel) 2021;13:2700. [PMID: 34070800 DOI: 10.3390/cancers13112700] [Reference Citation Analysis]
591 Dietrich CF, Teufel A, Sirlin CB, Dong Y. Surveillance of hepatocellular carcinoma by medical imaging. Quant Imaging Med Surg 2019;9:1904-10. [PMID: 31867241 DOI: 10.21037/qims.2019.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
592 Kaneko J, Kokudo T, Inagaki Y, Hasegawa K. Innovative treatment for hepatocellular carcinoma (HCC). Transl Gastroenterol Hepatol. 2018;3:78. [PMID: 30505965 DOI: 10.21037/tgh.2018.10.04] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
593 Zhu Q, Luo M, Zhou C, Chen Z, Huang W, Huang J, Zhao S, Yu X. [Effect of danusertib on cell cycle, apoptosis and autophagy of hepatocellular carcinoma HepG2 cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 2018;38:1476-84. [PMID: 30613017 DOI: 10.12122/j.issn.1673-4254.2018.12.13] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
594 Zhou Q, Gong N, Zhang D, Li J, Han X, Dou J, Huang J, Zhu K, Liang P, Liang XJ, Yu J. Mannose-Derived Carbon Dots Amplify Microwave Ablation-Induced Antitumor Immune Responses by Capturing and Transferring "Danger Signals" to Dendritic Cells. ACS Nano 2021;15:2920-32. [PMID: 33523631 DOI: 10.1021/acsnano.0c09120] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
595 Si Y, Wang X, Pan C, Wang Y, Lu Z. An Efficient Nomogram for Discriminating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma: A Retrospective Study. Front Oncol 2022;12:833999. [DOI: 10.3389/fonc.2022.833999] [Reference Citation Analysis]
596 Vogl TJ, Mader C, Michalik S, Hammerstingl R, Koch V. [Small hepatocellular carcinoma : Diagnostics according to guidelines and established in the clinical setting]. Radiologe 2022. [PMID: 35037980 DOI: 10.1007/s00117-021-00965-6] [Reference Citation Analysis]
597 Huang Y, Chen H, Zeng Y, Liu Z, Ma H, Liu J. Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection. Front Oncol 2020;10:593741. [PMID: 33598425 DOI: 10.3389/fonc.2020.593741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
598 Xu L, Lin J, Deng W, Luo W, Huang Y, Liu CQ, Zhang FP, Qin YF, Wong PP, Liu C. EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c. Oncogenesis 2020;9:101. [PMID: 33168810 DOI: 10.1038/s41389-020-00284-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
599 Oura K, Takuma K, Nakahara M, Tadokoro T, Fujita K, Mimura S, Tani J, Morishita A, Kobara H, Masaki T. Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature. Mol Clin Oncol 2021;15:154. [PMID: 34178325 DOI: 10.3892/mco.2021.2316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
600 Han Q, Deng H, Fan X, Wang X, Zhang X, Zhang K, Li N, Lv Y, Liu Z. Increased Serum Pentraxin 3 Levels are Associated with Poor Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1367-73. [PMID: 34805015 DOI: 10.2147/JHC.S337936] [Reference Citation Analysis]
601 Liu X, Liu Y, Liu Z, Zhang Y, Ma Y, Bai J, Yao H, Wang Y, Zhao X, Li R, Song X, Chen Y, Feng Z, Wang L. Identification of SLITRK6 as a Novel Biomarker in hepatocellular carcinoma by comprehensive bioinformatic analysis. Biochem Biophys Rep 2021;28:101157. [PMID: 34754951 DOI: 10.1016/j.bbrep.2021.101157] [Reference Citation Analysis]
602 Jiang C, Cheng G, Liao M, Huang J. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. World J Surg Oncol 2021;19:81. [PMID: 33741001 DOI: 10.1186/s12957-021-02188-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
603 Kalathil SG, Hutson A, Barbi J, Iyer R, Thanavala Y. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight 2019;4:130116. [PMID: 31391334 DOI: 10.1172/jci.insight.130116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
604 Cammarota A, Zanuso V, D’alessio A, Pressiani T, Personeni N, Rimassa L. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032641] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
605 Zhao S, Wang H. EVA1A Plays an Important Role by Regulating Autophagy in Physiological and Pathological Processes. Int J Mol Sci 2021;22:6181. [PMID: 34201121 DOI: 10.3390/ijms22126181] [Reference Citation Analysis]
606 Shen ZF, Liang X. Current status of radical laparoscopy for treating hepatocellular carcinoma with portal hypertension. World J Clin Cases 2021; 9(11): 2419-2432 [PMID: 33889608 DOI: 10.12998/wjcc.v9.i11.2419] [Reference Citation Analysis]
607 Alnammi M, Wortman J, Therrien J, Afnan J. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. Abdom Radiol (NY) 2022. [PMID: 35524803 DOI: 10.1007/s00261-022-03526-0] [Reference Citation Analysis]
608 Fang T, Lu Q. A-kinase interacting protein 1 (AKIP1) associates with advanced overall disease condition, tumor properties, and unfavorable prognosis in hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23213. [PMID: 32133702 DOI: 10.1002/jcla.23213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
609 Su F, Ioannou GN. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. Curr Hepatol Rep 2018;17:377-84. [PMID: 30923667 DOI: 10.1007/s11901-018-0424-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
610 Yang Y, Ge H, Li DQ, Xu AX. E2F1-Induced lncRNA BAIAP2-AS1 Overexpression Contributes to the Malignant Progression of Hepatocellular Carcinoma via miR-361-3p/SOX4 Axis. Dis Markers 2021;2021:6256369. [PMID: 34616498 DOI: 10.1155/2021/6256369] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
611 Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Front Immunol 2022;13:896752. [PMID: 35757756 DOI: 10.3389/fimmu.2022.896752] [Reference Citation Analysis]
612 Qi Y, Liu G. Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α. Drug Deliv 2021;28:171-82. [PMID: 33427515 DOI: 10.1080/10717544.2020.1870020] [Reference Citation Analysis]
613 Personeni N, Pressiani T, Rimassa L. Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. Health Sci Rep 2020;3:e147. [PMID: 32166192 DOI: 10.1002/hsr2.147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
614 Zhang C, Cui X, Feng L, Han Z, Peng D, Fu W, Xing Y. The deficiency of FKBP-5 inhibited hepatocellular progression by increasing the infiltration of distinct immune cells and inhibiting obesity-associated gut microbial metabolite. J Gastrointest Oncol 2021;12:711-21. [PMID: 34012660 DOI: 10.21037/jgo-21-71] [Reference Citation Analysis]
615 Wei N, Wu Z, Lu D, Xiao J, Zhou C, Chu S, Lv W. Expression of MMP-2 in residual VX2 liver tumor after transcatheter arterial embolization combined with portal venous embolization in an animal model. J Interv Med 2020;3:167-73. [PMID: 34805929 DOI: 10.1016/j.jimed.2020.08.006] [Reference Citation Analysis]
616 Bu X, Ma L, Liu S, Wen D, Kan A, Xu Y, Lin X, Shi M. A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2022;22:95. [PMID: 35193591 DOI: 10.1186/s12935-022-02507-z] [Reference Citation Analysis]
617 Gao F, Yu X, Meng R, Wang J, Jia L. STARD13 is positively correlated with good prognosis and enhances 5-FU sensitivity via suppressing cancer stemness in hepatocellular carcinoma cells. Onco Targets Ther 2018;11:5371-81. [PMID: 30214243 DOI: 10.2147/OTT.S170775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
618 Yang Q, Wang L, Liu J, Cao W, Pan Q, Li M. Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management. Cell Death Discov 2021;7:293. [PMID: 34650055 DOI: 10.1038/s41420-021-00675-x] [Reference Citation Analysis]
619 Ma G, Du X, Zhu J, Xu F, Yu H, Li J. Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. Journal of Drug Delivery Science and Technology 2021;63:102493. [DOI: 10.1016/j.jddst.2021.102493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
620 Gil-Gómez A, Rojas Á, Liu CH, Gallego-Duran R, Muñoz-Hernandez R, Fassina G, Pontisso P, Ampuero J, Romero-Gómez M. Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. World J Gastroenterol 2021; 27(48): 8343-8356 [DOI: 10.3748/wjg.v27.i48.8343] [Reference Citation Analysis]
621 Yu H, Mei XP, Su PF, Jin GZ, Zhou HK. A poor prognosis in human hepatocellular carcinoma is associated with low expression of DPP4. Braz J Med Biol Res 2020;53:e9114. [PMID: 32294701 DOI: 10.1590/1414-431X20209114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
622 Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676 [PMID: 32699581 DOI: 10.4251/wjgo.v12.i6.663] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
623 Deng M, Sun S, Zhao R, Guan R, Zhang Z, Li S, Wei W, Guo R. The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma. Mol Med 2022;28. [DOI: 10.1186/s10020-022-00445-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
624 Tong J, Ma X, Yu H, Yang J. SNHG15: a promising cancer-related long noncoding RNA. Cancer Manag Res 2019;11:5961-9. [PMID: 31308739 DOI: 10.2147/CMAR.S208054] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
625 Luo M, Sun H, Jiang Q, Chai Y, Li C, Yang B, Hong Z. Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma. Front Oncol 2021;11:777356. [PMID: 34926286 DOI: 10.3389/fonc.2021.777356] [Reference Citation Analysis]
626 Zhou J, Zheng Q, Chen Z. The Nrf2 Pathway in Liver Diseases. Front Cell Dev Biol 2022;10:826204. [DOI: 10.3389/fcell.2022.826204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
627 Baldari S, Di Rocco G, Magenta A, Picozza M, Toietta G. Extracellular Vesicles-Encapsulated MicroRNA-125b Produced in Genetically Modified Mesenchymal Stromal Cells Inhibits Hepatocellular Carcinoma Cell Proliferation. Cells 2019;8:E1560. [PMID: 31816923 DOI: 10.3390/cells8121560] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
628 Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Transl Oncol 2019;12:256-68. [PMID: 30439626 DOI: 10.1016/j.tranon.2018.10.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
629 Resino S, Fernández-Rodríguez A, Pineda-Tenor D, Gómez-Moreno AZ, Sánchez-Ruano JJ, Artaza-Varasa T, Muñoz-Gómez MJ, Virseda-Berdices A, Martín-Vicente M, Martínez I, Jiménez-Sousa MA. TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients. J Clin Med 2021;10:483. [PMID: 33525598 DOI: 10.3390/jcm10030483] [Reference Citation Analysis]
630 Bannaga AS, Tyagi H, Daulton E, Covington JA, Arasaradnam RP. Exploratory Study Using Urinary Volatile Organic Compounds for the Detection of Hepatocellular Carcinoma. Molecules 2021;26:2447. [PMID: 33922256 DOI: 10.3390/molecules26092447] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
631 Tong H, Liu X, Li T, Qiu W, Peng C, Shen B, Zhu Z. INTS8 accelerates the epithelial-to-mesenchymal transition in hepatocellular carcinoma by upregulating the TGF-β signaling pathway. Cancer Manag Res 2019;11:1869-79. [PMID: 30881114 DOI: 10.2147/CMAR.S184392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
632 Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci 2019;76:4203-19. [PMID: 31300868 DOI: 10.1007/s00018-019-03215-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
633 Li J, Xia T, Cao J, He D, Chen Z, Liang B, Song J. RP11-295G20.2 facilitates hepatocellular carcinoma progression via the miR-6884-3p/CCNB1 pathway. Aging (Albany NY) 2020;12:14918-32. [PMID: 32687483 DOI: 10.18632/aging.103552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
634 Xu J, Yan B, Zhang L, Zhou L, Zhang J, Yu W, Dong X, Yao L, Shan L. Theabrownin Induces Apoptosis and Tumor Inhibition of Hepatocellular Carcinoma Huh7 Cells Through ASK1-JNK-c-Jun Pathway. Onco Targets Ther 2020;13:8977-87. [PMID: 32982289 DOI: 10.2147/OTT.S254693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
635 Li Y, Li G, Chen X, Huang H, Liao L, Yuan T, Deng S. A Novel lncRNA NONHSAT053785 Acts as an Independent Risk Factor for Intrahepatic Metastasis of Hepatocellular Carcinoma. Onco Targets Ther 2020;13:5455-66. [PMID: 32606762 DOI: 10.2147/OTT.S254455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
636 Deng M, Li SH, Guo RP. Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. Am Surg 2021;:31348211054532. [PMID: 34743609 DOI: 10.1177/00031348211054532] [Reference Citation Analysis]
637 Zhao H, Xu J, Huang W, Zhan G, Zhao Y, Chen H, Yang X. Spatiotemporally Light-Activatable Platinum Nanocomplexes for Selective and Cooperative Cancer Therapy. ACS Nano 2019;13:6647-61. [PMID: 31083971 DOI: 10.1021/acsnano.9b00972] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
638 Hughey CC, Trefts E, Bracy DP, James FD, Donahue EP, Wasserman DH. Glycine N-methyltransferase deletion in mice diverts carbon flux from gluconeogenesis to pathways that utilize excess methionine cycle intermediates. J Biol Chem 2018;293:11944-54. [PMID: 29891549 DOI: 10.1074/jbc.RA118.002568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
639 Jiang Y, Chen P, Hu K, Dai G, Li J, Zheng D, Yuan H, He L, Xie P, Tu M, Peng S, Qu C, Lin W, Chung RT, Hong J. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. J Cell Mol Med 2021;25:1568-82. [PMID: 33410581 DOI: 10.1111/jcmm.16256] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
640 Song BG, Kim MJ, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. Dig Liver Dis 2021;53:210-5. [PMID: 33189588 DOI: 10.1016/j.dld.2020.10.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
641 Chen C, An L, Cheng Y, Luo X, Li Z, Liu X. Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. Front Oncol 2020;10:1404. [PMID: 32983970 DOI: 10.3389/fonc.2020.01404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
642 Wang Y, Sun L, Wang L, Liu Z, Li Q, Yao B, Wang C, Chen T, Tu K, Liu Q. Long non-coding RNA DSCR8 acts as a molecular sponge for miR-485-5p to activate Wnt/β-catenin signal pathway in hepatocellular carcinoma. Cell Death Dis 2018;9:851. [PMID: 30154476 DOI: 10.1038/s41419-018-0937-7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 74] [Article Influence: 16.0] [Reference Citation Analysis]
643 Zhang QJ, Li DZ, Lin BY, Geng L, Yang Z, Zheng SS. SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathway. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00176-4. [PMID: 34600815 DOI: 10.1016/j.hbpd.2021.09.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
644 He H, Ji B, Jia Z, Zhang Y, Wang X, Tao X, Liu Y, Jiang J. A Practical Model is Equivalent to the BALAD or BALAD-2 Score in Predicting Long-term Survival after Hepatectomy in Chinese Patients with Hepatocellular Carcinoma. J Cancer 2021;12:1474-82. [PMID: 33531992 DOI: 10.7150/jca.51593] [Reference Citation Analysis]
645 Luo Y, Feng Y, Song L, He GQ, Li S, Bai SS, Huang YJ, Li SY, Almutairi MM, Shi HL, Wang Q, Hong M. A network pharmacology-based study on the anti-hepatoma effect of Radix Salviae Miltiorrhizae. Chin Med 2019;14:27. [PMID: 31406500 DOI: 10.1186/s13020-019-0249-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
646 Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021; 27(17): 2025-2038 [PMID: 34007137 DOI: 10.3748/wjg.v27.i17.2025] [Reference Citation Analysis]
647 Sanz-garcía C, Fernández-iglesias A, Gracia-sancho J, Arráez-aybar LA, Nevzorova YA, Cubero FJ. The Space of Disse: The Liver Hub in Health and Disease. Livers 2021;1:3-26. [DOI: 10.3390/livers1010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
648 Harputluoglu M, Carr BI. Hepatitis B Before and After Hepatocellular Carcinoma. J Gastrointest Cancer 2021. [PMID: 34762265 DOI: 10.1007/s12029-021-00745-4] [Reference Citation Analysis]
649 Zhang G, Su L, Lv X, Yang Q. A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2021;21:522. [PMID: 34627241 DOI: 10.1186/s12935-021-02227-w] [Reference Citation Analysis]
650 Chen W, Mao Y, Liu C, Wu H, Chen S. Exosome in Hepatocellular Carcinoma: an update. J Cancer 2021;12:2526-36. [PMID: 33854614 DOI: 10.7150/jca.54566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
651 Shen Y, Wang H, Wei J, Li W. Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib. Onco Targets Ther 2021;14:5019-26. [PMID: 34675546 DOI: 10.2147/OTT.S332351] [Reference Citation Analysis]
652 Mohr R, Tacke F. Therapie des hepatozellulären Karzinoms – eine neue Dekade? Drug Res (Stuttg) 2021;71:S22-3. [PMID: 34788884 DOI: 10.1055/a-1606-5955] [Reference Citation Analysis]
653 Guo P, He Y, Chen L, Qi L, Liu D, Chen Z, Xiao M, Chen L, Luo Y, Zhang N, Guo H. Cytosolic phospholipase A2α modulates cell-matrix adhesion via the FAK/paxillin pathway in hepatocellular carcinoma. Cancer Biol Med 2019;16:377-90. [PMID: 31516757 DOI: 10.20892/j.issn.2095-3941.2018.0386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
654 Huang ZM, Zuo MX, Gu YK, Gu HF, Lai CX, Zhang TQ, Wang XC, An C, Huang JH. Computed tomography-guided radiofrequency ablation combined with transarterial embolization assisted by a three-dimensional visualization ablation planning system for hepatocellular carcinoma in challenging locations: a preliminary study. Abdom Radiol (NY) 2020;45:1181-92. [PMID: 32006072 DOI: 10.1007/s00261-020-02426-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
655 Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
656 Xie JY, Wei JX, Lv LH, Han QF, Yang WB, Li GL, Wang PX, Wu SB, Duan JX, Zhuo WF, Liu PQ, Min J. Angiopoietin-2 induces angiogenesis via exosomes in human hepatocellular carcinoma. Cell Commun Signal 2020;18:46. [PMID: 32183816 DOI: 10.1186/s12964-020-00535-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
657 González R, Rodríguez-Hernández MA, Negrete M, Ranguelova K, Rossin A, Choya-Foces C, Cruz-Ojeda P, Miranda-Vizuete A, Martínez-Ruiz A, Rius-Pérez S, Sastre J, Bárcena JA, Hueber AO, Padilla CA, Muntané J. Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer. Redox Biol 2020;34:101528. [PMID: 32388267 DOI: 10.1016/j.redox.2020.101528] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
658 Li B, Cao Y, Meng G, Qian L, Xu T, Yan C, Luo O, Wang S, Wei J, Ding Y, Yu D. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 2019;39:239-254. [PMID: 30555042 DOI: 10.1016/j.ebiom.2018.11.063] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 12.0] [Reference Citation Analysis]
659 Mohr R, Özdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, Hammerich L, Roderburg C. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. Int J Mol Sci 2021;22:1492. [PMID: 33540837 DOI: 10.3390/ijms22031492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
660 Ma ZJ, Wang Y, Li HF, Liu MH, Bi FR, Ma L, Ma H, Yan HL. LncZEB1-AS1 regulates hepatocellular carcinoma bone metastasis via regulation of the miR-302b-EGFR-PI3K-AKT axis. J Cancer 2020;11:5118-28. [PMID: 32742459 DOI: 10.7150/jca.45995] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
661 Fernández-Palanca P, Fondevila F, Méndez-Blanco C, Tuñón MJ, González-Gallego J, Mauriz JL. Antitumor Effects of Quercetin in Hepatocarcinoma In Vitro and In Vivo Models: A Systematic Review. Nutrients 2019;11:E2875. [PMID: 31775362 DOI: 10.3390/nu11122875] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
662 Mao B, Zhang L, Ning P, Ding F, Wu F, Lu G, Geng Y, Ma J. Preoperative prediction for pathological grade of hepatocellular carcinoma via machine learning-based radiomics.Eur Radiol. 2020;30:6924-6932. [PMID: 32696256 DOI: 10.1007/s00330-020-07056-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
663 Ke K, Chen G, Cai Z, Huang Y, Zhao B, Wang Y, Liao N, Liu X, Li Z, Liu J. Evaluation and prediction of hepatocellular carcinoma prognosis based on molecular classification. Cancer Manag Res. 2018;10:5291-5302. [PMID: 30464626 DOI: 10.2147/cmar.s178579] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
664 Guo X, Zhang W, Du J, Tao R, Dong W, Huang J, Zhang J, Pan Z, Zhou W, Zhu X, Liu H, Liu F. Acute-Phase Serum Amyloid A May Predict Microvascular Invasion and Early Tumor Recurrence in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Liver Resection. J Invest Surg 2022;:1-9. [PMID: 35143736 DOI: 10.1080/08941939.2022.2035858] [Reference Citation Analysis]
665 Lee JH, Joo I, Kang TW, Paik YH, Sinn DH, Ha SY, Kim K, Choi C, Lee G, Yi J, Bang WC. Deep learning with ultrasonography: automated classification of liver fibrosis using a deep convolutional neural network. Eur Radiol 2020;30:1264-73. [PMID: 31478087 DOI: 10.1007/s00330-019-06407-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
666 Bouattour M, Mehta N, He AR, Cohen EI, Nault JC. Systemic Treatment for Advanced Hepatocellular Carcinoma. Liver Cancer. 2019;8:341-358. [PMID: 31768344 DOI: 10.1159/000496439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
667 Bourcier B, Lagarce F, Lebreton V. Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization. J Pharm Biomed Anal 2021;210:114543. [PMID: 34991044 DOI: 10.1016/j.jpba.2021.114543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
668 Zhang ZS, Li HZ, Ma C, Xiao YD. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. BMC Cancer 2019;19:1162. [PMID: 31783814 DOI: 10.1186/s12885-019-6386-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
669 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol 2021;15:1245-51. [PMID: 34431725 DOI: 10.1080/17474124.2021.1973431] [Reference Citation Analysis]
670 Chen Y, Shang H, Wang C, Zeng J, Zhang S, Wu B, Cheng W. RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC. Int J Nanomedicine 2022;17:105-23. [PMID: 35027829 DOI: 10.2147/IJN.S343361] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
671 Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackovic D, Fine GC. The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.Oncoimmunology. 2020;9:1673129. [PMID: 32002284 DOI: 10.1080/2162402X.2019.1673129] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
672 Kong J, Zhang Q, Liang X, Sun W. FOXK2 downregulation suppresses EMT in hepatocellular carcinoma. Open Med (Wars) 2020;15:702-8. [PMID: 33313412 DOI: 10.1515/med-2020-0129] [Reference Citation Analysis]
673 Liu R, Kong W, Jiang Z, Zheng S, Yuan X, Ye L. ABL1 Is a Prognostic Marker and Associated with Immune Infiltration in Hepatocellular Carcinoma. J Oncol 2021;2021:1379706. [PMID: 34484330 DOI: 10.1155/2021/1379706] [Reference Citation Analysis]
674 Itoh S, Yoshizumi T, Kitamura Y, Yugawa K, Iseda N, Shimagaki T, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M. Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation. Hepatol Commun 2021;5:1278-89. [PMID: 34278175 DOI: 10.1002/hep4.1715] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
675 Liu D, Luo Y, Chen L, Chen L, Zuo D, Li Y, Zhang X, Wu J, Xi Q, Li G, Qi L, Yue X, Zhang X, Sun Z, Zhang N, Song T, Lu W, Guo H. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study. Cancer Biol Med 2021;18:256-70. [PMID: 33628599 DOI: 10.20892/j.issn.2095-3941.2020.0207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
676 Swed B, Gandarilla O, Chiu K, Halazun KH, Samstein B, Yantiss R, Brar G. Rare Histological Variants of Liver Cancer and Their Management: A Single-Institution Experience. Case Reports Hepatol 2021;2021:6654229. [PMID: 33968454 DOI: 10.1155/2021/6654229] [Reference Citation Analysis]
677 Huang KW, Jayant K, Lee PH, Yang PC, Hsiao CY, Habib N, Sodergren MH. Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. J Clin Med 2019;8:E385. [PMID: 30893948 DOI: 10.3390/jcm8030385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
678 Fu X, Zhang J, He X, Yan X, Wei J, Huang M, Liu Y, Lin J, Hu H, Liu L. Circular RNA MAN2B2 promotes cell proliferation of hepatocellular carcinoma cells via the miRNA-217/MAPK1 axis. J Cancer 2020;11:3318-26. [PMID: 32231737 DOI: 10.7150/jca.36500] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
679 Liao X, Zhan W, Tian B, Luo Y, Gu F, Li R. Circular RNA ZNF609 Promoted Hepatocellular Carcinoma Progression by Upregulating PAP2C Expression via Sponging miR-342-3p. Onco Targets Ther 2020;13:7773-83. [PMID: 32801783 DOI: 10.2147/OTT.S253936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
680 Zha Z, Li J. MicroRNA‑125a‑5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1. Int J Mol Med 2020;46:1849-61. [PMID: 33000203 DOI: 10.3892/ijmm.2020.4729] [Reference Citation Analysis]
681 Akuta N, Kawamura Y, Suzuki F, Kobayashi M, Arase Y, Saitoh S, Muraishi N, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Ikeda K, Kumada H. Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. Hepatol Int. [DOI: 10.1007/s12072-022-10313-y] [Reference Citation Analysis]
682 Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019;12:1629-40. [PMID: 30881018 DOI: 10.2147/OTT.S196713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
683 Gong C, Ai J, Fan Y, Gao J, Liu W, Feng Q, Liao W, Wu L. NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling. Onco Targets Ther 2019;12:8537-52. [PMID: 31802891 DOI: 10.2147/OTT.S217916] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
684 Zheng Y, Kong F, Liu S, Liu X, Pei D, Miao X. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy. Drug Deliv 2021;28:2033-43. [PMID: 34569906 DOI: 10.1080/10717544.2021.1983072] [Reference Citation Analysis]
685 Kong J, Li G, Chai J, Yu G, Liu Y, Liu J. Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2021. [PMID: 34160708 DOI: 10.1245/s10434-021-10317-2] [Reference Citation Analysis]
686 Byrne FL, Hargett SR, Lahiri S, Roy RJ, Berr SS, Caldwell SH, Hoehn KL. Serial MRI Imaging Reveals Minimal Impact of Ketogenic Diet on Established Liver Tumor Growth. Cancers (Basel) 2018;10:E312. [PMID: 30189621 DOI: 10.3390/cancers10090312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
687 Lian YF, Huang YL, Zhang YJ, Chen DM, Wang JL, Wei H, Bi YH, Jiang ZW, Li P, Chen MS, Huang YH. CACYBP Enhances Cytoplasmic Retention of P27Kip1 to Promote Hepatocellular Carcinoma Progression in the Absence of RNF41 Mediated Degradation. Theranostics 2019;9:8392-408. [PMID: 31754404 DOI: 10.7150/thno.36838] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
688 Geng N, Jin Y, Li Y, Zhu S, Bai H. AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma. Int J Med Sci 2020;17:1246-56. [PMID: 32547320 DOI: 10.7150/ijms.42956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
689 Zhang CY, Yang M. Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis. World J Hepatol 2022; 14(5): 956-971 [DOI: 10.4254/wjh.v14.i5.956] [Reference Citation Analysis]
690 Cheng C, Wu X, Shen Y, Li Q. KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC. Cancer Manag Res 2020;12:13241-57. [PMID: 33380832 DOI: 10.2147/CMAR.S285367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
691 Sugumar K, Markt SC, Hue JJ, Hoehn RS, Lee RT, Chavin KD, Rothermel LD, Winter JM, Hardacre JM, Ammori JB, Ocuin LM. Black race is independently associated with underutilization of transplantation for clinical T1 hepatocellular carcinoma. HPB (Oxford) 2021:S1365-182X(21)01690-7. [PMID: 34872866 DOI: 10.1016/j.hpb.2021.10.023] [Reference Citation Analysis]
692 Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol. 2019;12:133. [PMID: 31815633 DOI: 10.1186/s13045-019-0806-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
693 Bedon L, Dal Bo M, Mossenta M, Busato D, Toffoli G, Polano M. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. Int J Mol Sci 2021;22:1075. [PMID: 33499054 DOI: 10.3390/ijms22031075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
694 Huang J, Liu FC, Li L, Zhou WP, Jiang BG, Pan ZY. Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection. Cancer Med 2020;9:2791-802. [PMID: 32096346 DOI: 10.1002/cam4.2944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
695 Linck-Paulus L, Hellerbrand C, Bosserhoff AK, Dietrich P. Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma. Cells 2020;9:E114. [PMID: 31906510 DOI: 10.3390/cells9010114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
696 Kim S, Kim JH, Ko GY, Gwon DI, Shin JH, Yoon HK. Bronchial artery embolization for hemoptysis caused by metastatic hepatocellular carcinoma. Sci Rep 2022;12:6906. [PMID: 35484185 DOI: 10.1038/s41598-022-10972-9] [Reference Citation Analysis]
697 Fondevila F, Méndez-Blanco C, Fernández-Palanca P, González-Gallego J, Mauriz JL. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp Mol Med 2019;51:1-15. [PMID: 31551425 DOI: 10.1038/s12276-019-0308-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
698 Xu H, Schmidt R, Hamm CA, Schobert IT, He Y, Böning G, Jonczyk M, Hamm B, Gebauer B, Savic LJ. Comparison of intrahepatic progression patterns of hepatocellular carcinoma and colorectal liver metastases following CT-guided high dose-rate brachytherapy. Ther Adv Med Oncol 2021;13:17588359211042304. [PMID: 34539817 DOI: 10.1177/17588359211042304] [Reference Citation Analysis]
699 Xu D, Xu M, Jeong S, Qian Y, Wu H, Xia Q, Kong X. The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches. Front Pharmacol. 2018;9:1428. [PMID: 30670963 DOI: 10.3389/fphar.2018.01428] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 26.0] [Reference Citation Analysis]
700 Ali DA, Sabry NM, Kabel AM, Gaber RA, Mokhtar HM, Samy SM, Elrashidy MA, Salama SA, Abdelhai D. The Expression of Circulating miR-497 and Metadherin in Hepatocellular Carcinoma: Relation to the Tumor Characteristics and Patients' Survival. Medicina (Kaunas) 2021;57:866. [PMID: 34577789 DOI: 10.3390/medicina57090866] [Reference Citation Analysis]
701 Cheng F, Wang L, Zhang J. Circular RNA 0016788 displays as a biomarker for tumor progression and poor prognosis in surgical hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23300. [PMID: 32319701 DOI: 10.1002/jcla.23300] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
702 Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:598-609. [PMID: 30039640 DOI: 10.1111/apt.14913] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 15.8] [Reference Citation Analysis]
703 Liu W, Yang Z, Zou R, Qiu J, Shen J, Liao Y, Wang C, Zhang Y, Wang Y, Yuan Y, Li K, Zuo D, He W, Zheng Y, Li B, Yuan Y. Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study. J Cancer 2019;10:2857-67. [PMID: 31281462 DOI: 10.7150/jca.31246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
704 Aquina CT, Eskander MF, Pawlik TM. Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature. Front Oncol 2022;12:832405. [DOI: 10.3389/fonc.2022.832405] [Reference Citation Analysis]
705 Xu J, Zheng Q, Cheng X, Hu S, Zhang C, Zhou X, Sun P, Wang W, Su Z, Zou T, Song Z, Xia Y, Yi X, Gao Y. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. J Nanobiotechnology 2021;19:355. [PMID: 34717654 DOI: 10.1186/s12951-021-01101-1] [Reference Citation Analysis]
706 Ding Y, Yao J, Wen M, Liu X, Huang J, Zhang M, Zhang Y, Lv Y, Xie Z, Zuo J. The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma. PeerJ 2022;10:e13473. [DOI: 10.7717/peerj.13473] [Reference Citation Analysis]
707 Jiang J, Yan T, Guo F. Global DNA 5hmC and CK195hmC+ Contents: A Promising Biomarker for Predicting Prognosis in Small Hepatocellular Carcinoma. Curr Oncol 2021;28:3758-70. [PMID: 34677239 DOI: 10.3390/curroncol28050321] [Reference Citation Analysis]
708 Liu R, Jiang Z, Kong W, Zheng S, Dai T, Wang G. A Novel Nine-Gene Signature Associated With Immune Infiltration for Predicting Prognosis in Hepatocellular Carcinoma. Front Genet 2021;12:730732. [PMID: 34917126 DOI: 10.3389/fgene.2021.730732] [Reference Citation Analysis]
709 Lei Y, Yan W, Lin Z, Liu J, Tian D, Han P. Comprehensive analysis of partial epithelial mesenchymal transition-related genes in hepatocellular carcinoma. J Cell Mol Med 2021;25:448-62. [PMID: 33215860 DOI: 10.1111/jcmm.16099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
710 Zhang L, Yan ZP, Hou ZH, Huang P, Yang MJ, Zhang S, Zhang S, Zhang SH, Zhu XL, Ni CF, Li Q. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib. Front Mol Biosci 2021;8:624366. [PMID: 34124139 DOI: 10.3389/fmolb.2021.624366] [Reference Citation Analysis]
711 Yao F, Zhan Y, Li C, Lu Y, Chen J, Deng J, Wu Z, Li Q, Song Y, Chen B, Chen J, Tian K, Pu Z, Ni Y, Mou L. Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells. Front Cell Dev Biol 2021;9:734287. [PMID: 35059393 DOI: 10.3389/fcell.2021.734287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
712 Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D; Cochrane Hepato-Biliary Group. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd014798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
713 Zhu L, Guo W. Combined DNA Methylation and Transcriptomic Assessments to Determine a Prognostic Model for PD-1-Negative Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:708819. [PMID: 34458266 DOI: 10.3389/fcell.2021.708819] [Reference Citation Analysis]
714 Gao Y, Yin Z, Qi Y, Peng H, Ma W, Wang R, Li W. Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02462-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
715 Wang F, Numata K, Takeda A, Ogushi K, Fukuda H, Nihonmatsu H, Hara K, Chuma M, Tsurugai Y, Maeda S. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study. BMC Cancer 2021;21:1169. [PMID: 34717577 DOI: 10.1186/s12885-021-08897-z] [Reference Citation Analysis]
716 Duan J, Chen W, Xie J, Zhang M, Nie R, Liang H, Mei J, Han K, Xiang Z, Wang F, Teng K, Chen R, Deng M, Yin Y, Zhang N, Xie D, Cai M. A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01537-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
717 Corominas J, Sapena V, Sanduzzi-Zamparelli M, Millán C, Samper E, Llarch N, Iserte G, Torres F, Da Fonseca LG, Muñoz-Martínez S, Forner A, Bruix J, Boix L, Reig M. Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:426. [PMID: 33498698 DOI: 10.3390/cancers13030426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
718 Allaire M, Nault JC. Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:53-5. [PMID: 30881965 DOI: 10.21037/hbsn.2018.10.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
719 Zhou X, Cai BB, Hou XQ, Kang XK, Xu XX, Wang WM. Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma. Aging (Albany NY) 2020;12:11878-92. [PMID: 32568098 DOI: 10.18632/aging.103360] [Reference Citation Analysis]
720 Kim GW, Imam H, Khan M, Mir SA, Kim SJ, Yoon SK, Hur W, Siddiqui A. HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC. Hepatology 2021;73:533-47. [PMID: 32394474 DOI: 10.1002/hep.31313] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 36.0] [Reference Citation Analysis]
721 Luo L, Yao X, Xiang J, Huang F, Luo H. Identification of ferroptosis-related genes for overall survival prediction in hepatocellular carcinoma. Sci Rep 2022;12:10007. [PMID: 35705729 DOI: 10.1038/s41598-022-14554-7] [Reference Citation Analysis]
722 Yu Z, Li Y, Li Y, Zhang J, Li M, Ji L, Tang Y, Zheng Y, Sheng J, Han Q, Li F, Guo J, Wang L, Sun X, Gao Y, Feng H. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. J Immunother Cancer 2022;10:e004297. [PMID: 35618286 DOI: 10.1136/jitc-2021-004297] [Reference Citation Analysis]
723 Zhao F, Li C, Wu Y, Xia J, Zeng M, Li T, Xie K. Connective Tissue Growth Factor in Digestive System Cancers: A Review and Meta-Analysis. Biomed Res Int 2020;2020:8489093. [PMID: 33426067 DOI: 10.1155/2020/8489093] [Reference Citation Analysis]
724 Bannaga A, Metzger J, Voigtländer T, Pejchinovski M, Frantzi M, Book T, James S, Gopalakrishnan K, Mischak H, Manns MP, Arasaradnam RP. Pathophysiological Implications of Urinary Peptides in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3786. [PMID: 34359689 DOI: 10.3390/cancers13153786] [Reference Citation Analysis]
725 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
726 Meng XP, Tang TY, Ding ZM, Wang J, Lu CQ, Yu Q, Xia C, Zhang T, Long X, Xiao W, Wang YC, Ju S. Preoperative Microvascular Invasion Prediction to Assist in Surgical Plan for Single Hepatocellular Carcinoma: Better Together with Radiomics. Ann Surg Oncol 2022. [PMID: 35102453 DOI: 10.1245/s10434-022-11346-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
727 Wu J, Ding W, Wang Y, Liu S, Zhang X, Yang Q, Cai W, Yu X, Liu F, Kong D, Zhong H, Yu J, Liang P. Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation. International Journal of Hyperthermia 2022;39:595-604. [DOI: 10.1080/02656736.2022.2062463] [Reference Citation Analysis]
728 Liang L, Xu H, Dong Q, Qiu L, Lu L, Yang Q, Zhao W, Li Y. WTAP Is Correlated With Unfavorable Prognosis, Tumor Cell Proliferation, and Immune Infiltration in Hepatocellular Carcinoma. Front Oncol 2022;12:852000. [DOI: 10.3389/fonc.2022.852000] [Reference Citation Analysis]
729 Wang Z, Zhong Y, Zhang Z, Zhou K, Huang Z, Yu H, Liu L, Liu S, Yang H, Zhou J, Fan J, Wu L, Sun Y. Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma. Front Immunol 2022;13:847263. [PMID: 35371059 DOI: 10.3389/fimmu.2022.847263] [Reference Citation Analysis]
730 Kosaka Y, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Ando Y, Suehiro Y, Yamaoka K, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. Clin J Gastroenterol 2021. [PMID: 34291386 DOI: 10.1007/s12328-021-01481-9] [Reference Citation Analysis]
731 Huang Y, Huang X, Zeng J, Lin J. Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells. Front Oncol 2021;11:667669. [PMID: 34150633 DOI: 10.3389/fonc.2021.667669] [Reference Citation Analysis]
732 Raoul JL, Frenel JS, Raimbourg J, Gilabert M. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepat Oncol 2019;6:HEP11. [PMID: 31244990 DOI: 10.2217/hep-2019-0001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
733 Liu Z, Zhang Z, Mei H, Mao J, Zhou X. Distribution and clinical relevance of phospholipids in hepatocellular carcinoma. Hepatol Int 2020;14:544-55. [PMID: 32504407 DOI: 10.1007/s12072-020-10056-8] [Reference Citation Analysis]
734 Tong W, Yang L, Liu L, Liu X, Luo N. SPINDOC is Highly Expressed in Pan-Cancer Samples and Can Promote the Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating Wnt/β-Catenin Signaling Pathway. OTT 2022;Volume 15:555-70. [DOI: 10.2147/ott.s348843] [Reference Citation Analysis]
735 Su D, Wu B, Shi L. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e210037. [PMID: 33625508 DOI: 10.1001/jamanetworkopen.2021.0037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
736 Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18:112-127. [PMID: 33235387 DOI: 10.1038/s41423-020-00572-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
737 Liu B, Zhu X, Gao S, Guo J, Wang X, Cao G, Zhu L, Liu P, Xu H, Chen H, Zhang X, Liu S, Kou F. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma. J Interv Med 2019;2:91-6. [PMID: 34805879 DOI: 10.1016/j.jimed.2019.07.006] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
738 Bucalau AM, Tancredi I, Pezzullo M, Leveque R, Picchia S, Laethem JV, Verset G. Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. Hepat Oncol 2020;8:HEP31. [PMID: 33680430 DOI: 10.2217/hep-2020-0022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
739 Zhao Y, Li M, Miao N, Wei W, Dong Y, Tao C, Chen J, Pei Y, Guo L. Use of miRNA Sequencing to Reveal Hub miRNAs and the Effect of miR-582-3p/SMAD2 in the Progression of Hepatocellular Carcinoma. Front Genet 2022;13:819553. [PMID: 35386287 DOI: 10.3389/fgene.2022.819553] [Reference Citation Analysis]
740 Haubold J, Ludwig JM, Li Y, Buechter M, Wetter A, Umutlu L, Theysohn JM. Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization. PLoS One 2020;15:e0227972. [PMID: 31995589 DOI: 10.1371/journal.pone.0227972] [Reference Citation Analysis]
741 Wan Z, Wang X. Role of SLC39A6 in the development and progression of liver cancer. Oncol Lett 2022;23:77. [PMID: 35111246 DOI: 10.3892/ol.2022.13197] [Reference Citation Analysis]
742 Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol 2020;12:1758835920927602. [PMID: 32518599 DOI: 10.1177/1758835920927602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
743 Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma . World J Gastrointest Oncol 2021; 13(12): 2038-2049 [DOI: 10.4251/wjgo.v13.i12.2038] [Reference Citation Analysis]
744 Wang H, Yu H, Qian YW, Cao ZY, Wu MC, Cong WM. Impact of Surgical Margin on the Prognosis of Early Hepatocellular Carcinoma (≤5 cm): A Propensity Score Matching Analysis. Front Med (Lausanne) 2020;7:139. [PMID: 32478080 DOI: 10.3389/fmed.2020.00139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
745 Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Aoki T, Tanaka T, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep 2021;11:16663. [PMID: 34404856 DOI: 10.1038/s41598-021-96089-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
746 Yu L, Wang L, Wu X, Yi H. RSPO4-CRISPR alleviates liver injury and restores gut microbiota in a rat model of liver fibrosis. Commun Biol 2021;4:230. [PMID: 33603089 DOI: 10.1038/s42003-021-01747-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
747 Wu TT, Cai J, Tian YH, Chen JF, Cheng ZL, Pu CS, Shi WZ, Suo XP, Wu XJ, Dou XW, Zhang KM. MTF2 Induces Epithelial-Mesenchymal Transition and Progression of Hepatocellular Carcinoma by Transcriptionally Activating Snail. Onco Targets Ther 2019;12:11207-20. [PMID: 31908487 DOI: 10.2147/OTT.S226119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
748 Chandrashekar DS, Golonka RM, Yeoh BS, Gonzalez DJ, Heikenwälder M, Gerwirtz AT, Varambally S, Vijay-Kumar M. Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer. PLoS One 2020;15:e0234726. [PMID: 32559205 DOI: 10.1371/journal.pone.0234726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
749 Vaziri F, Colquhoun S, Wan YY. Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Res 2020;4:191-8. [PMID: 33343967 DOI: 10.1016/j.livres.2020.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
750 Yu J, Zhang H, Zhang Y, Zhang X. Integrated Analysis of the Altered lncRNA, microRNA, and mRNA Expression in HBV-Positive Hepatocellular Carcinoma. Life 2022;12:701. [DOI: 10.3390/life12050701] [Reference Citation Analysis]
751 Huang X, Xu L, Ma T, Yin X, Huang Z, Ran Y, Ni Y, Bi X, Che X. Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study. Front Oncol 2021;11:751159. [PMID: 34868952 DOI: 10.3389/fonc.2021.751159] [Reference Citation Analysis]
752 De Luca E, Marino D, Di Maio M. Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence. Cancer Manag Res 2020;12:3721-9. [PMID: 32547208 DOI: 10.2147/CMAR.S216220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
753 Qu C, He L, Yao N, Li J, Jiang Y, Li B, Peng S, Hu K, Chen D, Chen G, Huang W, Cao M, Fan J, Yuan Y, Ye W, Hong J. Myofibroblast-Specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model. Hepatology 2021;74:458-73. [PMID: 33609283 DOI: 10.1002/hep.31754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
754 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1646] [Cited by in F6Publishing: 1401] [Article Influence: 411.5] [Reference Citation Analysis]
755 Toshida K, Itoh S, Tomiyama T, Morinaga A, Kosai Y, Tomino T, Kurihara T, Nagao Y, Morita K, Harada N, Yoshizumi T. Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients. JGH Open. [DOI: 10.1002/jgh3.12777] [Reference Citation Analysis]
756 Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, Zhang H, Kong H, Yang Y, Lu Y. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis 2019;10:784. [PMID: 31611551 DOI: 10.1038/s41419-019-2023-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
757 Wan W, Shen Y, Li Q. MCM10 Acts as a Potential Prognostic Biomarker and Promotes Cell Proliferation in Hepatocellular Carcinoma: Integrated Bioinformatics Analysis and Experimental Validation. Cancer Manag Res 2020;12:9609-19. [PMID: 33116820 DOI: 10.2147/CMAR.S267493] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
758 Zhang Q, Feng Z, Gao M, Guo L. Determining novel candidate anti-hepatocellular carcinoma drugs using interaction networks and molecular docking between drug targets and natural compounds of SiNiSan. PeerJ 2021;9:e10745. [PMID: 33628636 DOI: 10.7717/peerj.10745] [Reference Citation Analysis]
759 Malnick SDH, Abdullah A, Neuman MG. Checkpoint Inhibitors and Hepatotoxicity. Biomedicines 2021;9:101. [PMID: 33494227 DOI: 10.3390/biomedicines9020101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
760 Pandit SK, Sandrini G, Merulla J, Nobili V, Wang X, Zangari A, Rinaldi A, Shinde D, Carbone GM, Catapano CV. Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6029. [PMID: 34885140 DOI: 10.3390/cancers13236029] [Reference Citation Analysis]
761 Pan X, Lin P, Feng F, Li J, Li Y, Dai W, Hu B, Yang X, Fan J, Li H, Li Y. Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophys Rep 2020;6:19-32. [DOI: 10.1007/s41048-019-00102-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
762 Bai C, Wang H, Dong D, Li T, Yu Z, Guo J, Zhou W, Li D, Yan R, Wang L, Wang Z, Li Y, Ren L. Urea as a By-Product of Ammonia Metabolism Can Be a Potential Serum Biomarker of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:650748. [PMID: 33869206 DOI: 10.3389/fcell.2021.650748] [Reference Citation Analysis]
763 Shi Y, Kong W, Lu Y, Zheng Y. Traditional Chinese Medicine Xiaoai Jiedu Recipe Suppresses the Development of Hepatocellular Carcinoma via Regulating the microRNA-29a/Signal Transducer and Activator of Transcription 3 Axis. Onco Targets Ther 2020;13:7329-42. [PMID: 32848411 DOI: 10.2147/OTT.S248797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
764 Huang S, Zhang C, Sun C, Hou Y, Zhang Y, Tam NL, Wang Z, Yu J, Huang B, Zhuang H, Zhou Z, Ma Z, Sun Z, He X, Zhou Q, Hou B, Wu L. Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma. Aging (Albany NY) 2020;12:3025-41. [PMID: 32045367 DOI: 10.18632/aging.102797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
765 Lee TH, Hirshman N, Cardona DM, Berg CL, Fowler KJ, Bashir MR, Ronald J. LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions. Dig Dis Sci 2022. [PMID: 35257246 DOI: 10.1007/s10620-022-07428-5] [Reference Citation Analysis]
766 Chen ZH, Ni QZ, Zhang XP, Ma N, Feng JK, Wang K, Li JJ, Xie D, Ma XY, Cheng SQ. NET1 promotes HCC growth and metastasis in vitro and in vivo via activating the Akt signaling pathway. Aging (Albany NY) 2021;13:10672-87. [PMID: 33839702 DOI: 10.18632/aging.202845] [Reference Citation Analysis]
767 Shimose S, Kawaguchi T, Iwamoto H, Tanaka M, Miyazaki K, Ono M, Niizeki T, Shirono T, Okamura S, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. Nutrients 2020;12:E1076. [PMID: 32295043 DOI: 10.3390/nu12041076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
768 De Matteis S, Ragusa A, Marisi G, De Domenico S, Casadei Gardini A, Bonafè M, Giudetti AM. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities. Oxid Med Cell Longev 2018;2018:7512159. [PMID: 30524660 DOI: 10.1155/2018/7512159] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 12.3] [Reference Citation Analysis]
769 Zhuang H, Zhou Z, Ma Z, Huang S, Gong Y, Zhang Z, Hou B, Yu W, Zhang C. Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection. Front Oncol 2020;10:556489. [PMID: 33312945 DOI: 10.3389/fonc.2020.556489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
770 Alves AF, Moura AC, Andreolla HF, Veiga ABGD, Fiegenbaum M, Giovenardi M, Almeida S. Gene expression evaluation of antioxidant enzymes in patients with hepatocellular carcinoma: RT-qPCR and bioinformatic analyses. Genet Mol Biol 2021;44:e20190373. [PMID: 33821873 DOI: 10.1590/1678-4685-GMB-2019-0373] [Reference Citation Analysis]
771 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
772 Chen KT, Tsai KF, Leung HWC, Chan ALF, Wang SY, Liang HL, Tang SY, Chou CK, Chen HY, Chan SH, Li MF. Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience. Medicina (Kaunas) 2021;57:779. [PMID: 34440985 DOI: 10.3390/medicina57080779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
773 Zhang Z, Zhu J, Huang Y, Li W, Cheng H. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. Diagn Pathol 2018;13:85. [PMID: 30390677 DOI: 10.1186/s13000-018-0763-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
774 Zhao Z, Zhang D, Wu F, Tu J, Song J, Xu M, Ji J. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. J Cell Mol Med 2021;25:549-60. [PMID: 33210432 DOI: 10.1111/jcmm.16108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
775 Manna D, Sarkar D. Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1243. [PMID: 32429062 DOI: 10.3390/cancers12051243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
776 Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. Hepatology 2020;72:2206-18. [PMID: 32064645 DOI: 10.1002/hep.31187] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 23.0] [Reference Citation Analysis]
777 Al-Ameri AAM, Wei X, Lin L, Shao Z, Guo H, Xie H, Zhou L, Zheng S, Xu X. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation. BMC Cancer. 2019;19:1136. [PMID: 31752756 DOI: 10.1186/s12885-019-6343-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
778 Dong Z, Chen Y, Yang C, Zhang M, Chen A, Yang J, Huang Y. STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma. Onco Targets Ther 2019;12:7175-91. [PMID: 31564902 DOI: 10.2147/OTT.S202122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
779 Bai N, Peng E, Xia F, Wang D, Li X, Li X. CircABCC2 Regulates He